entinostat profile

Entinostat, also known as SNDX-5613, is a potent and selective inhibitor of histone deacetylase (HDAC) enzymes. It is currently being investigated in clinical trials for the treatment of various cancers, including hematologic malignancies, solid tumors, and myelodysplastic syndromes. Entinostat has demonstrated promising preclinical activity, inhibiting the growth and proliferation of cancer cells by inducing cell cycle arrest and apoptosis. Its mechanism of action involves the inhibition of HDACs, which are enzymes that remove acetyl groups from histone proteins. This deacetylation process can silence genes involved in cell growth and differentiation. By inhibiting HDACs, entinostat increases histone acetylation, leading to the reactivation of these genes and promoting cancer cell death. Entinostat's importance lies in its potential to be a novel and effective treatment for cancers that are currently difficult to treat. The study of entinostat aims to determine its safety and efficacy in humans and to identify the optimal dosing and treatment strategies for different cancer types. '

ID Source	ID
PubMed CID	4261
CHEMBL ID	27759
CHEBI ID	132082
SCHEMBL ID	148309
MeSH ID	M0540391

Synonym
HY-12163
bay86-5274
n-[[4-[(2-aminoanilino)-oxomethyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester
pyridin-3-ylmethyl 4-(2-aminophenylcarbamoyl)benzylcarbamate
sndx 275
CHEBI:132082
entinostatum
bay 86-5274
nsc706995
n-(2-aminophenyl)-4-[n-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide
NCI60_038022
ms-27-275
NCGC00165833-02
NCGC00165833-01
entinostat ,
ms-275
sndx-275
nsc-706995
209783-80-2
carbamic acid, 3-pyridinylmethyl ester
ms 275
carbamic acid, ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3-pyridinylmethyl ester
ms 27-275
3-pyridinylmethyl ((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)carbamate
n-(2-aminophenyl)-4-(n-(pyridin-3-ylmethoxycarbonyl)aminomethyl)benzamide
ms275
pyridin-3-ylmethyl {4-[(2-aminophenyl)carbamoyl]benzyl}carbamate
carbamic acid, n-((4-(((2-aminophenyl)amino)carbonyl)phenyl)methyl)-, 3- pyridinylmethyl ester
pyridin-3-ylmethyl n-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate
benzamide-type inhibitor, 3
chembl27759 ,
bdbm19410
3-pyridylmethyl n-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate
carbamic acid, [[4-[[(2-aminophenyl)carbaonyl]phenyl]methyl]-, 3-pyridinylmethyl ester
ms-275-27
BRD-K77908580-001-02-1
EC-000.2117
entinostat (jan/usan/inn)
D09338
442532-99-2
FT-0667871
pyridin-3-ylmethyl n-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate
NCGC00165833-03
1zny4fkk9h ,
unii-1zny4fkk9h
entinostat [usan:inn]
nsc 706995
MS-275 - ENTINOSTAT
sndx 275;3-pyridylmethyl n-[[4-[(2-aminophenyl)carbamoyl]phenyl]methyl]carbamate
A815057
entinostat (ms-275,sndx-275)
BCP9000967
BCPP000155
ms-275,entinostat, sndx-275, ms-27-275
NCGC00165833-04
CS-0511
S1053
entinostat [jan]
entinostat [inn]
entinostat [who-dd]
entinostat [usan]
pyridin-3-ylmethyl ({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate
gtpl7007
zk 244894
CCG-208680
MLS006010183
smr004458705
SCHEMBL148309
n-(2-aminophenyl)-4-[n-(pyridin-3-ylmethoxycarbonyl)aminomethyl]benzamide
AKOS024262667
pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate
W-201831
n-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-3-pyridinylmethyl ester, carbamic acid
HB3983
HMS3648K12
DTXSID0041068
EX-A038
AC-8968
ms-275, a hdac1 and hdac3 inhibitor
HMS3654O11
mfcd08272435
(pyridin-3-yl)methyl 4-(2-aminophenylcarbamoyl)benzylcarbamate
(pyridin-3-yl)methyl n-({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate
EN300-6488260
NCGC00165833-13
entinostat (ms-275)
SW219667-1
DB11841
E1454
pyridin-3-ylmethyl 4-((2-aminophenyl)carbamoyl)benzylcarbamate.
n-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]carbamic acid 3-pyridinylmethyl ester
Z2037280922
entinostat (ms-275, sndx-275) ,
AS-17906
SR-01000946382-1
sr-01000946382
BCP01824
Q1281020
BRD-K77908580-001-04-7
entinostat (ms-275;sndx-275)
SB16665
HMS3426G07
AMY31163
HMS3744O17
carbamic acid, n-[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]-, 3-pyridinylmethyl ester
NCGC00165833-11
BP-25653
nsc-756642
nsc756642
entinostat, free base
pyridin-3-ylmethyl4-((2-aminophenyl)carbamoyl)benzylcarbamate

Excerpt	Reference	Relevance
"Entinostat is an oral inhibitor of class I histone deacetylases intended for endocrine therapy-resistant patients with hormone receptor-positive (HR+) advanced or metastatic breast cancer (BC). "	( Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer. Iwata, H; Kimura, R; Lee, MJ; Masuda, N; Nishimura, Y; Saji, S; Sawaki, M; Shimomura, A; Tamura, K; Trepel, J; Yasojima, H; Yuno, A, 2021)	2.4
"Entinostat is a synthetic benzamide derivative histone deacetylase (HDAC) inhibitor, which potently and selectively inhibits class I and IV HDAC enzymes. "	( Entinostat: a promising treatment option for patients with advanced breast cancer. Connolly, RM; Piekarz, R; Rudek, MA, 2017)	3.34
"Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-positive (ER+) breast cancer. "	( Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata Cruickshank, S; Ismail-Khan, RR; Klein, PM; Lee, MJ; Lichinitser, M; Melichar, B; Miller, KD; Munster, PN; Trepel, JB; Yardley, DA, 2013)	2.05
"Entinostat is a histone deacetylase inhibitor that has been combined with AZA with significant clinical activity in a previous phase I dose finding study."	( Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. Czader, M; Erba, HP; Figueroa, ME; Gabrilove, J; Gore, SD; Greenberg, PL; Herman, J; Juckett, M; Ketterling, R; Litzow, M; Malick, L; Melnick, A; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS, 2014)	1.37
"Entinostat is an orally bioavailable class I HDAC inhibitor with a long half-life, which is under evaluation in haematological and solid tumour malignancies."	( Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Barth, MJ; Czuczman, MS; Frys, S; Gu, JJ; Hernandez-Ilizaliturri, FJ; Hu, Q; Mavis, C; Simons, Z; Skitzki, J; Song, L, 2015)	2.58
"Entinostat is a selective HDAC inhibitor that has shown anti-neoplastic activity and tolerability in hematologic and solid tumors, including lung cancer."	( Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. Raez, LE; Rolfo, C; Ruiz, R, 2015)	2.58
"Entinostat is an emerging HDACi that has shown promise in multiple preclinical studies."	( Entinostat for treatment of solid tumors and hematologic malignancies. Gore, L; Knipstein, J, 2011)	2.53
"Entinostat is a well-tolerated HDACi that demonstrates promising therapeutic potential in both solid and hematologic malignancies. "	( Entinostat for treatment of solid tumors and hematologic malignancies. Gore, L; Knipstein, J, 2011)	3.25

Excerpt	Reference	Relevance
"Entinostat treatment changed the expression of genes involved in 22 pathways, including downregulation of DNA damage response. "	( Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells. Ecker, J; Hielscher, T; Jamaladdin, N; Milde, T; Oehme, I; Peterziel, H; Ridinger, J; Valinciute, G; van Tilburg, CM; Vollmer, J; Witt, O, 2023)	2.35
"Entinostat treatment significantly reduced the number of degenerating neurons and TUNEL-positive cells after ICH in comparison to vehicle-treated controls."	( Entinostat improves acute neurological outcomes and attenuates hematoma volume after Intracerebral Hemorrhage. Bonsack, F; Sukumari-Ramesh, S, 2021)	2.79
"Entinostat treatment decreased the growth of both subcutaneously and omental ID8 tumors and prolonged survival in immunocompetent C57BL/6 mice. "	( The antitumor effects of entinostat in ovarian cancer require adaptive immunity. Arend, RC; Buchsbaum, DJ; Forero, A; Katre, AA; Londono, AI; McCaw, TR; Meza-Perez, S; Norian, LA; Randall, TD; Smith, HJ; Straughn, JM; Yang, ES, 2018)	2.23
"Entinostat treatment partially restored KCNH2 and Cav1.3 gene expressions in failing hearts, and inhibited the development of cardiac fibrosis in vivo."	( Histone deacetylase inhibition by Entinostat for the prevention of electrical and structural remodeling in heart failure. Eckardt, L; Freundt, JK; Frommeyer, G; Grotthoff, JS; Hempel, G; Jacobs, AH; Lange, PS; Schäfers, M; Spieker, T; Stypmann, J; Wötzel, F, 2019)	1.51
"Entinostat treatment reduced the association of the Her-2 protein with HSP-90, possibly by reducing the stability of Her-2 protein."	( HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Brodie, AH; Goloubeva, OG; Kazi, AA; Sabnis, GJ; Shah, P, 2013)	1.46
"Entinostat pretreatment of colon carcinoma and sarcoma cells, NK cells, or both led to enhanced overall cytotoxicity in vitro, which was reversed by NKG2D blockade, and inhibited growth of tumor xenografts."	( The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Cobanoglu, ZS; Denman, CJ; Gottschalk, SM; Hughes, DP; Kiany, S; Kleinerman, ES; Lau, CC; Lee, DA; Zhu, S, 2015)	1.42
"Entinostat treatment was able to reduce the CD44(high)/CD24(low) cell population, ALDH-1 activity, as well as protein and mRNA expression of known TIC markers such as Bmi-1, Nanog, and Oct-4."	( Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells. Kazi, A; Sabnis, G; Schech, A; Shah, P; Yu, S, 2015)	1.43
"Entinostat treatment altered cell cycle progression, resulting in a significant increase in the fraction of cells present in the G0/G1 phase at low micromolar concentrations."	( The histone deacetylase inhibitor Entinostat enhances polymer-mediated transgene expression in cancer cell lines. Barua, S; Christensen, MD; Elmer, JJ; Haynes, KA; Lehrman, J; Rege, K, 2016)	1.43
"Entinostat treatment leads to upregulation of Cathepsin L1, and the HLA-DR peptidome of the Entinostat treated cells is consistent with increased Cathepsin L1 mediated proteolysis."	( Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Blanck, G; Cronin, K; Delgado, JC; Escobar, H; Lloyd, MC; Reyes-Vargas, E; Rockwood, AL; Szekeres, K, 2013)	1.11
"Treatment with entinostat and azacytidine of ID8 cells in vitro increased mRNA levels of Cd74, Ciita, and H2-Aa, H2-Eb1."	( Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. Arend, RC; Buchsbaum, DJ; Forero, A; Katre, A; Londoño, A; Meza-Perez, S; Norian, LA; Peabody, JE; Randall, TD; Smith, HJ; Straughn, JM; Turner, TB, 2017)	0.79
"Treatment with entinostat had no effect on erbB2/erbB3 mRNA, suggesting a transcription-independent mechanism."	( Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Huang, J; Lee, CK; Liu, B; Lyu, H; Tan, J; Wang, J; Wang, S, 2013)	0.97
"Treatment with entinostat significantly reduced tumor formation at the primary site as well as lung metastasis."	( Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells. Kazi, A; Sabnis, G; Schech, A; Shah, P; Yu, S, 2015)	1.05

Excerpt	Reference	Relevance
" Histone deacetylase inhibitors (HDACi) at high concentrations inhibit tumor growth and can increase NKG2D ligand expression on tumor targets, but are widely regarded as toxic to NK cells."	( The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells. Cobanoglu, ZS; Denman, CJ; Gottschalk, SM; Hughes, DP; Kiany, S; Kleinerman, ES; Lau, CC; Lee, DA; Zhu, S, 2015)	0.69
"These results suggest that epigenetic changes at the striatal Drd2 promoter drive age-related increases in antipsychotic side effect susceptibility, and HDAC inhibitors may be an effective adjunct treatment strategy to reduce side effects in aged populations."	( Histone deacetylase inhibitors reverse age-related increases in side effects of haloperidol in mice. Csernansky, JG; Dong, H; Fang, D; Fisher, DW; Montalvo-Ortiz, JL; Rodríguez, G, 2017)	0.46

Excerpt	Reference	Relevance
"The objective of this study was to define the maximum-tolerated dose (MTD), the recommended phase II dose, the dose-limiting toxicity, and determine the pharmacokinetic (PK) and pharmacodynamic profiles of MS-275."	( Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. Acharya, M; Chung, EJ; Elsayed, Y; Figg, WD; Headlee, D; Hwang, K; Kalnitskiy, M; Melillo, G; Monga, M; Murgo, A; Ryan, QC; Sausville, EA; Sparreboom, A; Trepel, JB; Ye, J; Zwiebel, J, 2005)	0.33
" Preliminary PK analysis suggested the half-life of MS-275 in humans was 39 to 80 hours, substantially longer than predicted by preclinical studies."	( Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. Acharya, M; Chung, EJ; Elsayed, Y; Figg, WD; Headlee, D; Hwang, K; Kalnitskiy, M; Melillo, G; Monga, M; Murgo, A; Ryan, QC; Sausville, EA; Sparreboom, A; Trepel, JB; Ye, J; Zwiebel, J, 2005)	0.33
" The aim of this study was to develop a versatile and sensitive technique for the pharmacodynamic (PD) assessment of HDAC inhibitor activity as monotherapy and in combination therapy."	( Histone deacetylase inhibitor pharmacodynamic analysis by multiparameter flow cytometry. Chung, EJ; Gojo, I; Karp, JE; Kong, HS; Lee, MJ; Lee, S; Ryan, Q; Sausville, EA; Telford, WG; Trepel, JB, 2005)	0.33
" In vivo pharmacokinetic data were obtained from 64 adult patients (36 male/28 female; median age, 57 years) receiving MS-275 orally (dose range, 2 to 12 mg/m2)."	( Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Acharya, MR; Figg, WD; Gojo, I; Hwang, K; Karp, JE; Ryan, Q; Sausville, EA; Sparreboom, A; Venitz, J, 2006)	0.33
" Pharmacokinetic variables revealed dose-dependent and dose-proportional increases."	( A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Coffin, D; Eckhardt, SG; Gore, L; McCoy, C; O'Bryant, CL; Rothenberg, ML; Sandler, AB; Scholz, C; Schott, A; Schultz, MK, 2008)	0.35
" It possesses optimized pharmacokinetic properties in preclinical species, has a clean off-target profile, and is negative in a microbial mutagenicity (Ames) test."	( Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties. Fiore, F; Fonsi, M; Gonzalez Paz, O; Jones, P; Kinzel, O; Llauger-Bufi, L; Monteagudo, E; Pescatore, G; Rowley, M; Schultz-Fademrecht, C; Steinkühler, C, 2009)	0.35
"Herein, we describe the pharmacokinetic optimization of a series of class-selective histone deacetylase (HDAC) inhibitors and the subsequent identification of candidate predictive biomarkers of hepatocellular carcinoma (HCC) tumor response for our clinical lead using patient-derived HCC tumor xenograft models."	( Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response. Cai, J; Chen, D; Chen, J; Chen, L; Chen, T; Feng, L; Guo, L; He, Y; Ji, Y; Jin, TG; Li, S; Liang, C; Lin, X; Liu, Y; Lu, X; Mei, J; Ning, Z; Pan, D; Pan, S; Peng, Z; Ren, S; Ren, Y; Rong, Y; Shan, S; She, J; Tang, G; Wang, Z; Wong, JC; Wu, X; Xu, C; Zhang, C; Zhang, M; Zhang, N; Zhang, W; Zhang, X; Zhang, Z; Zhao, R; Zhao, W; Zhou, M, 2012)	0.38
" This study examined whether oral administration of MS-275 to the rats with lapatinib led to any pharmacokinetic interactions."	( Pharmacokinetic interaction of entinostat and lapatinib following single and co-oral administration in rats. Chen, M; Hu, L; Yang, X; Zhang, Q, 2014)	0.69

Excerpt	Reference	Relevance
"To investigate the antiproliferative effect of the histone deacetylase (HDAC) inhibitor MS-275 on cholangiocarcinoma cells alone and in combination with conventional cytostatic drugs (gemcitabine or doxorubicin) or the novel anticancer agents sorafenib or bortezomib."	( Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007)	0.34
" Furthermore, additive anti-neoplastic effects were observed when MS-275 treatment was combined with gemcitabine or doxorubicin, while combination with the multi-kinase inhibitor sorafenib or the proteasome inhibitor bortezomib resulted in overadditive anti-neoplastic effects."	( Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007)	0.34
"The growth of human cholangiocarcinoma cells can be potently inhibited by MS-275 alone or in combination with conventional cytostatic drugs or new, targeted anticancer agents."	( Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007)	0.34
" These results demonstrate that compound 2 and its combination with SAHA are potentially useful agents that warrant further preclinical development for treatment of prostate cancer."	( Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Belosay, A; Gediya, LK; Khandelwal, A; Njar, VC; Purushottamachar, P, 2008)	0.35
" The objective of this study was to determine the safety, tolerability, and the pharmacokinetic (PK)/pharmacodynamic (PD) profiles of the HDAC inhibitor entinostat in combination with 13-cis retinoic acid (CRA) in patients with solid tumours."	( Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Altiok, S; Carducci, MA; Pili, R; Qian, D; Rudek, MA; Salumbides, B; Zhao, M; Zwiebel, J, 2012)	0.83
" Entinostat 10 mg orally once every 2 weeks in combination with sorafenib 400 mg orally twice daily, representing full single agent doses of each drug was identified as the recommended phase 2 dose (RP2D)."	( A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Adjei, AA; Brady, W; DePaolo, D; Ding, Y; Dy, GK; Fetterly, G; Ma, WW; Ngamphaiboon, N; Reungwetwattana, T; Zhao, Y, 2015)	1.57
" Subsequently, we demonstrated Entinostat (HDAC1 inhibitor) combination with Fludarabine significantly induced apoptosis in TP53 mutations CLL cells."	( Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1/HO-1 pathway. Chen, B; Fang, Q; He, Z; Li, P; Ma, D; Ren, M; Wang, J; Zhe, N; Zhong, Q; Zhou, Z, 2019)	2.24
" This study aimed to evaluate the anticancer effects of MS-275 combined with DDP on ESCC cell line EC9706 both in vitro and in vivo, and to investigate the possible mechanisms that mediate these effects."	( MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells. Cui, Y; Guan, F; Li, Y; Li, Z; Liu, H; Liu, T; Ma, S; Wang, Y; Zhang, Y; Zhang, Z, 2020)	0.56
"Entinostat at the selected dose levels in combination with a standard dose of enzalutamide showed a promising safety profile in this small phase I study BACKGROUND: Entinostat inhibits prostate cancer (PCa) growth and suppresses Treg cell function in vitro and in vivo."	( Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. Burgess, B; Elkon, J; Lin, J; Ma, Y; Noonepalle, S; Palmer, E; Ricart, B; Siegel, R; Villagra, A; Zevallos-Delgado, C, 2021)	2.4
"This was a phase I study to explore the safety and preliminary efficacy of entinostat (3 and 5 mg orally per week) in combination with enzalutamide in castration resistant PCa (CRPC)."	( Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. Burgess, B; Elkon, J; Lin, J; Ma, Y; Noonepalle, S; Palmer, E; Ricart, B; Siegel, R; Villagra, A; Zevallos-Delgado, C, 2021)	1.19
"Entinostat 5 mg weekly in combination with enzalutamide showed an acceptable safety profile in this small phase I study."	( Phase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. Burgess, B; Elkon, J; Lin, J; Ma, Y; Noonepalle, S; Palmer, E; Ricart, B; Siegel, R; Villagra, A; Zevallos-Delgado, C, 2021)	2.4

Excerpt	Reference	Relevance
"New orally bioavailable 5-(thiophen-2-yl)-substituted 2-aminobenzamide-series histone deacetylase inhibitors were synthesized."	( Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain. Baba, K; Hirata, M; Hirata, Y; Kawaratani, Y; Nagaoka, Y; Ohmomo, Y; Shibano, M; Taniguchi, M; Uesato, S; Yasuda, M, 2012)	0.38
" Through a combination of conformational constraint and scaffold hopping, we lowered the in vivo clearance (CL) and significantly improved the bioavailability (F) and exposure (AUC) of our HDAC inhibitors while maintaining selectivity toward the class I HDAC family with particular potency against HDAC1, resulting in clinical lead 5 (HDAC1 IC₅₀ = 60 nM, mouse CL = 39 mL/min/kg, mouse F = 100%, mouse AUC after single oral dose at 10 mg/kg = 6316 h·ng/mL)."	( Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response. Cai, J; Chen, D; Chen, J; Chen, L; Chen, T; Feng, L; Guo, L; He, Y; Ji, Y; Jin, TG; Li, S; Liang, C; Lin, X; Liu, Y; Lu, X; Mei, J; Ning, Z; Pan, D; Pan, S; Peng, Z; Ren, S; Ren, Y; Rong, Y; Shan, S; She, J; Tang, G; Wang, Z; Wong, JC; Wu, X; Xu, C; Zhang, C; Zhang, M; Zhang, N; Zhang, W; Zhang, X; Zhang, Z; Zhao, R; Zhao, W; Zhou, M, 2012)	0.38
" The subcutaneous dosing route for consecutive days and reduced bioavailability of 5-azacytidine because of inactivation by cytidine deaminase may limit the expansion of epigenetic therapy into Phase III trials."	( Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Belinsky, SA; Cheng, YS; Grimes, MJ; Kuehl, PJ; March, TH; Picchi, MA; Reed, MD; Tellez, CS; Tessema, M, 2013)	0.39
" Entinostat is an orally bioavailable class I HDAC inhibitor with a long half-life, which is under evaluation in haematological and solid tumour malignancies."	( Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Barth, MJ; Czuczman, MS; Frys, S; Gu, JJ; Hernandez-Ilizaliturri, FJ; Hu, Q; Mavis, C; Simons, Z; Skitzki, J; Song, L, 2015)	2.77
" What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model."	( Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. Chou, CJ; Huang, Y; Jia, Y; Li, X; Liang, X; Xu, W; Zang, J; Zhang, Y, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Importantly, in vivo preclinical studies showed that 009P1 and 009P2 dramatically suppressed KSHV+ lymphoma progression with oral bioavailability and minimal visible toxicity."	( Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas. Chen, J; Chen, Z; Dai, L; Kendrick, S; Li, HY; Lin, Z; Phuc, T; Qin, Z; Wang, Z; Xu, Z; Yang, D, 2023)	0.91

Excerpt	Relevance	Reference
" Based on PK data from the q14-day schedule, a more frequent dosing schedule, weekly x 4, repeated every 6 weeks is presently being evaluated."	( Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. Acharya, M; Chung, EJ; Elsayed, Y; Figg, WD; Headlee, D; Hwang, K; Kalnitskiy, M; Melillo, G; Monga, M; Murgo, A; Ryan, QC; Sausville, EA; Sparreboom, A; Trepel, JB; Ye, J; Zwiebel, J, 2005)	0.33
" Furthermore, MS-275 can be added to the list of cancer drugs where BSA-based dosing is not more accurate than fixed dosing."	( Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Acharya, MR; Figg, WD; Gojo, I; Hwang, K; Karp, JE; Ryan, Q; Sausville, EA; Sparreboom, A; Venitz, J, 2006)	0.33
" A dose-response relationship was observed between the parameter k2 in this formula and the concentration of the cytotoxic agent etoposide, in high-grade glioma cells was independent of incubation time."	( Measuring cytotoxicity: a new perspective on LC50. Aguilera, D; Das, C; Gopalakrishnan, V; Vasquez, H; Wolff, J; Zage, P; Zhang, M, )	0.13
"To evaluate the toxicity profile, pharmacologic, and biological properties of 3-pyridylmethyl N-{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate (MS-275), a histone deacetylase inhibitor, when administered orally on three different dosing schedules."	( A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Coffin, D; Eckhardt, SG; Gore, L; McCoy, C; O'Bryant, CL; Rothenberg, ML; Sandler, AB; Scholz, C; Schott, A; Schultz, MK, 2008)	0.35
" Hypophosphatemia and asthenia were dose limiting on the weekly and twice-weekly dosing schedules; there was no dose-limiting toxicity on the every other week schedule."	( A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Coffin, D; Eckhardt, SG; Gore, L; McCoy, C; O'Bryant, CL; Rothenberg, ML; Sandler, AB; Scholz, C; Schott, A; Schultz, MK, 2008)	0.35
" Twice-weekly dosing was not tolerable due to asthenia, and further evaluation of this schedule was halted."	( A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Coffin, D; Eckhardt, SG; Gore, L; McCoy, C; O'Bryant, CL; Rothenberg, ML; Sandler, AB; Scholz, C; Schott, A; Schultz, MK, 2008)	0.35
" The subcutaneous dosing route for consecutive days and reduced bioavailability of 5-azacytidine because of inactivation by cytidine deaminase may limit the expansion of epigenetic therapy into Phase III trials."	( Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model. Belinsky, SA; Cheng, YS; Grimes, MJ; Kuehl, PJ; March, TH; Picchi, MA; Reed, MD; Tellez, CS; Tessema, M, 2013)	0.39
" Delayed dosing did not reduce adhesions."	( Histone deacetylase inhibitors decrease intra-abdominal adhesions with one intraoperative dose by reducing peritoneal fibrin deposition pathways. Cassidy, MR; Gainsbury, ML; Heydrick, S; Sheldon, HK; Sherburne, AC; Stucchi, AF, 2014)	0.4
" A single, intraoperative intervention provides an ideal dosing strategy and indicates an exciting new role for HDACIs in adhesion prevention."	( Histone deacetylase inhibitors decrease intra-abdominal adhesions with one intraoperative dose by reducing peritoneal fibrin deposition pathways. Cassidy, MR; Gainsbury, ML; Heydrick, S; Sheldon, HK; Sherburne, AC; Stucchi, AF, 2014)	0.4
" However, the prolonged administration of AZA by itself seems to increase HN rate compared with standard dosing and warrants additional investigation."	( Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. Czader, M; Erba, HP; Figueroa, ME; Gabrilove, J; Gore, SD; Greenberg, PL; Herman, J; Juckett, M; Ketterling, R; Litzow, M; Malick, L; Melnick, A; Paietta, E; Prebet, T; Smith, MR; Sun, Z; Tallman, MS, 2014)	0.65
" Additionally, the dose-response curve test indicated that MS-275 has a U-shape effect on ethanol self-administration with the dose of 500 µM as the most efficient dose."	( The Class I-Specific HDAC Inhibitor MS-275 Decreases Motivation to Consume Alcohol and Relapse in Heavy Drinking Rats. Alaux-Cantin, S; Jeanblanc, J; Jeanblanc, V; Lemoine, S; Naassila, M, 2015)	0.42
" The N-hydroxyl group of this motif is highly subject to sulfation/glucoronidation-based inactivation in humans; compounds containing this motif require much higher dosing in clinic to achieve therapeutic concentrations."	( Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia. Chou, CJ; Inks, ES; Li, J; McClure, JJ; Peterson, YK; Zhang, C, 2016)	0.43

Role	Description
EC 3.5.1.98 (histone deacetylase) inhibitor	An EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the function of histone deacetylase (EC 3.5.1.98).
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducer	Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
benzamides
pyridines	Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
carbamate ester	Any ester of carbamic acid or its N-substituted derivatives.
substituted aniline
primary amino compound	A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATAD5 protein, partial	Homo sapiens (human)	Potency	9.3169	0.0041	10.8903	31.5287	AID624247; AID624252; AID686934; AID720565
PPM1D protein	Homo sapiens (human)	Potency	5.2300	0.0052	9.4661	32.9993	AID1347411
EWS/FLI fusion protein	Homo sapiens (human)	Potency	3.9273	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	Homo sapiens (human)	Potency	1.9953	0.0165	25.3078	41.3999	AID602332
tyrosine-protein kinase Yes	Homo sapiens (human)	Potency	15.4103	0.0000	5.0182	79.2586	AID686947
Interferon beta	Homo sapiens (human)	Potency	5.2300	0.0033	9.1582	39.8107	AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histone deacetylase 8	Schistosoma mansoni	IC50 (µMol)	30.0000	0.3034	1.3350	3.6200	AID1446915
Histone deacetylase 3	Homo sapiens (human)	IC50 (µMol)	3.4838	0.0004	0.6196	10.0000	AID1263144; AID1280295; AID1293874; AID1293875; AID1294943; AID1340801; AID1380938; AID1380954; AID1403456; AID1408543; AID1453365; AID1525779; AID1541444; AID1548728; AID1556401; AID1596080; AID1691039; AID1732165; AID1737648; AID1740014; AID1797850; AID1798524; AID1798526; AID1802398; AID1846973; AID1864216; AID1865258; AID1881855; AID1882461; AID1901146; AID1901148; AID1917928; AID292436; AID294382; AID313731; AID316888; AID316931; AID324949; AID328795; AID364648; AID374818; AID421212; AID488275; AID525002; AID551597; AID622254; AID664380; AID717827; AID748112; AID90208; AID90211; AID90529
Histone deacetylase 3	Homo sapiens (human)	Ki	0.7300	0.0002	0.4237	8.1900	AID1873437; AID1873440; AID1873449; AID1873480; AID496803
Bromodomain-containing protein 4	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0004	0.4032	9.0500	AID1727731; AID1727732
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	0.7300	0.0001	1.7536	10.0000	AID609494
Leukotriene A-4 hydrolase	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0005	1.2854	7.6500	AID1441630; AID1441631
Androgen receptor	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0000	0.8753	10.0000	AID1888465
Tissue factor	Homo sapiens (human)	IC50 (µMol)	8.0000	0.0001	0.7344	10.0000	AID360094; AID360095
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	3.9300	0.0000	2.3983	10.0000	AID1401904
Histone deacetylase 4	Homo sapiens (human)	IC50 (µMol)	11.4980	0.0006	1.0526	10.0000	AID1293874; AID1293875; AID1294943; AID1340801; AID1380938; AID1466062; AID1548733; AID1578487; AID1596080; AID1737649; AID1740016; AID1798524; AID1798526; AID1802398; AID1864216; AID1865258; AID1901148; AID1901156; AID292436; AID294382; AID313732; AID316888; AID328796; AID328797; AID329915; AID364648; AID385685; AID385686; AID421212; AID525000; AID622254; AID664382; AID717827; AID764213; AID90208; AID90211; AID90529
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	30.0000	0.0009	1.9014	10.0000	AID609493; AID613341
Histone deacetylase 1	Homo sapiens (human)	IC50 (µMol)	2.5019	0.0001	0.5543	9.9000	AID1203889; AID1231807; AID1235132; AID1280294; AID1293874; AID1293875; AID1294943; AID1308513; AID1340801; AID1380938; AID1380952; AID1401902; AID1403454; AID1453363; AID1466061; AID1474461; AID1486677; AID1525777; AID1541446; AID1548244; AID1548726; AID1556399; AID1578485; AID1586077; AID1596049; AID1596080; AID1691037; AID1727729; AID1732163; AID1737644; AID1740012; AID1797850; AID1798524; AID1798526; AID1802398; AID1846972; AID1864216; AID1865258; AID1879890; AID1881853; AID1882460; AID1888466; AID1901147; AID1901148; AID1915537; AID1915555; AID1917926; AID274110; AID292436; AID294382; AID303014; AID313729; AID316888; AID316892; AID316896; AID324948; AID328793; AID329914; AID364648; AID374811; AID420324; AID421212; AID488273; AID488358; AID525003; AID538408; AID551595; AID609489; AID622254; AID650229; AID664039; AID664379; AID670719; AID717827; AID748114; AID764214; AID90208; AID90211; AID90347; AID90348; AID90529; AID90666
Histone deacetylase 1	Homo sapiens (human)	Ki	0.3060	0.0000	0.4988	8.1900	AID1873442; AID496801
Histone deacetylase-like amidohydrolase	Alcaligenaceae bacterium FB188	IC50 (µMol)	118.0000	1.0000	1.1000	1.2000	AID420319
Histone deacetylase-like amidohydrolase	Alcaligenaceae bacterium FB188	Ki	100.0000	0.7000	3.0500	9.2000	AID420317
Histone deacetylase 7	Homo sapiens (human)	IC50 (µMol)	9.5417	0.0007	1.0260	9.9000	AID1293874; AID1293875; AID1294943; AID1340801; AID1380938; AID1548735; AID1578489; AID1596080; AID1737651; AID1740017; AID1798524; AID1802398; AID1846975; AID1864216; AID1865258; AID1901148; AID292436; AID294382; AID313735; AID316888; AID328800; AID364648; AID374821; AID421212; AID524997; AID622254; AID717827; AID90208; AID90211; AID90529
Histone deacetylase 2	Homo sapiens (human)	IC50 (µMol)	3.3769	0.0001	0.7221	9.9700	AID1203890; AID1231808; AID1293874; AID1293875; AID1294943; AID1340801; AID1380938; AID1380953; AID1401903; AID1403455; AID1453364; AID1466055; AID1486678; AID1541445; AID1548244; AID1548727; AID1556400; AID1578486; AID1586078; AID1596050; AID1596080; AID1691038; AID1732164; AID1737645; AID1740013; AID1797850; AID1798524; AID1802398; AID1864216; AID1865258; AID1881854; AID1901148; AID1917927; AID292436; AID294382; AID303015; AID313730; AID316888; AID328794; AID364648; AID374817; AID421212; AID488274; AID525001; AID551596; AID622254; AID650228; AID670720; AID717827; AID748113; AID90208; AID90211; AID90347; AID90529
Histone deacetylase 2	Homo sapiens (human)	Ki	0.1835	0.0000	0.4709	8.1900	AID1873438; AID1873441; AID1873450; AID496802
Polyamine deacetylase HDAC10	Homo sapiens (human)	IC50 (µMol)	6.7189	0.0005	0.7245	9.9000	AID1293874; AID1293875; AID1294943; AID1340801; AID1380938; AID1578491; AID1596080; AID1732167; AID1737653; AID1802398; AID1864216; AID1865258; AID1901148; AID292436; AID294382; AID316888; AID364648; AID421212; AID524995; AID622254; AID664384; AID717827; AID90208; AID90211; AID90529
Histone deacetylase 11	Homo sapiens (human)	IC50 (µMol)	4.1865	0.0003	0.9298	9.9000	AID1293874; AID1293875; AID1294943; AID1340801; AID1380938; AID1467234; AID1467241; AID1596080; AID1864216; AID1865258; AID1901148; AID292436; AID294382; AID316888; AID364648; AID421212; AID622254; AID717827; AID90208; AID90211; AID90529
NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0060	1.6250	9.0000	AID664385
Histone deacetylase 8	Homo sapiens (human)	IC50 (µMol)	9.0640	0.0007	0.9947	9.9000	AID1203891; AID1231809; AID1280297; AID1293874; AID1293875; AID1294943; AID1340801; AID1380938; AID1466064; AID1548732; AID1586083; AID1596080; AID1691040; AID1732166; AID1737647; AID1740015; AID1797850; AID1798524; AID1802398; AID1846976; AID1864216; AID1865258; AID1879896; AID1901148; AID1901154; AID292436; AID294382; AID313736; AID316888; AID316893; AID328801; AID364648; AID374822; AID421212; AID488277; AID524996; AID622254; AID664381; AID717827; AID90208; AID90211; AID90529
Histone deacetylase 6	Homo sapiens (human)	IC50 (µMol)	16.4399	0.0000	0.5376	9.9000	AID1280296; AID1293874; AID1293875; AID1294943; AID1340801; AID1380938; AID1401904; AID1466063; AID1541443; AID1586081; AID1596034; AID1596080; AID1727730; AID1737646; AID1740019; AID1798524; AID1798526; AID1802398; AID1846974; AID1864216; AID1865258; AID1879893; AID1882459; AID1901145; AID1901148; AID292436; AID294382; AID313734; AID316888; AID316899; AID328799; AID364648; AID374820; AID421212; AID488276; AID524999; AID538409; AID622254; AID664383; AID717827; AID764212; AID90208; AID90211; AID90529
Histone deacetylase 9	Homo sapiens (human)	IC50 (µMol)	8.2189	0.0005	0.9413	9.9000	AID1293874; AID1293875; AID1294943; AID1340801; AID1380938; AID1548736; AID1578490; AID1596080; AID1737652; AID1740018; AID1802398; AID1864216; AID1865258; AID1901148; AID292436; AID294382; AID316888; AID364648; AID421212; AID524994; AID622254; AID717827; AID90208; AID90211; AID90529
Histone deacetylase 5	Homo sapiens (human)	IC50 (µMol)	6.9528	0.0007	0.9610	10.0000	AID1293874; AID1293875; AID1294943; AID1340801; AID1380938; AID1548734; AID1578488; AID1596080; AID1737650; AID1798524; AID1802398; AID1864216; AID1865258; AID1901148; AID292436; AID294382; AID313733; AID316888; AID328798; AID364648; AID374819; AID421212; AID524998; AID622254; AID717827; AID90208; AID90211; AID90529
Histone deacetylase	Plasmodium falciparum (malaria parasite P. falciparum)	IC50 (µMol)	0.9400	0.0006	0.1688	0.9400	AID414980
Nuclear receptor corepressor 2	Homo sapiens (human)	IC50 (µMol)	1.1850	0.0017	0.5952	8.0000	AID1408543; AID1541444; AID1548728; AID1556401; AID1691039; AID1901146
Nuclear receptor corepressor 2	Homo sapiens (human)	Ki	0.8225	0.0003	0.3325	3.2000	AID1873437; AID1873440; AID1873449; AID1873480
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Histone deacetylase 3	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0300	1.8512	6.7000	AID93030
Histone deacetylase 4	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0300	2.3523	6.7000	AID93030
Histone deacetylase 1	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0300	1.9877	6.7000	AID316943; AID93030
Histone deacetylase 1	Homo sapiens (human)	Kd	0.2190	0.0121	0.1049	0.2820	AID1802399
Histone deacetylase 7	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0300	2.3211	6.7000	AID93030
Histone deacetylase 2	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0300	1.8575	6.7000	AID93030
Histone deacetylase 2	Homo sapiens (human)	Kd	0.2190	0.0121	0.1130	0.2820	AID1802399
Polyamine deacetylase HDAC10	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0300	2.5465	6.7000	AID93030
Histone deacetylase 11	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0300	2.5465	6.7000	AID93030
Histone deacetylase 8	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0300	2.2734	6.7000	AID93030
Histone deacetylase 6	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0052	1.5998	6.7000	AID93030
Histone deacetylase 9	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0300	2.3266	6.7000	AID93030
Histone deacetylase 5	Homo sapiens (human)	EC50 (µMol)	1.0000	0.0300	2.5465	6.7000	AID93030
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
negative regulation of myotube differentiation	Histone deacetylase 3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
establishment of mitotic spindle orientation	Histone deacetylase 3	Homo sapiens (human)
in utero embryonic development	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein phosphorylation	Histone deacetylase 3	Homo sapiens (human)
chromatin organization	Histone deacetylase 3	Homo sapiens (human)
transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
protein deacetylation	Histone deacetylase 3	Homo sapiens (human)
regulation of mitotic cell cycle	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein ubiquitination	Histone deacetylase 3	Homo sapiens (human)
regulation of protein stability	Histone deacetylase 3	Homo sapiens (human)
positive regulation of TOR signaling	Histone deacetylase 3	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 3	Homo sapiens (human)
regulation of multicellular organism growth	Histone deacetylase 3	Homo sapiens (human)
positive regulation of protein import into nucleus	Histone deacetylase 3	Homo sapiens (human)
regulation of circadian rhythm	Histone deacetylase 3	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 3	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 3	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 3	Homo sapiens (human)
negative regulation of JNK cascade	Histone deacetylase 3	Homo sapiens (human)
spindle assembly	Histone deacetylase 3	Homo sapiens (human)
establishment of skin barrier	Histone deacetylase 3	Homo sapiens (human)
cellular response to fluid shear stress	Histone deacetylase 3	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Histone deacetylase 3	Homo sapiens (human)
DNA repair-dependent chromatin remodeling	Histone deacetylase 3	Homo sapiens (human)
cornified envelope assembly	Histone deacetylase 3	Homo sapiens (human)
negative regulation of cardiac muscle cell differentiation	Histone deacetylase 3	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 3	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
chromatin organization	Bromodomain-containing protein 4	Homo sapiens (human)
DNA damage response	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of DNA-templated transcription	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Bromodomain-containing protein 4	Homo sapiens (human)
regulation of inflammatory response	Bromodomain-containing protein 4	Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitment	Bromodomain-containing protein 4	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
proteolysis	Leukotriene A-4 hydrolase	Homo sapiens (human)
lipid metabolic process	Leukotriene A-4 hydrolase	Homo sapiens (human)
response to zinc ion	Leukotriene A-4 hydrolase	Homo sapiens (human)
leukotriene biosynthetic process	Leukotriene A-4 hydrolase	Homo sapiens (human)
protein metabolic process	Leukotriene A-4 hydrolase	Homo sapiens (human)
peptide catabolic process	Leukotriene A-4 hydrolase	Homo sapiens (human)
response to peptide hormone	Leukotriene A-4 hydrolase	Homo sapiens (human)
type I pneumocyte differentiation	Leukotriene A-4 hydrolase	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
MAPK cascade	Androgen receptor	Homo sapiens (human)
in utero embryonic development	Androgen receptor	Homo sapiens (human)
regulation of systemic arterial blood pressure	Androgen receptor	Homo sapiens (human)
epithelial cell morphogenesis	Androgen receptor	Homo sapiens (human)
transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
signal transduction	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Androgen receptor	Homo sapiens (human)
cell-cell signaling	Androgen receptor	Homo sapiens (human)
spermatogenesis	Androgen receptor	Homo sapiens (human)
single fertilization	Androgen receptor	Homo sapiens (human)
positive regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of gene expression	Androgen receptor	Homo sapiens (human)
male somatic sex determination	Androgen receptor	Homo sapiens (human)
intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
intracellular receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of intracellular estrogen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
Leydig cell differentiation	Androgen receptor	Homo sapiens (human)
multicellular organism growth	Androgen receptor	Homo sapiens (human)
positive regulation of phosphorylation	Androgen receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Androgen receptor	Homo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of cell differentiation	Androgen receptor	Homo sapiens (human)
negative regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of integrin biosynthetic process	Androgen receptor	Homo sapiens (human)
positive regulation of DNA-templated transcription	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Androgen receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase III	Androgen receptor	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Androgen receptor	Homo sapiens (human)
regulation of developmental growth	Androgen receptor	Homo sapiens (human)
animal organ formation	Androgen receptor	Homo sapiens (human)
male genitalia morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
negative regulation of epithelial cell proliferation	Androgen receptor	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Androgen receptor	Homo sapiens (human)
activation of prostate induction by androgen receptor signaling pathway	Androgen receptor	Homo sapiens (human)
morphogenesis of an epithelial fold	Androgen receptor	Homo sapiens (human)
lateral sprouting involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
prostate gland growth	Androgen receptor	Homo sapiens (human)
prostate gland epithelium morphogenesis	Androgen receptor	Homo sapiens (human)
epithelial cell differentiation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
tertiary branching involved in mammary gland duct morphogenesis	Androgen receptor	Homo sapiens (human)
mammary gland alveolus development	Androgen receptor	Homo sapiens (human)
positive regulation of epithelial cell proliferation involved in prostate gland development	Androgen receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Androgen receptor	Homo sapiens (human)
cellular response to estrogen stimulus	Androgen receptor	Homo sapiens (human)
cellular response to testosterone stimulus	Androgen receptor	Homo sapiens (human)
seminiferous tubule development	Androgen receptor	Homo sapiens (human)
non-membrane-bounded organelle assembly	Androgen receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Androgen receptor	Homo sapiens (human)
regulation of protein localization to plasma membrane	Androgen receptor	Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway	Androgen receptor	Homo sapiens (human)
male gonad development	Androgen receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Androgen receptor	Homo sapiens (human)
positive regulation of gene expression	Tissue factor	Homo sapiens (human)
positive regulation of interleukin-8 production	Tissue factor	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Tissue factor	Homo sapiens (human)
activation of plasma proteins involved in acute inflammatory response	Tissue factor	Homo sapiens (human)
activation of blood coagulation via clotting cascade	Tissue factor	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	Tissue factor	Homo sapiens (human)
blood coagulation	Tissue factor	Homo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathway	Tissue factor	Homo sapiens (human)
protein processing	Tissue factor	Homo sapiens (human)
positive regulation of cell migration	Tissue factor	Homo sapiens (human)
positive regulation of TOR signaling	Tissue factor	Homo sapiens (human)
positive regulation of angiogenesis	Tissue factor	Homo sapiens (human)
positive regulation of positive chemotaxis	Tissue factor	Homo sapiens (human)
cytokine-mediated signaling pathway	Tissue factor	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 4	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 4	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 4	Homo sapiens (human)
protein deacetylation	Histone deacetylase 4	Homo sapiens (human)
inflammatory response	Histone deacetylase 4	Homo sapiens (human)
nervous system development	Histone deacetylase 4	Homo sapiens (human)
positive regulation of cell population proliferation	Histone deacetylase 4	Homo sapiens (human)
negative regulation of myotube differentiation	Histone deacetylase 4	Homo sapiens (human)
negative regulation of transcription by competitive promoter binding	Histone deacetylase 4	Homo sapiens (human)
response to denervation involved in regulation of muscle adaptation	Histone deacetylase 4	Homo sapiens (human)
cardiac muscle hypertrophy in response to stress	Histone deacetylase 4	Homo sapiens (human)
protein sumoylation	Histone deacetylase 4	Homo sapiens (human)
B cell differentiation	Histone deacetylase 4	Homo sapiens (human)
positive regulation of protein sumoylation	Histone deacetylase 4	Homo sapiens (human)
peptidyl-lysine deacetylation	Histone deacetylase 4	Homo sapiens (human)
B cell activation	Histone deacetylase 4	Homo sapiens (human)
regulation of protein binding	Histone deacetylase 4	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Histone deacetylase 4	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 4	Homo sapiens (human)
negative regulation of glycolytic process	Histone deacetylase 4	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone deacetylase 4	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 4	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	Histone deacetylase 4	Homo sapiens (human)
type I interferon-mediated signaling pathway	Histone deacetylase 4	Homo sapiens (human)
response to interleukin-1	Histone deacetylase 4	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of myotube differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 1	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
chromatin organization	Histone deacetylase 1	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 1	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	Histone deacetylase 1	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
protein deacetylation	Histone deacetylase 1	Homo sapiens (human)
endoderm development	Histone deacetylase 1	Homo sapiens (human)
positive regulation of cell population proliferation	Histone deacetylase 1	Homo sapiens (human)
epidermal cell differentiation	Histone deacetylase 1	Homo sapiens (human)
positive regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
negative regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
hippocampus development	Histone deacetylase 1	Homo sapiens (human)
neuron differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of cell migration	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Histone deacetylase 1	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 1	Homo sapiens (human)
cellular response to platelet-derived growth factor stimulus	Histone deacetylase 1	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Histone deacetylase 1	Homo sapiens (human)
regulation of cell fate specification	Histone deacetylase 1	Homo sapiens (human)
embryonic digit morphogenesis	Histone deacetylase 1	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 1	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	Histone deacetylase 1	Homo sapiens (human)
negative regulation by host of viral transcription	Histone deacetylase 1	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 1	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone deacetylase 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 1	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Histone deacetylase 1	Homo sapiens (human)
oligodendrocyte differentiation	Histone deacetylase 1	Homo sapiens (human)
positive regulation of oligodendrocyte differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of androgen receptor signaling pathway	Histone deacetylase 1	Homo sapiens (human)
hair follicle placode formation	Histone deacetylase 1	Homo sapiens (human)
eyelid development in camera-type eye	Histone deacetylase 1	Homo sapiens (human)
fungiform papilla formation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of canonical Wnt signaling pathway	Histone deacetylase 1	Homo sapiens (human)
negative regulation of stem cell population maintenance	Histone deacetylase 1	Homo sapiens (human)
positive regulation of stem cell population maintenance	Histone deacetylase 1	Homo sapiens (human)
regulation of stem cell differentiation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway	Histone deacetylase 1	Homo sapiens (human)
heterochromatin formation	Histone deacetylase 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 7	Homo sapiens (human)
vasculogenesis	Histone deacetylase 7	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 7	Homo sapiens (human)
protein deacetylation	Histone deacetylase 7	Homo sapiens (human)
cell-cell junction assembly	Histone deacetylase 7	Homo sapiens (human)
protein sumoylation	Histone deacetylase 7	Homo sapiens (human)
negative regulation of interleukin-2 production	Histone deacetylase 7	Homo sapiens (human)
negative regulation of osteoblast differentiation	Histone deacetylase 7	Homo sapiens (human)
regulation of mRNA processing	Histone deacetylase 7	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Histone deacetylase 7	Homo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transduction	Histone deacetylase 7	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 2	Homo sapiens (human)
response to amphetamine	Histone deacetylase 2	Homo sapiens (human)
cardiac muscle hypertrophy	Histone deacetylase 2	Homo sapiens (human)
chromatin remodeling	Histone deacetylase 2	Homo sapiens (human)
positive regulation of cell population proliferation	Histone deacetylase 2	Homo sapiens (human)
response to xenobiotic stimulus	Histone deacetylase 2	Homo sapiens (human)
epidermal cell differentiation	Histone deacetylase 2	Homo sapiens (human)
positive regulation of epithelial to mesenchymal transition	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transcription by competitive promoter binding	Histone deacetylase 2	Homo sapiens (human)
negative regulation of neuron projection development	Histone deacetylase 2	Homo sapiens (human)
dendrite development	Histone deacetylase 2	Homo sapiens (human)
negative regulation of cell migration	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Histone deacetylase 2	Homo sapiens (human)
response to caffeine	Histone deacetylase 2	Homo sapiens (human)
heterochromatin formation	Histone deacetylase 2	Homo sapiens (human)
response to lipopolysaccharide	Histone deacetylase 2	Homo sapiens (human)
positive regulation of interleukin-1 production	Histone deacetylase 2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Histone deacetylase 2	Homo sapiens (human)
circadian regulation of gene expression	Histone deacetylase 2	Homo sapiens (human)
positive regulation of collagen biosynthetic process	Histone deacetylase 2	Homo sapiens (human)
cellular response to heat	Histone deacetylase 2	Homo sapiens (human)
response to nicotine	Histone deacetylase 2	Homo sapiens (human)
protein modification process	Histone deacetylase 2	Homo sapiens (human)
response to cocaine	Histone deacetylase 2	Homo sapiens (human)
odontogenesis of dentin-containing tooth	Histone deacetylase 2	Homo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT protein	Histone deacetylase 2	Homo sapiens (human)
regulation of cell fate specification	Histone deacetylase 2	Homo sapiens (human)
embryonic digit morphogenesis	Histone deacetylase 2	Homo sapiens (human)
negative regulation of apoptotic process	Histone deacetylase 2	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	Histone deacetylase 2	Homo sapiens (human)
negative regulation of MHC class II biosynthetic process	Histone deacetylase 2	Homo sapiens (human)
positive regulation of proteolysis	Histone deacetylase 2	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Histone deacetylase 2	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Histone deacetylase 2	Homo sapiens (human)
behavioral response to ethanol	Histone deacetylase 2	Homo sapiens (human)
positive regulation of oligodendrocyte differentiation	Histone deacetylase 2	Homo sapiens (human)
response to hyperoxia	Histone deacetylase 2	Homo sapiens (human)
hair follicle placode formation	Histone deacetylase 2	Homo sapiens (human)
negative regulation of dendritic spine development	Histone deacetylase 2	Homo sapiens (human)
eyelid development in camera-type eye	Histone deacetylase 2	Homo sapiens (human)
fungiform papilla formation	Histone deacetylase 2	Homo sapiens (human)
cellular response to hydrogen peroxide	Histone deacetylase 2	Homo sapiens (human)
cellular response to retinoic acid	Histone deacetylase 2	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Histone deacetylase 2	Homo sapiens (human)
positive regulation of male mating behavior	Histone deacetylase 2	Homo sapiens (human)
negative regulation of stem cell population maintenance	Histone deacetylase 2	Homo sapiens (human)
positive regulation of stem cell population maintenance	Histone deacetylase 2	Homo sapiens (human)
cellular response to dopamine	Histone deacetylase 2	Homo sapiens (human)
response to amyloid-beta	Histone deacetylase 2	Homo sapiens (human)
regulation of stem cell differentiation	Histone deacetylase 2	Homo sapiens (human)
negative regulation of peptidyl-lysine acetylation	Histone deacetylase 2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Polyamine deacetylase HDAC10	Homo sapiens (human)
DNA repair	Polyamine deacetylase HDAC10	Homo sapiens (human)
chromatin organization	Polyamine deacetylase HDAC10	Homo sapiens (human)
regulation of DNA-templated transcription	Polyamine deacetylase HDAC10	Homo sapiens (human)
macroautophagy	Polyamine deacetylase HDAC10	Homo sapiens (human)
positive regulation of mismatch repair	Polyamine deacetylase HDAC10	Homo sapiens (human)
homologous recombination	Polyamine deacetylase HDAC10	Homo sapiens (human)
negative regulation of DNA-templated transcription	Polyamine deacetylase HDAC10	Homo sapiens (human)
polyamine deacetylation	Polyamine deacetylase HDAC10	Homo sapiens (human)
spermidine deacetylation	Polyamine deacetylase HDAC10	Homo sapiens (human)
epigenetic regulation of gene expression	Polyamine deacetylase HDAC10	Homo sapiens (human)
chromatin organization	Histone deacetylase 11	Homo sapiens (human)
oligodendrocyte development	Histone deacetylase 11	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 11	Homo sapiens (human)
single strand break repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
rDNA heterochromatin formation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
pyrimidine dimer repair by nucleotide-excision repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
DNA synthesis involved in DNA repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
angiogenesis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
ovulation from ovarian follicle	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
intracellular glucose homeostasis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of protein phosphorylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of endothelial cell proliferation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of adaptive immune response	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
chromatin organization	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein deacetylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
triglyceride mobilization	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
DNA damage response	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
response to oxidative stress	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
spermatogenesis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of mitotic cell cycle	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
muscle organ development	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of cell population proliferation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to starvation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of gene expression	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of centrosome duplication	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of triglyceride biosynthetic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of cholesterol efflux	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of lipid storage	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of glucose metabolic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of macroautophagy	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein ubiquitination	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
peptidyl-lysine acetylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
macrophage differentiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of prostaglandin biosynthetic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
heterochromatin formation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein destabilization	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of TOR signaling	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of endodeoxyribonuclease activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
response to insulin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
circadian regulation of gene expression	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
leptin-mediated signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of smooth muscle cell apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
intracellular triglyceride homeostasis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of peroxisome proliferator activated receptor signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of cell population proliferation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to glucose starvation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of phosphorylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
response to hydrogen peroxide	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
behavioral response to starvation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cholesterol homeostasis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transduction	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of DNA-binding transcription factor activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of DNA damage response, signal transduction by p53 class mediator	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of neuron apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of blood vessel endothelial cell migration	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
response to leptin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of MHC class II biosynthetic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of fat cell differentiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of gluconeogenesis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of DNA repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of angiogenesis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of cell cycle	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of DNA-templated transcription	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of transcription by glucose	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of insulin receptor signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
white fat cell differentiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of helicase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of smooth muscle cell differentiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
maintenance of nucleus location	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
fatty acid homeostasis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of androgen receptor signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of macrophage cytokine production	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to hydrogen peroxide	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of bile acid biosynthetic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
UV-damage excision repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to tumor necrosis factor	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to hypoxia	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to ionizing radiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of protein serine/threonine kinase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of brown fat cell differentiation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
stress-induced premature senescence	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
energy homeostasis	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein depropionylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
DNA repair-dependent chromatin remodeling	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
regulation of cellular response to heat	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of signal transduction by p53 class mediator	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of protein acetylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of adipose tissue development	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cellular response to leukemia inhibitory factor	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of macrophage apoptotic process	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of cAMP-dependent protein kinase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of cAMP-dependent protein kinase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of cellular response to testosterone stimulus	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of peptidyl-lysine acetylation	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of cellular senescence	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of cellular senescence	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
positive regulation of double-strand break repair	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone deacetylase 8	Homo sapiens (human)
chromatin organization	Histone deacetylase 8	Homo sapiens (human)
mitotic sister chromatid cohesion	Histone deacetylase 8	Homo sapiens (human)
negative regulation of protein ubiquitination	Histone deacetylase 8	Homo sapiens (human)
regulation of protein stability	Histone deacetylase 8	Homo sapiens (human)
regulation of telomere maintenance	Histone deacetylase 8	Homo sapiens (human)
epigenetic regulation of gene expression	Histone deacetylase 8	Homo sapiens (human)
polyamine deacetylation	Histone deacetylase 6	Homo sapiens (human)
spermidine deacetylation	Histone deacetylase 6	Homo sapiens (human)
positive regulation of signaling receptor activity	Histone deacetylase 6	Homo sapiens (human)
protein polyubiquitination	Histone deacetylase 6	Homo sapiens (human)
response to amphetamine	Histone deacetylase 6	Homo sapiens (human)
protein deacetylation	Histone deacetylase 6	Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteins	Histone deacetylase 6	Homo sapiens (human)
intracellular protein transport	Histone deacetylase 6	Homo sapiens (human)
autophagy	Histone deacetylase 6	Homo sapiens (human)
actin filament organization	Histone deacetylase 6	Homo sapiens (human)
negative regulation of microtubule depolymerization	Histone deacetylase 6	Homo sapiens (human)
regulation of autophagy	Histone deacetylase 6	Homo sapiens (human)
positive regulation of epithelial cell migration	Histone deacetylase 6	Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic process	Histone deacetylase 6	Homo sapiens (human)
regulation of macroautophagy	Histone deacetylase 6	Homo sapiens (human)
axonal transport of mitochondrion	Histone deacetylase 6	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Histone deacetylase 6	Homo sapiens (human)
regulation of protein stability	Histone deacetylase 6	Homo sapiens (human)
protein destabilization	Histone deacetylase 6	Homo sapiens (human)
lysosome localization	Histone deacetylase 6	Homo sapiens (human)
protein-containing complex disassembly	Histone deacetylase 6	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Histone deacetylase 6	Homo sapiens (human)
cellular response to heat	Histone deacetylase 6	Homo sapiens (human)
peptidyl-lysine deacetylation	Histone deacetylase 6	Homo sapiens (human)
response to immobilization stress	Histone deacetylase 6	Homo sapiens (human)
cellular response to topologically incorrect protein	Histone deacetylase 6	Homo sapiens (human)
erythrocyte enucleation	Histone deacetylase 6	Homo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway	Histone deacetylase 6	Homo sapiens (human)
negative regulation of protein-containing complex disassembly	Histone deacetylase 6	Homo sapiens (human)
regulation of fat cell differentiation	Histone deacetylase 6	Homo sapiens (human)
negative regulation of gene expression, epigenetic	Histone deacetylase 6	Homo sapiens (human)
negative regulation of proteolysis	Histone deacetylase 6	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone deacetylase 6	Homo sapiens (human)
collateral sprouting	Histone deacetylase 6	Homo sapiens (human)
negative regulation of axon extension involved in axon guidance	Histone deacetylase 6	Homo sapiens (human)
positive regulation of dendrite morphogenesis	Histone deacetylase 6	Homo sapiens (human)
negative regulation of oxidoreductase activity	Histone deacetylase 6	Homo sapiens (human)
response to corticosterone	Histone deacetylase 6	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
transcription corepressor binding	Histone deacetylase 3	Homo sapiens (human)
chromatin binding	Histone deacetylase 3	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 3	Homo sapiens (human)
protein binding	Histone deacetylase 3	Homo sapiens (human)
enzyme binding	Histone deacetylase 3	Homo sapiens (human)
cyclin binding	Histone deacetylase 3	Homo sapiens (human)
chromatin DNA binding	Histone deacetylase 3	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 3	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 3	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 3	Homo sapiens (human)
protein decrotonylase activity	Histone deacetylase 3	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 3	Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activity	Histone deacetylase 3	Homo sapiens (human)
transcription cis-regulatory region binding	Bromodomain-containing protein 4	Homo sapiens (human)
p53 binding	Bromodomain-containing protein 4	Homo sapiens (human)
chromatin binding	Bromodomain-containing protein 4	Homo sapiens (human)
transcription coregulator activity	Bromodomain-containing protein 4	Homo sapiens (human)
transcription coactivator activity	Bromodomain-containing protein 4	Homo sapiens (human)
protein binding	Bromodomain-containing protein 4	Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activity	Bromodomain-containing protein 4	Homo sapiens (human)
enzyme binding	Bromodomain-containing protein 4	Homo sapiens (human)
lysine-acetylated histone binding	Bromodomain-containing protein 4	Homo sapiens (human)
RNA polymerase II C-terminal domain binding	Bromodomain-containing protein 4	Homo sapiens (human)
P-TEFb complex binding	Bromodomain-containing protein 4	Homo sapiens (human)
histone reader activity	Bromodomain-containing protein 4	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
RNA binding	Leukotriene A-4 hydrolase	Homo sapiens (human)
aminopeptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
epoxide hydrolase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
leukotriene-A4 hydrolase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
protein binding	Leukotriene A-4 hydrolase	Homo sapiens (human)
peptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
zinc ion binding	Leukotriene A-4 hydrolase	Homo sapiens (human)
tripeptide aminopeptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
metalloaminopeptidase activity	Leukotriene A-4 hydrolase	Homo sapiens (human)
transcription cis-regulatory region binding	Androgen receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
RNA polymerase II general transcription initiation factor binding	Androgen receptor	Homo sapiens (human)
transcription coactivator binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Androgen receptor	Homo sapiens (human)
chromatin binding	Androgen receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Androgen receptor	Homo sapiens (human)
nuclear receptor activity	Androgen receptor	Homo sapiens (human)
G protein-coupled receptor activity	Androgen receptor	Homo sapiens (human)
signaling receptor binding	Androgen receptor	Homo sapiens (human)
steroid binding	Androgen receptor	Homo sapiens (human)
androgen binding	Androgen receptor	Homo sapiens (human)
protein binding	Androgen receptor	Homo sapiens (human)
beta-catenin binding	Androgen receptor	Homo sapiens (human)
zinc ion binding	Androgen receptor	Homo sapiens (human)
enzyme binding	Androgen receptor	Homo sapiens (human)
ATPase binding	Androgen receptor	Homo sapiens (human)
molecular adaptor activity	Androgen receptor	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Androgen receptor	Homo sapiens (human)
POU domain binding	Androgen receptor	Homo sapiens (human)
molecular condensate scaffold activity	Androgen receptor	Homo sapiens (human)
estrogen response element binding	Androgen receptor	Homo sapiens (human)
serine-type endopeptidase activity	Tissue factor	Homo sapiens (human)
protease binding	Tissue factor	Homo sapiens (human)
protein binding	Tissue factor	Homo sapiens (human)
phospholipid binding	Tissue factor	Homo sapiens (human)
cytokine receptor activity	Tissue factor	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
transcription cis-regulatory region binding	Histone deacetylase 4	Homo sapiens (human)
histone binding	Histone deacetylase 4	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 4	Homo sapiens (human)
protein binding	Histone deacetylase 4	Homo sapiens (human)
zinc ion binding	Histone deacetylase 4	Homo sapiens (human)
SUMO transferase activity	Histone deacetylase 4	Homo sapiens (human)
potassium ion binding	Histone deacetylase 4	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 4	Homo sapiens (human)
identical protein binding	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 4	Homo sapiens (human)
molecular adaptor activity	Histone deacetylase 4	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 4	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 4	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
nucleosomal DNA binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
core promoter sequence-specific DNA binding	Histone deacetylase 1	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 1	Homo sapiens (human)
p53 binding	Histone deacetylase 1	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 1	Homo sapiens (human)
protein binding	Histone deacetylase 1	Homo sapiens (human)
enzyme binding	Histone deacetylase 1	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 1	Homo sapiens (human)
Krueppel-associated box domain binding	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 1	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 1	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 1	Homo sapiens (human)
E-box binding	Histone deacetylase 1	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 1	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 1	Homo sapiens (human)
promoter-specific chromatin binding	Histone deacetylase 1	Homo sapiens (human)
chromatin binding	Histone deacetylase 7	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 7	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 7	Homo sapiens (human)
protein kinase C binding	Histone deacetylase 7	Homo sapiens (human)
protein binding	Histone deacetylase 7	Homo sapiens (human)
SUMO transferase activity	Histone deacetylase 7	Homo sapiens (human)
protein kinase binding	Histone deacetylase 7	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 7	Homo sapiens (human)
metal ion binding	Histone deacetylase 7	Homo sapiens (human)
14-3-3 protein binding	Histone deacetylase 7	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 7	Homo sapiens (human)
nucleosomal DNA binding	Histone deacetylase 2	Homo sapiens (human)
chromatin binding	Histone deacetylase 2	Homo sapiens (human)
RNA binding	Histone deacetylase 2	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 2	Homo sapiens (human)
protein binding	Histone deacetylase 2	Homo sapiens (human)
enzyme binding	Histone deacetylase 2	Homo sapiens (human)
heat shock protein binding	Histone deacetylase 2	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 2	Homo sapiens (human)
histone binding	Histone deacetylase 2	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 2	Homo sapiens (human)
NF-kappaB binding	Histone deacetylase 2	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 2	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 2	Homo sapiens (human)
protein de-2-hydroxyisobutyrylase activity	Histone deacetylase 2	Homo sapiens (human)
promoter-specific chromatin binding	Histone deacetylase 2	Homo sapiens (human)
protein lysine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
protein binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
zinc ion binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
enzyme binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
protein lysine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase binding	Polyamine deacetylase HDAC10	Homo sapiens (human)
acetylputrescine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
acetylspermidine deacetylase activity	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 11	Homo sapiens (human)
protein binding	Histone deacetylase 11	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 11	Homo sapiens (human)
NAD+ ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
p53 binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
transcription coactivator activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
transcription corepressor activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
histone deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nuclear receptor binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent histone deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
enzyme binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent histone H3K14 deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein lysine deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent protein lysine deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
histone binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
identical protein binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
HLH domain binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
bHLH transcription factor binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
metal ion binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent histone H3K9 deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent histone H4K16 deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
mitogen-activated protein kinase binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
lysine-acetylated histone binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
protein-propionyllysine depropionylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
DNA-binding transcription factor binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
histone H4K12 deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
histone H3K deacetylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD-dependent histone decrotonylase activity	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
keratin filament binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
promoter-specific chromatin binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
NAD+ binding	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 8	Homo sapiens (human)
protein binding	Histone deacetylase 8	Homo sapiens (human)
Hsp70 protein binding	Histone deacetylase 8	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 8	Homo sapiens (human)
metal ion binding	Histone deacetylase 8	Homo sapiens (human)
Hsp90 protein binding	Histone deacetylase 8	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 8	Homo sapiens (human)
histone decrotonylase activity	Histone deacetylase 8	Homo sapiens (human)
acetylspermidine deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 6	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 6	Homo sapiens (human)
actin binding	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
protein binding	Histone deacetylase 6	Homo sapiens (human)
beta-catenin binding	Histone deacetylase 6	Homo sapiens (human)
microtubule binding	Histone deacetylase 6	Homo sapiens (human)
zinc ion binding	Histone deacetylase 6	Homo sapiens (human)
enzyme binding	Histone deacetylase 6	Homo sapiens (human)
polyubiquitin modification-dependent protein binding	Histone deacetylase 6	Homo sapiens (human)
ubiquitin protein ligase binding	Histone deacetylase 6	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 6	Homo sapiens (human)
tubulin deacetylase activity	Histone deacetylase 6	Homo sapiens (human)
alpha-tubulin binding	Histone deacetylase 6	Homo sapiens (human)
ubiquitin binding	Histone deacetylase 6	Homo sapiens (human)
tau protein binding	Histone deacetylase 6	Homo sapiens (human)
beta-tubulin binding	Histone deacetylase 6	Homo sapiens (human)
misfolded protein binding	Histone deacetylase 6	Homo sapiens (human)
Hsp90 protein binding	Histone deacetylase 6	Homo sapiens (human)
dynein complex binding	Histone deacetylase 6	Homo sapiens (human)
transcription factor binding	Histone deacetylase 6	Homo sapiens (human)
transcription corepressor activity	Histone deacetylase 9	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
protein kinase C binding	Histone deacetylase 9	Homo sapiens (human)
protein binding	Histone deacetylase 9	Homo sapiens (human)
histone H3K14 deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
histone H3K9 deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
histone H4K16 deacetylase activity	Histone deacetylase 9	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 9	Homo sapiens (human)
metal ion binding	Histone deacetylase 9	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 9	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 9	Homo sapiens (human)
transcription cis-regulatory region binding	Histone deacetylase 5	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Histone deacetylase 5	Homo sapiens (human)
transcription corepressor binding	Histone deacetylase 5	Homo sapiens (human)
chromatin binding	Histone deacetylase 5	Homo sapiens (human)
histone deacetylase activity	Histone deacetylase 5	Homo sapiens (human)
protein kinase C binding	Histone deacetylase 5	Homo sapiens (human)
protein binding	Histone deacetylase 5	Homo sapiens (human)
protein lysine deacetylase activity	Histone deacetylase 5	Homo sapiens (human)
identical protein binding	Histone deacetylase 5	Homo sapiens (human)
histone deacetylase binding	Histone deacetylase 5	Homo sapiens (human)
metal ion binding	Histone deacetylase 5	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Histone deacetylase 5	Homo sapiens (human)
DNA-binding transcription factor binding	Histone deacetylase 5	Homo sapiens (human)
DNA binding	Nuclear receptor corepressor 2	Homo sapiens (human)
chromatin binding	Nuclear receptor corepressor 2	Homo sapiens (human)
transcription corepressor activity	Nuclear receptor corepressor 2	Homo sapiens (human)
Notch binding	Nuclear receptor corepressor 2	Homo sapiens (human)
protein binding	Nuclear receptor corepressor 2	Homo sapiens (human)
nuclear glucocorticoid receptor binding	Nuclear receptor corepressor 2	Homo sapiens (human)
histone deacetylase binding	Nuclear receptor corepressor 2	Homo sapiens (human)
nuclear retinoid X receptor binding	Nuclear receptor corepressor 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleus	Histone deacetylase 3	Homo sapiens (human)
nucleoplasm	Histone deacetylase 3	Homo sapiens (human)
cytoplasm	Histone deacetylase 3	Homo sapiens (human)
Golgi apparatus	Histone deacetylase 3	Homo sapiens (human)
cytosol	Histone deacetylase 3	Homo sapiens (human)
plasma membrane	Histone deacetylase 3	Homo sapiens (human)
mitotic spindle	Histone deacetylase 3	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 3	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 3	Homo sapiens (human)
nucleus	Histone deacetylase 3	Homo sapiens (human)
condensed nuclear chromosome	Bromodomain-containing protein 4	Homo sapiens (human)
nucleus	Bromodomain-containing protein 4	Homo sapiens (human)
nucleoplasm	Bromodomain-containing protein 4	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
extracellular region	Leukotriene A-4 hydrolase	Homo sapiens (human)
nucleoplasm	Leukotriene A-4 hydrolase	Homo sapiens (human)
cytosol	Leukotriene A-4 hydrolase	Homo sapiens (human)
extracellular exosome	Leukotriene A-4 hydrolase	Homo sapiens (human)
tertiary granule lumen	Leukotriene A-4 hydrolase	Homo sapiens (human)
ficolin-1-rich granule lumen	Leukotriene A-4 hydrolase	Homo sapiens (human)
cytosol	Leukotriene A-4 hydrolase	Homo sapiens (human)
nucleus	Leukotriene A-4 hydrolase	Homo sapiens (human)
plasma membrane	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
nucleoplasm	Androgen receptor	Homo sapiens (human)
cytoplasm	Androgen receptor	Homo sapiens (human)
cytosol	Androgen receptor	Homo sapiens (human)
nuclear speck	Androgen receptor	Homo sapiens (human)
chromatin	Androgen receptor	Homo sapiens (human)
protein-containing complex	Androgen receptor	Homo sapiens (human)
nucleus	Androgen receptor	Homo sapiens (human)
extracellular space	Tissue factor	Homo sapiens (human)
plasma membrane	Tissue factor	Homo sapiens (human)
external side of plasma membrane	Tissue factor	Homo sapiens (human)
cell surface	Tissue factor	Homo sapiens (human)
membrane	Tissue factor	Homo sapiens (human)
collagen-containing extracellular matrix	Tissue factor	Homo sapiens (human)
serine-type peptidase complex	Tissue factor	Homo sapiens (human)
plasma membrane	Tissue factor	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
nucleus	Histone deacetylase 4	Homo sapiens (human)
nucleoplasm	Histone deacetylase 4	Homo sapiens (human)
cytoplasm	Histone deacetylase 4	Homo sapiens (human)
cytosol	Histone deacetylase 4	Homo sapiens (human)
nuclear speck	Histone deacetylase 4	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 4	Homo sapiens (human)
chromatin	Histone deacetylase 4	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 4	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
nucleus	Histone deacetylase 1	Homo sapiens (human)
nucleoplasm	Histone deacetylase 1	Homo sapiens (human)
cytoplasm	Histone deacetylase 1	Homo sapiens (human)
cytosol	Histone deacetylase 1	Homo sapiens (human)
NuRD complex	Histone deacetylase 1	Homo sapiens (human)
neuronal cell body	Histone deacetylase 1	Homo sapiens (human)
Sin3-type complex	Histone deacetylase 1	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 1	Homo sapiens (human)
chromatin	Histone deacetylase 1	Homo sapiens (human)
heterochromatin	Histone deacetylase 1	Homo sapiens (human)
transcription repressor complex	Histone deacetylase 1	Homo sapiens (human)
protein-containing complex	Histone deacetylase 1	Homo sapiens (human)
nucleus	Histone deacetylase 1	Homo sapiens (human)
nucleus	Histone deacetylase 7	Homo sapiens (human)
nucleoplasm	Histone deacetylase 7	Homo sapiens (human)
cytoplasm	Histone deacetylase 7	Homo sapiens (human)
cytosol	Histone deacetylase 7	Homo sapiens (human)
chromosome, telomeric region	Histone deacetylase 2	Homo sapiens (human)
nucleus	Histone deacetylase 2	Homo sapiens (human)
nucleoplasm	Histone deacetylase 2	Homo sapiens (human)
cytoplasm	Histone deacetylase 2	Homo sapiens (human)
NuRD complex	Histone deacetylase 2	Homo sapiens (human)
Sin3-type complex	Histone deacetylase 2	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 2	Homo sapiens (human)
chromatin	Histone deacetylase 2	Homo sapiens (human)
protein-containing complex	Histone deacetylase 2	Homo sapiens (human)
ESC/E(Z) complex	Histone deacetylase 2	Homo sapiens (human)
nucleus	Histone deacetylase 2	Homo sapiens (human)
nucleus	Polyamine deacetylase HDAC10	Homo sapiens (human)
nucleoplasm	Polyamine deacetylase HDAC10	Homo sapiens (human)
cytoplasm	Polyamine deacetylase HDAC10	Homo sapiens (human)
cytosol	Polyamine deacetylase HDAC10	Homo sapiens (human)
intracellular membrane-bounded organelle	Polyamine deacetylase HDAC10	Homo sapiens (human)
histone deacetylase complex	Polyamine deacetylase HDAC10	Homo sapiens (human)
nucleus	Histone deacetylase 11	Homo sapiens (human)
plasma membrane	Histone deacetylase 11	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 11	Homo sapiens (human)
nucleolus	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cytoplasm	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
ESC/E(Z) complex	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cytosol	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
fibrillar center	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nucleus	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nuclear envelope	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nuclear inner membrane	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nucleoplasm	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nucleolus	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cytoplasm	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
mitochondrion	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
cytosol	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
PML body	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
eNoSc complex	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
chromatin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
euchromatin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
heterochromatin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
chromatin silencing complex	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
rDNA heterochromatin	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nucleus	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nuclear inner membrane	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nucleoplasm	NAD-dependent protein deacetylase sirtuin-1	Homo sapiens (human)
nuclear chromosome	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 8	Homo sapiens (human)
nucleoplasm	Histone deacetylase 8	Homo sapiens (human)
cytoplasm	Histone deacetylase 8	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 8	Homo sapiens (human)
nucleus	Histone deacetylase 6	Homo sapiens (human)
nucleoplasm	Histone deacetylase 6	Homo sapiens (human)
cytoplasm	Histone deacetylase 6	Homo sapiens (human)
multivesicular body	Histone deacetylase 6	Homo sapiens (human)
centrosome	Histone deacetylase 6	Homo sapiens (human)
cytosol	Histone deacetylase 6	Homo sapiens (human)
microtubule	Histone deacetylase 6	Homo sapiens (human)
caveola	Histone deacetylase 6	Homo sapiens (human)
inclusion body	Histone deacetylase 6	Homo sapiens (human)
aggresome	Histone deacetylase 6	Homo sapiens (human)
axon	Histone deacetylase 6	Homo sapiens (human)
dendrite	Histone deacetylase 6	Homo sapiens (human)
cell leading edge	Histone deacetylase 6	Homo sapiens (human)
ciliary basal body	Histone deacetylase 6	Homo sapiens (human)
perikaryon	Histone deacetylase 6	Homo sapiens (human)
perinuclear region of cytoplasm	Histone deacetylase 6	Homo sapiens (human)
axon cytoplasm	Histone deacetylase 6	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 6	Homo sapiens (human)
microtubule associated complex	Histone deacetylase 6	Homo sapiens (human)
nucleus	Histone deacetylase 9	Homo sapiens (human)
nucleoplasm	Histone deacetylase 9	Homo sapiens (human)
cytoplasm	Histone deacetylase 9	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 9	Homo sapiens (human)
transcription regulator complex	Histone deacetylase 9	Homo sapiens (human)
histone methyltransferase complex	Histone deacetylase 9	Homo sapiens (human)
nucleus	Histone deacetylase 5	Homo sapiens (human)
nucleoplasm	Histone deacetylase 5	Homo sapiens (human)
cytoplasm	Histone deacetylase 5	Homo sapiens (human)
Golgi apparatus	Histone deacetylase 5	Homo sapiens (human)
cytosol	Histone deacetylase 5	Homo sapiens (human)
nuclear speck	Histone deacetylase 5	Homo sapiens (human)
histone deacetylase complex	Histone deacetylase 5	Homo sapiens (human)
nucleus	Nuclear receptor corepressor 2	Homo sapiens (human)
nucleoplasm	Nuclear receptor corepressor 2	Homo sapiens (human)
membrane	Nuclear receptor corepressor 2	Homo sapiens (human)
nuclear matrix	Nuclear receptor corepressor 2	Homo sapiens (human)
nuclear body	Nuclear receptor corepressor 2	Homo sapiens (human)
chromatin	Nuclear receptor corepressor 2	Homo sapiens (human)
transcription repressor complex	Nuclear receptor corepressor 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (920)

Assay ID	Title	Year	Journal	Article
AID1798524	HDAC Activity Assay from Article 10.1021/jm800079s: \\A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.\\	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1802398	Enzymatic HDAC Activity Assay from Article 10.1074/jbc.M113.490706: \\Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.\\	2013	The Journal of biological chemistry, Sep-13, Volume: 288, Issue:37	Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
AID1797850	HDAC Enzyme Activity Assay from Article 10.1021/jm701079h: \\Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.\\	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
AID1798526	HDAC Activity Assay from Article 10.1016/j.bmcl.2008.02.025: \\Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.\\	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID1802399	Proteros Reporter Displacement Assay from Article 10.1074/jbc.M113.490706: \\Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.\\	2013	The Journal of biological chemistry, Sep-13, Volume: 288, Issue:37	Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability.
AID1799021	pfHDAC-1 Enzyme Assay from Article 10.1021/jm801654y: \\Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.\\	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346134	Human histone deacetylase 1 (3.5.1.- Histone deacetylases (HDACs))	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1346077	Human histone deacetylase 3 (3.5.1.- Histone deacetylases (HDACs))	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1346090	Human histone deacetylase 9 (3.5.1.- Histone deacetylases (HDACs))	2008	The Biochemical journal, Jan-15, Volume: 409, Issue:2	Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
AID1346077	Human histone deacetylase 3 (3.5.1.- Histone deacetylases (HDACs))	2008	The Biochemical journal, Jan-15, Volume: 409, Issue:2	Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
AID1346082	Human histone deacetylase 2 (3.5.1.- Histone deacetylases (HDACs))	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1346134	Human histone deacetylase 1 (3.5.1.- Histone deacetylases (HDACs))	2008	The Biochemical journal, Jan-15, Volume: 409, Issue:2	Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
AID1346082	Human histone deacetylase 2 (3.5.1.- Histone deacetylases (HDACs))	2008	The Biochemical journal, Jan-15, Volume: 409, Issue:2	Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID385685	Inhibition of flag-tagged HDAC4 by pull-down assay	2007	Proceedings of the National Academy of Sciences of the United States of America, Oct-30, Volume: 104, Issue:44	Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.
AID1548274	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay
AID417069	Activation of mouse Wnt3a signaling expressed in HEK293 STF cells assessed as increase in transcriptional activity after 24 hrs by luciferase reporter gene-based lactate dehydrogenase assay	2009	Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6	Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives.
AID1853065	Inhibition of HDAC1-CoREST-LSD1 (unknown origin) using Boc-(Ac)Lys-AMC as substrate preincubated with compound for 1 hrs followed by substrate addition and measured after 1 hrs by fluorescent assay	2022	RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12	A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras.
AID1901159	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID664385	Inhibition of SIRT1	2012	European journal of medicinal chemistry, Jul, Volume: 53	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID1466057	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1467233	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells at 5 uM using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated followed by substrate addition after 30 mins by fluorometric method	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID1541562	Inhibition of class 1 HDAC in human Cal27CisR cells assessed as increase in histone H3 acetylation at 1 uM measured after 24 hrs by immunoblot analysis	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID374828	Antiproliferative activity against human G401 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1732162	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID392619	Cytotoxicity against human DU145 cells by MTT assay	2009	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4	N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1).
AID1556404	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 1 to 5 uM incubated for 24 hrs by MTS assay	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
AID609496	Cardiac safety index, Ratio of IC50 for human ERG to IC50 for human HCT116 cells	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1846961	Antiproliferative activity against human YCC-11 cells assessed as inhibition of cell viability
AID374829	Antiproliferative activity against human A2780 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1596058	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 1 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=77%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1280296	Inhibition of KDAC6 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID650218	Induction of cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by flow cytometry (Rvb = 9.5 %)	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1596055	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 0.25 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=77%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1454687	Drug uptake in iv dosed rat brain after 90 mins by PET imaging method relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID1401926	Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at G0/G1 phase at 4 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 80.65%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1881854	Inhibition of HDAC2 (unknown origin)	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	NO-HDAC dual inhibitors.
AID328798	Inhibition of HDAC5 expressed in Escherichia coli	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID488273	Inhibition of HDAC1	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID610086	Inhibition of HDAC by fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
AID1548305	Induction of cell cycle arrest in bortezomib resistant human KM3/BTZ cells assessed as accumulation at G2/M phase at 100 nM incubated for 24 hrs in presence of bortezomib by propidium iodide staining based flow cytometry (Rvb = 9.1%)
AID1596042	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1706071	Increase in LPS/IFNgamma-induced IL6 mRNA expression in mouse RAW26.7 cells at 1 uM incubated for 20 hrs followed by LPS/IFNgamma stimulation and measured after 4 hrs by RT-qPCR analysis	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
AID525024	Inhibition of HDAC in human CFBE41o- cell line assessed as increase in CFTR mRNA at 1 uM by RT-PCR	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID650211	Toxicity in human HCT116 cells xenografted in BALB/c- nu.nu mouse assessed as relative body weight change at 45 mg/kg, po administered every alternate days for 14 days measured up to day 16	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID316899	Inhibition of HDAC6	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID538413	Selectivity index, ratio of IC50 for recombinant human HDAC1 to IC50 for recombinant human HDAC6	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Inhibitors selective for HDAC6 in enzymes and cells.
AID1873471	Inhibition of full length C-terminal His-tagged HDAC1 (unknown origin) assessed as dissociation half-life of EI complex using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence based assay	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID748114	Inhibition of HDAC1 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1737666	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as accumulation of cells at subG1 phase at 16 uM for 48 hrs by PI staining based flow cytometry analysis
AID1676600	Binding affinity to zinc ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1401910	Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 0.125 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.29%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1596049	Inhibition of human recombinant His-tagged HDAC1 (482 residues) expressed in baculovirus infected insect cells using FLUOR DE LYS SIRT1 as substrate incubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence method	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1853066	Inhibition of HDAC2-CoREST-LSD1 (unknown origin) using Boc-(Ac)Lys-AMC as substrate preincubated with compound for 1 hrs followed by substrate addition and measured after 1 hrs by fluorescent assay	2022	RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12	A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras.
AID328807	Antiproliferative activity against human A549 cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1586083	Inhibition of human HDAC8 using RHKAcKAc as substrate by fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID1263144	Inhibition of human recombinant HDAC3 using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorescence assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1873427	Inhibition of HDAC3 (unknown origin) at 2 uM preincubated for 1 hr followed by 100-fold dilution and subsequent substrate addition measured after 1 hr	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID525011	Inhibition of HDAC expressed in hamster BHK cell line assessed as increase in plasma membrane Fdelta508 CFTR protein at 5 uM by immunofluorescence method	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID777593	Effect on HDAC in human HaCaT cells assessed as upregulation of miR-16-1# at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1466061	Inhibition of recombinant human full length HDAC1 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1401900	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID414981	Antimalarial activity against Plasmodium falciparum 3D7 by [3H]hypoxanthine uptake	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
AID488363	Antitumor activity against human HCT116 cells xenografted in BALB/c nu/nu mouse assessed as reduction of tumor mass at 45 mg/kg, po administered on days 2, 4, 7, 9, 11, 14 and 16 measured on day 18 relative to control	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1847014	Toxicity in C57BL/6 mouse allografted with mouse B16-F10 cells assessed as body weight loss at 100 mg/kg, ip administered for 14 days
AID664040	Growth inhibition of human HCT116 cells after 2 days by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID1235133	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	2015	European journal of medicinal chemistry, Jul-15, Volume: 100	Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
AID1431812	Selectivity ratio of IC50 for human KDAC1 to IC50 for human KDAC3	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID622254	Inhibition of human HDAC in HeLa cells after 30 mins by Fluor de Lys fluorescence assay	2011	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20	The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity.
AID777572	Modulation of mouse C2C12 cell proliferation at 0.1 uM after 72 hrs	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1887685	Cytotoxicity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID664041	Growth inhibition of human U251 cells after 2 days by MTT assay	2012	European journal of medicinal chemistry, Jul, Volume: 53	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID1466381	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID670717	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.
AID316887	Antiproliferative activity against human MKN45 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1596057	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 0.25 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=16.17%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1676592	Binding affinity to Gallium ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID664380	Inhibition of HDAC3	2012	European journal of medicinal chemistry, Jul, Volume: 53	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID1596062	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 4 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=6.83%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1578491	Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1596034	Inhibition of human recombinant His-tagged HDAC6 expressed in baculovirus infected insect cells using FLUOR DE LYS SIRT1 as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence method	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1466388	Antiproliferative activity against HEL cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1401917	Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 4 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.09%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1676590	Binding affinity to Nickel cation assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1901175	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated H3K9 at 5 uM preincubated for 6 hrs followed by compound washout and measured up to 48 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1864219	Binding affinity to 5' FAM-labeled c-myc G4-quadruplex DNA Pu22 (unknown origin) at 50 uM by fluorescence quench assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID519591	Selectivity index, ratio of IC50 for human WI38 cells to IC50 for chloroquine-resistant Plasmodium falciparum Dd2	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1864216	Inhibition of HDAC in human HeLa nuclear extract incubated for 30 mins by fluorescence-based Glo-luminescence assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID777594	Effect on HDAC in human HaCaT cells assessed as downregulation of miR-589 at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID613341	Inhibition of human ERG by automated Q-patch assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID1431821	Selectivity ratio of IC50 for human KDAC6 to IC50 for human KDAC8	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1917926	Inhibition of HDAC1 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer's disease.
AID1401901	Inhibition of HDAC in human HeLa cell extract using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1401923	Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at G0/G1 phase at 1 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 80.65%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID360095	Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay	2007	The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39	Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1915581	Cytotoxicity against human DU-145 cells	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1380964	Inhibition of HDAC1/HDAC2/HDAC3 in human HeLa cells assessed as increase in intracellular acetyl-histone H4 levels at 1 uM after 6 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1873439	Inhibition of full length C-terminal His-tagged HDAC1 (unknown origin) assessed as inhibition constant (Ki) using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence based assay	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1847021	Toxicity in C57BL/6 mouse allografted with mouse B16-F10 cells assessed as morphological abnormalities in liver at 5 mg/kg, ip administered for 14 days in presence of (2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone by H and E staining based analys
AID1424833	Induction of apoptosis in human MV4-11 cells at 5 uM after 24 to 48 hrs by Annexin V-PI staining based flow cytometry	2018	European journal of medicinal chemistry, May-25, Volume: 152	Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
AID1293874	Inhibition of HDAC in human HeLa nuclear extract using fluor de lys as substrate after 10 to 15 mins by spectrofluorometry	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Identification of new quinic acid derivatives as histone deacetylase inhibitors by fluorescence-based cellular assay.
AID316892	Inhibition of HDAC1	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID328794	Inhibition of HDAC2	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID420329	Inhibition of HDAC from RT extract	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1727731	Inhibition of His-tagged BRD4 bromodomain 1 (unknown origin) using [Lys (5,8,12,16) Ac] H4(1-21) as substrate by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID708276	Growth inhibition of human Bel7404 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1308513	Inhibition of recombinant HDAC1 (unknown origin) using of Fluor-de-Lys substrate incubated for 10 mins by fluorimetric assay	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
AID1737645	Inhibition of human recombinant HDAC2 expressed in baculovirus using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate by Fluorescence analysis
AID1401892	Antiproliferative activity against human A375 cells at 8 uM after 72 hrs by CCK-8 assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1453362	Inhibition of class 2 HDAC in HEL cells using Boc-Lys (triflouroacetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID201624	Compound was tested for antiproliferative activity against human SK-BR-3 cancer cell lines	2003	Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26	Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
AID1431818	Selectivity ratio of IC50 for human KDAC8 to IC50 for human KDAC3	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1467234	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated for 3 hrs followed by substrate addition after 30 mins by fluorometric method	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID525020	Inhibition of HDAC in human CFBE41o- cell line assessed as total CFTR protein level including CFTR glycoform at 1 uM by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1453364	Inhibition of HDAC2 (unknown origin) using Boc-Lys (acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by fluorescence assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID524998	Inhibition of HDAC5 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1706072	Increase in LPS/IFNgamma-induced TNFalpha mRNA expression in mouse RAW26.7 cells at 1 uM incubated for 20 hrs followed by LPS/IFNgamma stimulation and measured after 4 hrs by RT-qPCR analysis	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
AID613298	In vitro cardiac safety index, ratio of IC50 for human ERG to IC50 for human HCT116 cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID519593	Selectivity index, ratio of IC50 for human WI38 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID329915	Inhibition of human HDAC4 in U937 cells by immunoprecipitation assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1401897	Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1586067	Growth inhibition of human KB cells after 48 hrs by SRB assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID1466395	Antitumor activity against human U937 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 50 mg/kg/day administered via oral gavage for 13 days measured every 3 days	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1732172	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as sub-G1 phase at 8 uM incubated for 72 hrs by PI staining based flow cytometry analysis (Rvb = 0.8 %)	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1380944	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID374821	Inhibition of wild type His-tagged HDAC7 catalytic domain T515-L952 expressed in Escherichia coli	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID316925	Inhibition of human HepG2 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1454688	Half life in human at 6 mg/m2, po	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID1740019	Inhibition of recombinant human HDAC6 using pan-HDAC substrate incubated for 3 hrs by fluorescence method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1431815	Selectivity ratio of IC50 for human KDAC1 to IC50 for human KDAC8	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1596039	Antiproliferative activity against human A549 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1676593	Binding affinity to Gallium ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID328808	Antiproliferative activity against human G401 cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1467242	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells at 2 uM using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated for 3 hrs followed by substrate addition after 30 mins by fluorometric method	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID374820	Inhibition of C-terminal FLAG-tagged HDAC6 expressed in mammalian cells	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1203895	Antiproliferative activity against human U937 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID364648	Inhibition of human recombinant HDAC by fluorimetric assay	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.
AID1401903	Inhibition of human recombinant HDAC2 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1548735	Inhibition of recombinant human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1474454	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID1548293	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as early apoptotic cells level at 50 nM incubated for 24 hrs in presence of bortezomib by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 1.39%)
AID1474462	Cytotoxicity against HUVEC after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID488366	Cell cycle arrest in human HCT116 cells assessed as accumulation at subG1 phase at 10 uM after 48 hrs by flow cytometry analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID488368	Cell cycle arrest in human HCT116 cells assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs by flow cytometry analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1231814	Antiproliferative activity against human U937 cells incubated for 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID1466380	Inhibition of class 1 HDAC in human HL60 cells using Boc-Ac-Lys-AMC as substrate incubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID324948	Inhibition of HDAC1 in HEK293 cells	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID1548284	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as viable cells level at 50 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 98.1%)
AID1401912	Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 1 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 97.14%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1548734	Inhibition of recombinant human HDAC5 using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1380952	Inhibition of HDAC1 (unknown origin) using fluorogenic substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1474456	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID329916	Induction of histone H4 hyperacetylation in human U937 cells	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1732201	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as increase in accumulation of G1 phase at 4 uM incubated for 24 hrs by PI staining based flow cytometry analysis	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1466064	Inhibition of recombinant human full length HDAC8 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1189850	Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Hydroxamic acids block replication of hepatitis C virus.
AID1901163	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1846955	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based MTT assay
AID1441699	Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA at 10 uM preincubated for 10 mins followed by substrate addition measured after 10 mins	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID374818	Inhibition of human C-terminal FLAG-tagged HDAC3 in HEK293 cells	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1541441	Inhibition of human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells at 10 uM ZMAL as substrate incubated for 90 mins by fluorescence assay relative to control	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID316896	Inhibition of human HDAC1	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1401902	Inhibition of human recombinant HDAC1 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID492802	Inhibition of human recombinant HDAC4 at 5 uM after 15 mins by fluorimetric assay	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID1876491	Antiproliferative activity against human U-251 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.
AID664039	Inhibition of HDAC1 using Fluor de Lys as substrate by fluorescence analysis	2012	European journal of medicinal chemistry, Jul, Volume: 53	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID777606	Induction of NO release in human HaCaT cells at 10 uM after 1 to 5 hrs by DAF-2D-based FACS analysis relative to DMSO-treated control	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1888470	Antiproliferative activity against human LNCAP cells assessed as reduction in cell viability at 100 uM incubated for 5 days	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.
AID421212	Inhibition of HDAC from human HeLa cells assessed as of histone H3 acetylation	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID50586	Inhibitory concentration against colon HCT116 cell line	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID1181316	Induction of granulocytic differentiation in human U937 cells assessed as increase in CD11c expression at 5 uM after 48 hrs by FACS method	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID1453363	Inhibition of HDAC1 (unknown origin) using Boc-Lys (acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by fluorescence assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID670718	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.
AID1873449	Inhibition of full length C-terminal His-tagged HDAC3 (unknown origin)/N-terminal GST-tagged NCoR2 (unknown origin) assessed as apparent inhibition constant using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated with enzyme for 0.5 to 2 hrs followed by s	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID364642	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.
AID525035	Inhibition of CFTR transcription assessed as decrease of CFTR protein level at 50 uM by immunoblot method	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID488276	Inhibition of HDAC6	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID1873440	Inhibition of full length C-terminal His-tagged HDAC3 (unknown origin)/N-terminal GST-tagged NCoR2 (unknown origin) assessed as equilibrium inhibition constant (Ki,1) using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluoresc	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1676588	Binding affinity to Zinc ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID316936	Inhibition of HDAC7	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID519583	Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 infected in O+ human erythrocytes by [3H]hypoxanthine incorporation assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1887684	Cytotoxicity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID1263145	Inhibition of human recombinant HDAC6 using Boc-Lys(Ac)-AMC as substrate after 30 mins by fluorescence assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1466062	Inhibition of recombinant human full length HDAC4 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1737641	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID519592	Selectivity index, ratio of IC50 for breast fibroblasts to IC50 for chloroquine-resistant Plasmodium falciparum Dd2	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1556408	Inhibition of HDAC1/2 in LPS/IFNgamma-stimulated mouse RAW264.7 cells assessed as upregulation of iNOS gene expression at 1 uM pretreated for 16 hrs followed by LPS stimulation and measured after 4 hrs by RT-qPCR analysis	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
AID1548728	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr fo	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1466063	Inhibition of recombinant human full length HDAC6 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1879900	Inhibition of HDAC1 in human MV4-11 cells assessed as accumulation of acetylated histone H3 at 5 uM measured by immunoblotting method	2022	European journal of medicinal chemistry, Apr-15, Volume: 234	Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells.
AID1732165	Inhibition of HDAC3 (unknown origin) using fluorogenic-(RHKKAc) as substrate by fluorescence assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1453359	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID650229	Inhibition of HDAC1	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1846954	Inhibition of recombinant HDAC3 (unknown origin) at 1 uM relative to control
AID374830	Antiproliferative activity against human MCF7 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1453366	Selectivity ratio of IC50 for HDAC2 (unknown origin) to IC50 for HDAC1 (unknown origin)	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID524999	Inhibition of HDAC6 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1676597	Binding affinity to cupric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID488360	Antitumor activity against human HCT116 cells xenografted in BALB/c nu/nu mouse assessed as reduction of tumor growth at 45 mg/kg, po administered on days 2, 4, 7, 9, 11, 14 and 16	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1873444	Inhibition of full length C-terminal FLAG-tagged HDAC2 (unknown origin) assessed as rate constant (k-2) of EI complex using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence based assay	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1548302	Induction of cell cycle arrest in bortezomib resistant human KM3/BTZ cells assessed as accumulation at G2/M phase at 100 nM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 9.1%)
AID1467243	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells at 2 uM using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated for 3 hrs followed by substrate addition after 30 mins in presence of 0.2 uM S	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID313730	Inhibition of HDAC2	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID1846980	Selectivity index, ratio of IC50 for Inhibition of full length N-terminal GST-tagged human recombinant HDAC7 (501 to 952 residues) expressed in Baculovirus system using Ac-Leu-Gly-Lys (Ac)-AMC as substrate to IC50 for inhibition of full length recombinant
AID1401906	Selectivity ratio of IC50 for human recombinant HDAC2 to IC50 for human recombinant HDAC6	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1876490	Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.
AID717813	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate assessed as remaining activity at 7.81 x 10'-6 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID102521	Inhibitory concentration against lung H446 cell line	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID488369	Cell cycle arrest in human HCT116 cells assessed as accumulation at S phase at 10 uM after 24 hrs by flow cytometry analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1676591	Binding affinity to Nickel cation assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1401924	Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at S phase at 1 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 5.21%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID316888	Inhibition of HDAC from human SNU16 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1846974	Inhibition of full length N-terminal GST-tagged human recombinant HDAC6 (1 to 1215 residues) expressed in Baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys (Ac)-AMC as substrate pretreated for 5 mins followed by substrate addition and measured after 30
AID328809	Antiproliferative activity against human A2780 cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1732209	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID519590	Toxicity in breast fibroblasts	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1737665	Induction of apoptosis in human MDA-MB-231 cells assessed as increase in cleaved PARP-1 level incubated for 24 hrs by Western blot analysis
AID488370	Cell cycle arrest in human HCT116 cells assessed as accumulation at S phase at 10 uM after 48 hrs by flow cytometry analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID328801	Inhibition of HDAC8 expressed in Escherichia coli	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1846976	Inhibition of full length C-terminal his-tagged human recombinant HDAC8 (142 to 143 residues) expressed in baculovirus in Sf9 insect cells using Ac-Leu-Gly-Lys (Tfa)-AMC as substrate pretreated for 5 mins followed by substrate addition and measured after
AID1548297	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as early apoptotic cells level at 200 nM incubated for 24 hrs in presence of bortezomib by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 1.39%)
AID1596044	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID329928	Inhibition of human HDAC4 in U937 cells assessed as residual activity at 5 uM	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1732190	Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1231809	Inhibition of recombinant HDAC8 (unknown origin) incubated for 10 mins using Boc-Lys(acetyl)-AMC fluorogenic substrate by homogeneous fluorescence release assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID1732192	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID764214	Inhibition of human recombinant HDAC1 using p53 residues 379-382 (RHKKAc) as substrate	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID650224	Induction of cell cycle arrest in human HCT116 cells assessed as accumulation at SubG1 phase at 10 uM after 24 hrs by flow cytometry (Rvb = 5.7 %)	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1596075	Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.88%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1732158	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID374826	Antiproliferative activity against human P53 expressing HCT116 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1732164	Inhibition of HDAC2 (unknown origin) using fluorogenic-(RHKKAc) as substrate by fluorescence assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1732169	Antiproliferative activity against HDACi-resistant human YCC3/7 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID777591	Effect on HDAC in human HaCaT cells assessed as upregulation of miR-661 at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID420317	Displacement of Atto700-HA from Bordetella / Alcaligenes strain FB188 HDAH by fluorescence anisotropy	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1727732	Inhibition of His-tagged BRD4 bromodomain 2 (unknown origin) using [Lys (5,8,12,16) Ac] H4(1-21) as substrate by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1401925	Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at G2/M phase at 1 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 14.14%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1548292	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as viable cells level at 50 nM incubated for 24 hrs in presence of bortezomib by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 98.1%)
AID610087	Anticancer activity against human HCT116 cells after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
AID43458	Inhibitory concentration against breast MCF-7 cell line	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID1401899	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1691036	Antiproliferative activity against human KB7D cells incubated for 48 hrs by SRB assay
AID161227	Inhibitory concentration against prostate DU145 cell line	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID764213	Inhibition of human recombinant HDAC4 using p53 residues 379-382 (RHKKAc) as substrate	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID538409	Inhibition of recombinant human HDAC6 using Boc-Lys(Ac)-AMC as substrate by fluorometric analysis	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Inhibitors selective for HDAC6 in enzymes and cells.
AID1586069	Growth inhibition of human MKN45 cells after 48 hrs by SRB assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID1901174	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated H4K5 at 5 uM treated for 48 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID496803	Inhibition of human HDAC3	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID1596040	Antiproliferative activity against human A549 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1293872	Inhibition of HDAC in mouse C127-LT cells assessed as activation of EGFP expression at 1 uM after 24 hrs by fluorescence microscopy	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Identification of new quinic acid derivatives as histone deacetylase inhibitors by fluorescence-based cellular assay.
AID1881855	Inhibition of HDAC3 (unknown origin)	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	NO-HDAC dual inhibitors.
AID1873438	Inhibition of full length C-terminal FLAG-tagged HDAC2 (unknown origin) assessed as inhibition constant (Ki) using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence based assay	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1556409	Inhibition of HDAC1/2 in LPS/IFNgamma-stimulated mouse RAW264.7 cells assessed as upregulation of IL-10 gene expression at 1 uM pretreated for 16 hrs followed by LPS stimulation and measured after 4 hrs by RT-qPCR analysis	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
AID1596068	Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=93.5%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1431813	Selectivity ratio of IC50 for human KDAC6 to IC50 for human KDAC1	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID292436	Inhibition of HDAC in HeLa cells	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
AID1401894	Antiproliferative activity against human HeLa cells at 8 uM after 72 hrs by CCK-8 assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1453361	Inhibition of class 1 HDAC in HEL cells using Boc-Lys (acetyl)-AMC as substrate preincubated for 3 hrs followed by substrate addition measured after 3 hrs by fluorescence assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID1901161	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID364641	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.
AID1431816	Selectivity ratio of IC50 for human KDAC6 to IC50 for human KDAC3	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1865259	Inhibition of wild type SHP2 (unknown origin) using DiFMUP as substrate preincubated for 30 mins followed by substrate addition and measured after 30 mins by microplate reader method	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1737655	Cytotoxicity against human K562 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
AID1737664	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as accumulation of cells at G1 phase at 4 uM for 24 hrs in presence of nocodazole by PI staining based flow cytometry analysis
AID1474452	Selectivity ratio of IC50 for HDAC1 (unknown origin) to IC50 for HDAC in human HCT116 cells	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID1596053	Inhibition of cell migration in human SMMC7721 cells at 0.5 uM measured after 48 hrs by microscopic analysis	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1263142	Antagonist activity at luciferase-fused ERalpha in human HEK293 cells expressing eYFP assessed as reduction of E2-induced estrogenic activity after 2 hrs by BRET assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1541443	Inhibition of human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells ZMAL as substrate incubated for 90 mins by fluorescence assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID329917	Induction of alpha tubulin hyperacetylation in human U937 cells	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID269160	Antitumor activity against human HCT116 cells xenografted in mouse at 20 mg/kg, ip	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.
AID1691034	Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay
AID1732207	Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID613340	Antiproliferative activity against human H1299 cells	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID1324233	Inhibition of HDAC6 in human LNCAP cells assessed as inhibition of DHT-induced alpha-tubulin deacetylation by measuring increase in alpha-tubulin acetylation at 10 uM measured after 24 hrs relative to control	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID1548294	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as late apoptotic cells level at 50 nM incubated for 24 hrs in presence of bortezomib by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.38%)
AID1474460	Inhibition of HDAC in human HCT116 cells using Boc-Lys (epsilon-Ac)-AMC as substrate pretreated for 18 hrs followed by substrate addition after 3 hrs by fluorescence assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID650226	Inhibition of HDAC1 in human HCT116 cells assessed as hyperacetylation of histone H3 at 10 uM after 24 hrs by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1732161	Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID316931	Inhibition of HDAC3	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1901167	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated H4K5 at 5 uM measured after 24 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID525021	Inhibition of HDAC in human CFBE41o- cell line assessed as total CFTR protein level including CFTR glycoform at 5 uM by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1691035	Antiproliferative activity against human KB-VIN cells incubated for 48 hrs by SRB assay
AID328796	Inhibition of HDAC4 expressed in Escherichia coli	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1466059	Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1901158	Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1596060	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 1 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=16.17%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1676599	Binding affinity to cupric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1737667	Induction of apoptosis in human MDA-MB-231 cells assessed as increase in cleaved caspase-3 level incubated for 24 hrs by Western blot analysis
AID1474459	Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID1596043	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID525005	Inhibition of HDAC7 in Fdelta508 CFTR-expressing human CFBE41o- monolayers assessed as increase in short circuit currents at 0.5 uM	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID8302	Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay	2003	Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26	Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
AID1235135	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	2015	European journal of medicinal chemistry, Jul-15, Volume: 100	Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
AID1737639	Cytotoxicity against human HDACi-sensitive YCC-11 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
AID385431	Inhibition of TNF-alpha-induced tissue factor activity in HUVEC at 30 uM preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay	2007	The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39	Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID708274	Growth inhibition of human SKHEP1 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1548289	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as early apoptotic cells level at 200 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 1.39%)
AID1578487	Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1453360	Antiproliferative activity against human SK-N-BE(2) cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID1235134	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	2015	European journal of medicinal chemistry, Jul-15, Volume: 100	Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
AID316941	Inhibition of HDAC9	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1479828	Inhibition of class 1 HDAC in human MV4-11 cells assessed as induction of histone hyperacetylation at 5 uM after 24 hrs by Western blot method	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID90211	Inhibitory activity against Histone deacetylase (HDAC) in K 562 erythroleukemia cells	2003	Bioorganic & medicinal chemistry letters, Nov-17, Volume: 13, Issue:22	Heterocyclic ketones as inhibitors of histone deacetylase.
AID44724	Inhibitory concentration against bladder T24 cell line	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID1691040	Inhibition of human recombinant HDAC8 using RHKAcKAc-AMC as substrate measured after 60 mins by fluorescence assay
AID50591	Inhibitory concentration against colon SW48 cell line	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID1401908	Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 0.125 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 97.14%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1732167	Inhibition of HDAC10 (unknown origin) using fluorogenic-(RHKKAc) as substrate by fluorescence assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID777588	Effect on HDAC in human HaCaT cells assessed as upregulation of miR-126# at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1293873	Inhibition of HDAC in mouse C127-LT cells assessed as activation of EGFP expression at 10 uM after 24 hrs by fluorescence microscopy	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Identification of new quinic acid derivatives as histone deacetylase inhibitors by fluorescence-based cellular assay.
AID328805	Antiproliferative activity against human HeLa cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID607635	Inhibition of HDAC6 in human Hela cells assessed as increase in alpha-tubulin acetylation at 0.6 uM after 16 hrs by immunofluorescence microscopy	2011	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14	A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.
AID1466058	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1873446	Inhibition of full length C-terminal His-tagged HDAC3 (unknown origin)/N-terminal GST-tagged NCoR2 (unknown origin) assessed as rate constant (k2) of EI complex using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence b	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID90348	Ability to inhibit recombinant human histone deacetylase 1 (HDAC-1).	2004	Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1	(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.
AID1596063	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G2/M phase at 4 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=16.17%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1732202	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as increase in accumulation of G2/M phase at 2.5 uM incubated for 24 hrs by PI staining based flow cytometry analysis	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1454683	Decrease in alcohol intake in rat model of voluntary heavy drinking assessed as decrease in motivation to consume alcohol at 500 uM, icv administered twice relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID1446910	Inhibition of Schistosoma mansoni KDAC8 at 30 uM using (FAM)-labeled peptide as substrate after 60 mins by microfluidic assay	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.
AID1548301	Induction of cell cycle arrest in bortezomib resistant human KM3/BTZ cells assessed as accumulation at S phase at 100 nM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 46%)
AID1727733	Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CCK8 assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1431817	Selectivity ratio of IC50 for human KDAC3 to IC50 for human KDAC6	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1596051	Selectivity ratio of IC50 for human recombinant His-tagged HDAC6 expressed in baculovirus infected insect cells to IC50 of human recombinant His-tagged HDAC1 (482 residues) expressed in baculovirus infected insect cells	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1548288	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as viable cells level at 200 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 98.1%)
AID313736	Inhibition of HDAC8	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID1294934	Inhibition of HDAC in human HeLa nuclear extract using Boc-acetyl-lysine-AMC as substrate incubated for 30 mins in dark by microplate reader analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116	Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID1737651	Inhibition of human recombinant HDAC7 expressed in baculovirus using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate by Fluorescence analysis
AID1556400	Inhibition of human recombinant C-terminal FLAG-tagged HDAC2 using Boc-Lys-(epsilon-Ac)-AMC as fluorogenic substrate incubated for 90 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
AID1737653	Inhibition of human recombinant HDAC10 expressed in baculovirus using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate by Fluorescence analysis
AID1873450	Inhibition of full length C-terminal FLAG-tagged HDAC2 (unknown origin) assessed as apparent inhibition constant using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated with enzyme for 0.5 to 2 hrs followed by substrate addition and measured after 30 mins	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID650213	Antitumor activity against human HCT116 cells xenografted in BALB/c nu/nu mouse assessed as suppression of tumor growth at 45 mg/kg, po administered every alternate days for 14 days measured up to day 16 relative to control	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1873448	Inhibition of full length C-terminal His-tagged HDAC1 (unknown origin) assessed as rate constant (k2) of EI complex using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence based assay	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID329919	Induction of apoptosis in human U937 cells	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1380943	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID488361	Toxicity in human HCT116 cells xenografted BALB/c nu/nu mouse assessed increase of running behavior at 45 mg/kg, po administered on days 2, 4, 7, 9, 11, 14 and 16	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1548295	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as necrotic cells level at 50 nM incubated for 24 hrs in presence of bortezomib by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.11%)
AID1915555	Inhibition of human recombinant HDAC1 (unknown origin) using MAZ1600 as substrate preincubated for 3 hrs followed by substrate addition by multilabel plate reader method	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1441631	Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID488365	Cell cycle arrest in human HCT116 cells assessed as accumulation at subG1 phase at 10 uM after 24 hrs by flow cytometry analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1548278	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells at 100 nM in presence of bortezomib incubated for 24 hrs by TUNEL assay
AID525026	Inhibition of HDAC in human CFBE41o- cell line assessed as correction of mutant Fdelta508 CFTR trafficking to cell surface as glycoform at 5 uM by Immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1453356	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID1530562	Antiplasmodial activity against asynchronous form of Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition at 10 uM after 48 hrs by SYBR green1 staining based flow cytometry relative to control	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID90837	Inhibitory concentration ratio against HDAC6/HDAC1	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Histone deacetylase inhibitors.
AID777596	Effect on HDAC in human HaCaT cells assessed as downregulation of miR-663B at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1401928	Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at G2/M phase at 4 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 14.14%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1380939	Inhibition of VEGFR-2 (unknown origin) at 0.2 uM after 40 mins by kinase-Glo assay relative to control	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID492801	Inhibition of human recombinant HDAC1 at 5 uM after 15 mins by fluorimetric assay	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID777599	Effect on HDAC in human HaCaT cells assessed as upregulation of miR-193b# at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID551597	Inhibition of HDAC3	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy.
AID1189854	Therapeutic index, ratio of CC50 for human HuH7 cells to EC50 for HCV genotype 1b infected in human Huh7 cells	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Hydroxamic acids block replication of hepatitis C virus.
AID1431814	Selectivity ratio of IC50 for human KDAC8 to IC50 for human KDAC1	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID324957	Inhibition of HDAC6 in HEK293 cells at 10 uM	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID303014	Inhibition of human recombinant HDAC1	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
AID525034	In vivo inhibition of HDAC	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1548285	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as early apoptotic cells level at 50 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 1.39%)
AID650225	Inhibition of HDAC2 in human HCT116 cells assessed as hyperacetylation of histone H3 at 10 uM after 24 hrs by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID708270	Growth inhibition of human HGC27 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1821968	Antiproliferative activity against human YCC-11 cells assessed as cell growth inhibition
AID1737648	Inhibition of human recombinant HDAC3 expressed in baculovirus using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate by Fluorescence analysis
AID1740016	Inhibition of recombinant human HDAC4 using pan-HDAC substrate incubated for 3 hrs by fluorescence method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1901176	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated H4K5 at 5 uM preincubated for 6 hrs followed by compound washout and measured up to 48 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID620534	Reactivation of MeCp2 mutant expression in human GM11272 cells after 6 days by PCR method	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18	Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression.
AID524994	Inhibition of HDAC9 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID488362	Toxicity in human HCT116 cells xenografted BALB/c nu/nu mouse assessed weight loss at 45 mg/kg, po administered on days 2, 4, 7, 9, 11, 14	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1401915	Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 1 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 2.48%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1821969	Antiproliferative activity against human YCC3/7 cells assessed as cell growth inhibition
AID1401909	Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 0.125 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.09%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID717814	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate assessed as remaining activity at 3.91 x 10'-6 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1401916	Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 4 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 97.14%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID374812	Antiproliferative activity against human P53-deficient HeLa cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1882460	Displacement of [3H]-acetylated histones from HDAC1 derived from human K562 cell nuclear extract incubated for 10 mins by liquid scintillation counting method	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID328795	Inhibition of HDAC3	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1466412	Induction of apoptosis in human HL60 cells assessed as increase in cleaved PARP level at 5 uM after 48 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1737649	Inhibition of human recombinant HDAC4 expressed in baculovirus using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate by Fluorescence analysis
AID1454685	Lipophilicity, log D of the compound at pH 7.4	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID708277	Growth inhibition of human Bel7402 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID717827	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1231808	Inhibition of recombinant HDAC2 (unknown origin) incubated for 10 mins using Boc-Lys(acetyl)-AMC fluorogenic substrate by homogeneous fluorescence release assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID1454682	Decrease in alcohol intake in rat model of voluntary heavy drinking assessed as decrease in operant alcohol self-administration at 500 uM, icv administered twice relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID1203890	Inhibition of recombinant HDAC2 (unknown origin) using fluorogenic substrate Boc-Lys (acetyl)-AMC after 20 mins by homogeneous fluorescence release assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1203894	Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1453367	Selectivity ratio of IC50 for HDAC3 (unknown origin) to IC50 for HDAC1 (unknown origin)	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID1917928	Inhibition of HDAC3 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer's disease.
AID488367	Cell cycle arrest in human HCT116 cells assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs by flow cytometry analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1732196	Inhibition of HDAC in human MDA-MB-231 cells assessed as increase in p21 expression at 4 uM incubated for 24 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID613343	Inhibition of human ERG at 30 uM	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID316885	Antiproliferative activity against human A549 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1737646	Inhibition of human recombinant HDAC6 expressed in baculovirus using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate by Fluorescence analysis
AID328799	Inhibition of HDAC6 at 10 uM	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1727730	Inhibition of HDAC6 (unknown origin) by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID374819	Inhibition of wild type His-tagged HDAC5 catalytic domain T678-L1122 expressed in Escherichia coli	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1586082	Inhibition of human HDAC7 using Boc-Lys(trifluoroacetyl)-AMC as substrate by fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID1846958	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based CCK-8 assay
AID313734	Inhibition of HDAC6	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID1231813	Antiproliferative activity against human NCI-H661 cells incubated for 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID1293875	Inhibition of HDAC in human HeLa cells using Boc-Lys(AC)-AMC as substrate after 24 to 48 hrs by spectrofluorometry	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Identification of new quinic acid derivatives as histone deacetylase inhibitors by fluorescence-based cellular assay.
AID328810	Antiproliferative activity against human renal epithelial cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1586078	Inhibition of human HDAC2 using RHKKAc as substrate by fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID1401898	Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1873442	Inhibition of full length C-terminal His-tagged HDAC1 (unknown origin) assessed as equilibrium inhibition constant (Ki,1) using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence based assay	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1280295	Inhibition of KDAC3 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID1847001	Induction of apoptosis in mouse B16-F10 cells assessed as early apoptotic cells at 100 nM incubated for 48 hrs by Annexin V-FITC/PI analysis (Rvb = 1.68 %)
AID777595	Effect on HDAC in human HaCaT cells assessed as downregulation of miR-766 at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID488274	Inhibition of HDAC2	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID374822	Inhibition of C-terminal His-tagged HDAC8 expressed in Escherichia coli	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1596077	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1596050	Inhibition of human recombinant His-tagged HDAC2 (1 to 582 residues) expressed in baculovirus infected insect cells using FLUOR DE LYS Green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence me	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1466390	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1486671	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1732160	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1887683	Cytotoxicity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID1676595	Binding affinity to Ferric ion assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1732166	Inhibition of HDAC8 (unknown origin) using fluorogenic-(RHKKAc) as substrate by fluorescence assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1441630	Inhibition of recombinant human LTA4H aminopeptidase activity expressed in Escherichia coli BL21 (DE3) pLysS assessed as formation of p-NA from Ala-p-NA preincubated for 10 mins followed by substrate addition measured after 10 mins	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID609492	Thermodynamic solubility of the compound at pH 6.8	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1380953	Inhibition of HDAC2 (unknown origin) using fluorogenic Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID329927	Inhibition of human HDAC1 in U937 cells assessed as residual activity at 5 uM	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID613295	Antiproliferative activity against human HCT116 cells assessed as growth inhibition	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.
AID748113	Inhibition of HDAC2 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID1441700	Inhibition of recombinant human LTA4H Epoxide Hydrolase expressed in Escherichia coli BL21 (DE3) pLysS at 10 uM preincubated for 10 mins followed by addition of LTA4 as substrate measured after 15 mins by reverse-phase HPLC analysis	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID610090	Anticancer activity against human A2780 cells after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
AID1380938	Inhibition of HDAC in human HeLa cell nuclear extract using fluorogenic Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID524995	Inhibition of HDAC10 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1764296	Inhibition of HDAC6 in human CAL-27 cells assessed as accumulation of acetylated alpha-tubulin at 1 uM for 24 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1847002	Induction of apoptosis in mouse B16-F10 cells assessed as late apoptotic cells at 100 nM incubated for 48 hrs by Annexin V-FITC/PI analysis (Rvb = 0.00 %)
AID1596048	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID329914	Inhibition of human HDAC1 in U937 cells by immunoprecipitation assay	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1466408	Induction of apoptosis in human HL60 cells assessed as decrease in procaspase-3 level at 5 uM after 48 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID328832	Toxicity in ip dosed BALB/c mouse assessed as maximum tolerated dose	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1847000	Induction of apoptosis in mouse B16-F10 cells assessed as viable cells at 100 nM incubated for 48 hrs by Annexin V-FITC/PI analysis (Rvb = 98.3 %)
AID1879890	Inhibition of recombinant human HDAC1 using ZMAL (Z-(Ac)Lys-AMC as substrate incubated for 20 mins and measured by homogenous fluorescence assay	2022	European journal of medicinal chemistry, Apr-15, Volume: 234	Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells.
AID777600	Effect on HDAC in human HaCaT cells assessed as upregulation of miR-21# at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1466413	Toxicity in BALB/c nude mouse xenografted with human U937 cells assessed as body weight loss at 100 mg/kg/day administered via oral gavage for 13 days	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID364644	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.
AID777590	Effect on HDAC in human HaCaT cells assessed as upregulation of miR-1227 at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1203893	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1548296	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as viable cells level at 200 nM incubated for 24 hrs in presence of bortezomib by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 98.1%)
AID1486674	Inhibition of HDAC1 (unknown origin) at 10 uM using Ac-Leu-GlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1888465	Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.
AID1525779	Inhibition of HADC3 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1676601	Binding affinity to Zinc ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID80683	In vitro antiproliferative activity against human cancer cell line HCT116 using MTT assay	2004	Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1	(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.
AID1586085	Inhibition of human HDAC10 using RHKKAc as substrate by fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID1466393	Antiproliferative activity against human ES2 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID385692	Inhibition of HDAC4 catalytic domain expressed in HEK293 cells upto 10,000 nM by Biomol assay	2007	Proceedings of the National Academy of Sciences of the United States of America, Oct-30, Volume: 104, Issue:44	Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.
AID525025	Inhibition of HDAC in human CFBE41o- cell line assessed as increase in CFTR mRNA at 0.1 uM by RT-PCR	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1380948	Antiproliferative activity against human HEL cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID610088	Anticancer activity against human MDA-MB-231 cells after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
AID1486675	Inhibition of HDAC2 (unknown origin) at 10 uM using Ac-Leu-GlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID764212	Inhibition of human recombinant HDAC6 using p53 residues 379-382 (RHKKAc) as substrate	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID1453365	Inhibition of HDAC3 (unknown origin) using Boc-Lys (acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by fluorescence assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID1556401	Inhibition of human recombinant C-terminal His-tagged HDAC3/NCOR2 using Boc-Lys-(epsilon-Ac)-AMC as fluorogenic substrate incubated for 90 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
AID1901146	Inhibition of C-terminal His-tagged human HDAC3 (1 to 428 residues)/N-terminal GST tagged human NCOR2 (395 to 489) expressed in baculovirus infected Sf9 insect cells using fluorogenic HDAC substrate measured after 30 mins by fluorimetry	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID519589	Toxicity in human WI38 cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1737644	Inhibition of human recombinant HDAC1 expressed in baculovirus using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate by Fluorescence analysis
AID1294943	Inhibition of HDAC in human HeLa cells using fluor de Lys as substrate incubated for 20 mins by microplate spectrofluorometric analysis	2016	European journal of medicinal chemistry, Jun-30, Volume: 116	Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.
AID1917927	Inhibition of HDAC2 (unknown origin)	2022	Bioorganic & medicinal chemistry letters, 11-15, Volume: 76	Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer's disease.
AID777598	Effect on HDAC in human HaCaT cells assessed as downregulation of miR-935 at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1541444	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 9	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID329918	Induction of p21 expression in human U937 cells	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1403468	Cytotoxicity against human HaCaT cells assessed as increase in dead cells 0.1 to 100 uM after 72 hrs by Trypan Blue-based assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors.
AID329926	Induction of granulocytic differentiation in human U937 cells assessed as CD11c expression at 5 uM after 30 hrs	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID524997	Inhibition of HDAC7 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1847023	Cardiotoxicity in C57BL/6 mouse ssessed as shortening of QTc level by ECG analysis
AID1548732	Inhibition of recombinant full length human C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluoresce	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1873472	Inhibition of full length C-terminal FLAG-tagged HDAC2 (unknown origin) assessed as dissociation half-life of EI complex using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence based assay	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1474453	Inhibition of HDAC in human A2780 cells using Boc-Lys (epsilon-Ac)-AMC as substrate pretreated for 18 hrs followed by substrate addition after 3 hrs by fluorescence assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID274110	Inhibition of HDAC1 (mean IC50)	2006	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23	A series of novel, potent, and selective histone deacetylase inhibitors.
AID1578490	Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID313729	Inhibition of HDAC1	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID1486677	Inhibition of HDAC1 (unknown origin) using Ac-Leu-GlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1737663	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as reduction in population between G1 to G2/M phases at 4 uM for 24 hrs by PI staining based flow cytometry analysis
AID1901156	Inhibition of HDAC4 (unknown origin) using FAM-RHKK(Ac)-NH2/FAM-RHKK(trifluoroacetyl)-NH2 as substrate preincubated for 15 mins followed by substrate addition and measured after 3 hrs by microfluidic chip based fluorescence assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1530563	Antiplasmodial activity against asynchronous form of Plasmodium falciparum 3D7 infected in human erythrocytes assessed as parasite growth inhibition after 48 hrs by SYBR green1 staining based flow cytometry	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Identification of novel quinazoline derivatives as potent antiplasmodial agents.
AID1846997	Induction of cell cycle arrest in mouse B16-F10 cells assessed as accumulation of cells in G2/M phase at 100 nM measured after 48 hrs by PI/RNaseA staining based flow cytometry analysis (Rvb= 5.76%)
AID1466055	Inhibition of recombinant human full length HDAC2 using Fluor-de-Lys as substrate after 60 mins by spectrofluorimetric analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1548892	Induction of apoptosis in human MV4-11 cells harboring wild type p53/FLT3-ITD mutant assessed as cleavage of pro-caspase 3 at 1000 to 5000 nM after 24 hrs by Western blot analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID385436	Inhibition of LPS-induced tissue factor activity in HUVEC at 30 uM preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay	2007	The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39	Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID328793	Inhibition of HDAC1	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1486676	Inhibition of HDAC6 (unknown origin) at 10 uM using Ac-Leu-GlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1596069	Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=2.88%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1847015	Antitumor activity against mouse B16-F10 cells allografted in C57BL/6 mouse assessed as reduction in tumor weight at 10 mg/kg, ip administered for 14 days in presence of (2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone
AID1401913	Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 1 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.09%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1431819	Selectivity ratio of IC50 for human KDAC3 to IC50 for human KDAC8	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1737642	Cytotoxicity in human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID609498	Half life in human liver microsomes	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1691039	Inhibition of human recombinant HDAC3/NCOR2 using RHKKAc-AMC as substrate measured after 60 mins by fluorescence assay
AID1401918	Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 4 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.29%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID708272	Growth inhibition of human SGC7901 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1380954	Inhibition of HDAC3 (unknown origin) using fluorogenic Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1401927	Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at S phase at 4 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 5.21%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1732168	Antiproliferative activity against HDACi-sensitive human YCC-11 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID329922	Inhibition of human HDAC4 in U937 cells at 5 uM	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1596052	Selectivity ratio of IC50 for human recombinant His-tagged HDAC6 expressed in baculovirus infected insect cells to IC50 of human recombinant His-tagged HDAC2 (1 to 582 residues) expressed in baculovirus infected insect cells	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1737656	Cytotoxicity against human KG -1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
AID650221	Induction of cell cycle arrest in human HCT116 cells assessed as accumulation at G0/G1 phase at 10 uM after 48 hrs by flow cytometry (Rvb = 81.9 %)	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID78450	Tested for antiproliferative activity against HCT116 colorectal human carcinoma cell using WST-1 assay	2002	Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10	Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group.
AID1466401	Antitumor activity against human HCT116 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 50 mg/kg/day administered via oral gavage for 16 days measured every 3 days	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID316891	Inhibition of HDAC	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1882459	Displacement of [3H]-acetylated histones HDAC6 derived from human K562 cell nuclear extract incubated for 10 mins by liquid scintillation counting method	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID1887682	Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID650230	Antiproliferative activity against human HCT116 cells after 3 days by WST-1 assay	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID73169	Inhibitory concentration against normal fibroblast MRHF cell line	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID1846962	Antiproliferative activity against human YCC3/7 cells assessed as inhibition of cell viability
AID1887690	Cytotoxicity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID708279	Growth inhibition of human SMMC7721 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID650227	Solubility of the compound in 10 % DMSO/Water	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID316895	Inhibition of human MCF7 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID664379	Inhibition of HDAC1	2012	European journal of medicinal chemistry, Jul, Volume: 53	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID313733	Inhibition of HDAC5	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID313732	Inhibition of HDAC4	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID90349	Inhibitory activity against Histone deacetylase (HDAC) from SNU-16 (human gastric adenocarcinoma) cells	2003	Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26	Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
AID1873441	Inhibition of full length C-terminal FLAG-tagged HDAC2 (unknown origin) assessed as equilibrium inhibition constant (Ki,1) using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence based assay	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1881853	Inhibition of HDAC1 (unknown origin)	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	NO-HDAC dual inhibitors.
AID1740014	Inhibition of recombinant human HDAC3 using pan-HDAC substrate incubated for 3 hrs by fluorescence method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1548244	Inhibition of HDAC1/2 in human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay
AID1732191	Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1308514	Inhibition of human BRD4 expressed in Escherichia coli BL21(DE3)-R3-pRARE2 by bromodomain alphascreen peptide displacement assay	2016	Bioorganic & medicinal chemistry letters, 06-15, Volume: 26, Issue:12	Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
AID1380968	Inhibition of VEGF-stimulated VEGFR2 phosphorylation in human HUVEC cells at 100 nM preincubated for 2 hrs followed by VEGF stimulation by Western blot analysis	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1541558	Inhibition of HDAC6 in human Cal27CisR cells assessed as acetylation of alpha-tubulin at 1 uM measured after 24 hrs by immunoblot analysis	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1403469	Cytotoxicity against mouse C2C12 cells assessed as increase in dead cells 0.5 to 10 uM after 72 hrs by Trypan Blue-based assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors.
AID1596080	Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1556399	Inhibition of human recombinant C-terminal His/FLAG-tagged HDAC1 using Boc-Lys-(epsilon-Ac)-AMC as fluorogenic substrate incubated for 90 mins by fluorescence based assay	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
AID525022	Inhibition of HDAC in human CFBE41o- cell line assessed as increase in total CFTR protein level including CFTR glycoform at 0.1 uM by immunoblot analysis	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1403455	Inhibition of FLAG-tagged HDAC2 (unknown origin) expressed in HEK293T cells using acetylated lysine side chain as substrate after 1 hr by colorimetric detection based assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors.
AID1453357	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID414980	Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells	2009	Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8	Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
AID1474455	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID1676602	Binding affinity to ferric ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1691038	Inhibition of recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected insect cells using RHKKAc-AMC as substrate measured after 60 mins by fluorescence assay
AID1737647	Inhibition of human recombinant HDAC8 expressed in baculovirus using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate by Fluorescence analysis
AID708273	Growth inhibition of human MGC803 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1901160	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1380940	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1596072	Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=93.5%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1596041	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1901166	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated H3K9 at 5 uM measured after 24 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID292437	Antiproliferative activity against HeLa cells by alamar blue assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Trithiocarbonates: exploration of a new head group for HDAC inhibitors.
AID1479838	Cell cycle arrest in human MV4-11 cells assessed as accumulation at sub-G1 phase at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric method	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID1431822	Selectivity ratio of IC50 for human KDAC1 to IC50 for human KDAC6	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1737657	Cytotoxicity against human THP-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
AID1596033	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1474461	Inhibition of HDAC1 (unknown origin) using deacetylase fluorogenic substrate pretreated for 5 mins followed by substrate addition after 30 mins by fluorescence assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID1676589	Binding affinity to Nickel cation assessed as performance ratio ratio by measuring product of accounting ratio and retention ratio at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1441632	Binding affinity to recombinant human LTA4H hydrolase assessed as change in melting temperature at 50 uM by SYPRO orange dye-based thermofluor assay	2017	Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis.
AID1181308	Inhibition of HDAC1 in human U937 cells assessed as increase in p21WAF1/CIP1 level at 5 uM by Western blotting method	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID1403456	Inhibition of human FLAG-tagged HDAC3 expressed in HEK293T cells using acetylated lysine side chain as substrate after 1 hr by colorimetric detection based assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors.
AID1578485	Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID492813	Inhibition of HDAC in human NB4 cells assessed as increase in histone H3 acetylation at 5 uM after 24 hrs by Western blot analysis	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID328828	Antitumor activity against human HCT116 cells xenografted BALB/c mouse assessed as tumor growth inhibition at 60 mg/kg, ip administered for 5 days per week for 2.5 weeks	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1846971	Inhibition of recombinant HDAC1 (unknown origin) at 1 uM
AID609489	Inhibition of purified recombinant HDAC1	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID93030	Effect on induced hyperacetylation of histones in whole cells	2004	Bioorganic & medicinal chemistry letters, Jan-05, Volume: 14, Issue:1	(2-amino-phenyl)-amides of omega-substituted alkanoic acids as new histone deacetylase inhibitors.
AID664382	Inhibition of HDAC4	2012	European journal of medicinal chemistry, Jul, Volume: 53	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID1401922	Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at G2/M phase at 0.125 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 14.14%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID286793	Increase in histone H3 acetylation in U937 cells at 5 uM after 24 hrs by Western blot analysis	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	Bispyridinium dienes: histone deacetylase inhibitors with selective activities.
AID1556406	Inhibition of HDAC1/2 in LPS/IFNgamma-stimulated mouse RAW264.7 cells assessed as upregulation of TNF-alpha gene expression at 1 uM pretreated for 16 hrs followed by LPS stimulation and measured after 4 hrs by RT-qPCR analysis	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
AID1401911	Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 0.125 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 2.48%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1380945	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1873480	Inhibition of full length C-terminal His-tagged HDAC3 (unknown origin)/N-terminal GST-tagged NCoR2 (unknown origin) assessed as inhibition constant of EI complex in the first binding step using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate in the presence of inosi	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1732159	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1596047	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1466410	Induction of apoptosis in human HL60 cells assessed as increase in cleaved caspase-3 level at 5 uM after 48 hrs by Western blot analysis	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID488357	Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID609494	Inhibition of CYP3A4	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1454684	Decrease in alcohol intake in rat model of voluntary heavy drinking assessed as decrease in relapse phenomenon after period of abstinence at 500 uM, icv administered twice relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID294382	Inhibition of HDAC by fluorescent assay	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid.
AID1486678	Inhibition of HDAC2 (unknown origin) using Ac-Leu-GlyLys(Ac)-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence analysis	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1401890	Antiproliferative activity against human MGC803 cells at 8 uM after 72 hrs by CCK-8 assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID708275	Growth inhibition of human QGY7701 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1380965	Inhibition of HDAC6 in human HeLa cells assessed as increase in intracellular acetyl-tubulin levels at 1 uM after 6 hrs by Western blot analysis	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID329921	Inhibition of human HDAC1 in U937 cells at 5 uM	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID316934	Inhibition of HDAC4	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1466060	Growth inhibition of human AsPC1 cells after 48 hrs by sulforhodamine B assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1293876	Inhibition of HDAC in human HeLa nuclear extract assessed as accumulation of acetylated histone H3 after 24 hrs by western blot analysis	2016	Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9	Identification of new quinic acid derivatives as histone deacetylase inhibitors by fluorescence-based cellular assay.
AID1873443	Inhibition of full length C-terminal His-tagged HDAC3 (unknown origin)/N-terminal GST-tagged NCoR2 (unknown origin) assessed as rate constant (k-2) of EI complex using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1449332	Inhibition of HDAC6 in human CAL27 cells assessed as accumulation of acetylated alpha tubulin at 1 uM after 24 hrs by immunoblot analysis	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1873437	Inhibition of full length C-terminal His-tagged HDAC3 (unknown origin)/N-terminal GST-tagged NCoR2 (unknown origin) assessed as inhibition constant (Ki) using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence based ass	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1596067	Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.88%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1706069	Increase in LPS/IFNgamma-induced IL-10 mRNA expression in mouse RAW26.7 cells at 1 uM incubated for 20 hrs followed by LPS/IFNgamma stimulation and measured after 4 hrs by RT-qPCR analysis	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
AID1865258	Inhibition of recombinant human HDAC using fluorogenic substrate preincubated for 5 mins followed by substrate addition and measured after 30 mins by fluorescence based microplate reader analysis	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
AID1740018	Inhibition of recombinant human HDAC9 using pan-HDAC substrate incubated for 3 hrs by fluorescence method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1408543	Inhibition of His6-tagged HDAC3/SMRT (395 to 489 residues) (unknown origin) co-expressed in baculovirus infected sf9 cells using (FAM)-labeled acetylated peptide substrate after 17 hrs by caliper microfluidic mobility shift assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
AID1231812	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID1879896	Inhibition of recombinant human HDAC8 using H2N-Arg- His-Lys(Ac)-Lys(Ac)-AMC as substrate incubated for 90 mins and measured after 20 mins by fluorescence assay	2022	European journal of medicinal chemistry, Apr-15, Volume: 234	Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells.
AID1486672	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1873447	Inhibition of full length C-terminal FLAG-tagged HDAC2 (unknown origin) assessed as rate constant (k2) of EI complex using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence based assay	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID777605	Inhibition of HDAC activity in human HaCaT cell lysate at 1 to 50 uM after 1 hr by colorimetry	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1737662	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as reduction in population at S phase at 4 uM for 24 hrs by PI staining based flow cytometry analysis
AID748112	Inhibition of HDAC3 (unknown origin) after 60 mins by fluorescence assay	2013	Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11	Discovery of the first histone deacetylase 6/8 dual inhibitors.
AID286792	Effect on alpha tubulin acetylation in U937 cells at 1 uM after 24 hrs by Western blot analysis	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	Bispyridinium dienes: histone deacetylase inhibitors with selective activities.
AID1401893	Antiproliferative activity against human HeLa cells at 2 uM after 72 hrs by CCK-8 assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID777592	Effect on HDAC in human HaCaT cells assessed as downregulation of miR-744# at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1737652	Inhibition of human recombinant HDAC9 expressed in baculovirus using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate by Fluorescence analysis
AID1474463	Therapeutic index, ratio of IC50 for HUVEC to IC50 for human HCT116 cells	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID1740012	Inhibition of recombinant human HDAC1 using pan-HDAC substrate incubated for 3 hrs by fluorescence method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1846975	Inhibition of full length N-terminal GST-tagged human recombinant HDAC7 (501 to 952 residues) expressed in Baculovirus system using Ac-Leu-Gly-Lys (Ac)-AMC as substrate pretreated for 5 mins followed by substrate addition and measured after 30 mins
AID1847020	Toxicity in C57BL/6 mouse allografted with mouse B16-F10 cells assessed as morphological abnormalities in liver at 10 mg/kg, ip administered for 14 days by H and E staining based analysis
AID524991	Inhibition of HDAC7 in human homozygous Fdelta508 primary bronchial epithelial cells assessed as increase in short circuit currents at 1 uM for 4, 6, and 8 days relative to control	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID1454689	Half life in human at 2 mg/m2 dosed twice a week	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID1548727	Inhibition of recombinant human HDAC2 expressed in baculovirus expression system using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID488358	Inhibition of HDAC1	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1486670	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID496802	Inhibition of human HDAC2	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID328806	Antiproliferative activity against human HCT116 cells by CellTiter-Blue cell viability assay	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID650217	Induction of cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase at 10 uM after 48 hrs by flow cytometry (Rvb = 5.4 %)	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1901162	Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1764298	Inhibition of class-1 HDAC in human CAL-27 cells assessed as induction of histone H-3 acetylation at 1 uM for 24 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1548290	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as late apoptotic cells level at 200 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.38%)
AID717815	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate assessed as remaining activity at 1.95 x 10'-6 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1846970	Inhibition of recombinant HDAC3 (unknown origin) at 1 uM
AID1454686	Drug uptake in iv dosed baboon brain after 90 mins by PET imaging method relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID374811	Inhibition of human C-terminal FLAG-tagged HDAC1 in HEK293 cells	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1915537	Inhibition of HDAC1 (unknown origin)	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1847017	Toxicity in C57BL/6 mouse allografted with mouse B16-F10 cells assessed as morphological abnormalities in kidney at 10 mg/kg, ip administered for 14 days by H and E staining based analysis
AID1453355	Inhibition of HDAC in human HeLa nuclear extract using Boc-Lys (acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition measured after 1 hr by fluorescence assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID1203896	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID316920	Antitumor activity against human HCT116 cells xenografted in nude mouse model at 20 mg/kg, ip	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID43462	Inhibitory concentration against breast MDA-MB-231 cell line	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID650220	Induction of cell cycle arrest in human HCT116 cells assessed as accumulation at S phase at 10 uM after 24 hrs by flow cytometry (Rvb = 10.6 %)	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1846973	Inhibition of recombinant HDAC3 (unknown origin) using Ac-Leu-Gly-Lys (Ac)-AMC as substrate pretreated for 5 mins followed by substrate addition and measured after 30 mins
AID551596	Inhibition of HDAC2	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy.
AID492806	Cell cycle arrest in human NB4 cells assessed as increase in accumulation at pre-G1 phase at 5 uM after 24 hrs by FACS analysis	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID1691037	Inhibition of recombinant human full-length C-terminal FLAG-His tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay
AID420319	Inhibition of Bordetella / Alcaligenes strain FB188 HDAH by fluorogenic enzyme assay	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1203889	Inhibition of recombinant HDAC1 (unknown origin) using fluorogenic substrate Boc-Lys (acetyl)-AMC after 20 mins by homogeneous fluorescence release assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1556405	Inhibition of HDAC1 in LPS/IFNgamma-stimulated mouse RAW blue cells assessed as upregulation of NFkappaB transcriptional activity by measuring increase in SEAP activity at 1 to 2.5 uM pretreated for 16 hrs followed by LPS stimulation and measured after 4	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
AID1596070	Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.73%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1586084	Inhibition of human HDAC9 using Boc-Lys(trifluoroacetyl)-AMC as substrate by fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID316903	Inhibition of human HCT116 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID488372	Cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase at 10 uM after 48 hrs by flow cytometry analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1203892	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1431811	Selectivity ratio of IC50 for human KDAC3 to IC50 for human KDAC1	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1548300	Induction of cell cycle arrest in bortezomib resistant human KM3/BTZ cells assessed as accumulation at G1 phase at 100 nM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 42%)
AID269168	Antitumor activity against human SW48 cells xenografted in mouse at 20 mg/kg, ip	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.
AID1474451	Selectivity ratio of IC50 for HDAC1 (unknown origin) to IC50 for HDAC in human A2780 cells	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID1901145	Inhibition of recombinant human N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in Sf9 insect cells using fluorogenic HDAC substrate 3 measured after 30 mins by fluorimetry	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1380956	Inhibition of HDAC8 (unknown origin) using fluorogenic Boc-Lys(trifluoroacetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1846972	Inhibition of full length recombinant human HDAC1 (1 to 482 residues) expressed in Baculovirus system using Ac-Leu-Gly-Lys (Ac)-AMC as substrate pretreated for 5 mins followed by substrate addition and measured after 30 mins
AID1740013	Inhibition of recombinant human HDAC2 using pan-HDAC substrate incubated for 3 hrs by fluorescence method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1181306	Inhibition of HDAC1 in human U937 cells assessed as increase in acetyl-histone H3 level at 5 uM by Western blotting method	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID421211	Antitumor activity against mouse ML1 cells	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Recent advances in the development of polyamine analogues as antitumor agents.
AID1887681	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Design, synthesis and biological evaluation of novel o-aminobenzamide derivatives as potential anti-gastric cancer agents in vitro and in vivo.
AID1181307	Inhibition of HDAC6 in human U937 cells assessed as increase in acetyl-alpha-tubulin level at 5 uM by Western blotting method	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.
AID551595	Inhibition of HDAC1	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Application of p21 and klf2 reporter gene assays to identify selective histone deacetylase inhibitors for cancer therapy.
AID1548303	Induction of cell cycle arrest in bortezomib resistant human KM3/BTZ cells assessed as accumulation at G1 phase at 100 nM incubated for 24 hrs in presence of bortezomib by propidium iodide staining based flow cytometry (Rvb = 42%)
AID1525777	Inhibition of HADC1 (unknown origin)	2020	Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases.
AID1596071	Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 1 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.88%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1424827	Inhibition of class 1 HDAC in human MV4-11 cells assessed as hyperacetylation of histone H3 at 200 nM after 24 hrs by Western blot analysis	2018	European journal of medicinal chemistry, May-25, Volume: 152	Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
AID1847034	In vivo inhibition of HDAC in tumor of mouse B16-F10 cells xenografted in C57BL/6 mouse assessed as increase in acetylated histone-H3 expression by H and E staining based immunohistochemistry method
AID324951	Inhibition of HDAC4 H976Y mutant expressed in Escherichia coli at 10 uM	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID1901148	Inhibition of HDAC in human HeLa cell nuclear extracts using color de Lys as substrate measured after 30 mins by colorimetric assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1467241	Inhibition of recombinant C-terminal His-tagged HDAC11 (unknown origin) expressed in baculovirus infected Sf9 cells using Ac-Arg-Gly-Lys(Ac)-AMC as substrate pretreated for 3 hrs followed by substrate addition after 30 mins in presence of 0.2 uM SAHA by f	2017	Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13	Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
AID1541446	Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate incubated for 90 mins by fluorescence assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1548733	Inhibition of recombinant human HDAC4 using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1732163	Inhibition of HDAC1 (unknown origin) using fluorogenic-(RHKKAc) as substrate by fluorescence assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1847024	Cardiotoxicity in C57BL/6 mouse ssessed as shortening of QTc level in presence of (2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone by ECG analysis
AID1578486	Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1586079	Inhibition of human HDAC3 using RHKKAc as substrate by fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID524996	Inhibition of HDAC8 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID525003	Inhibition of HDAC1 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID496801	Inhibition of human HDAC1	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Chemical phylogenetics of histone deacetylases.
AID609495	Ratio of IC50 for CYP3A4 to IC50 for human HCT116 cells	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1263146	Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1548291	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as necrotic cells level at 200 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.11%)
AID1401914	Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 1 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 0.29%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1846959	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell viability measured for 48 hrs in presence of (2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone by microplate reader based MTT assay
AID1596038	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID525000	Inhibition of HDAC4 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID316898	Inhibition of HDAC2	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID374831	Antiproliferative activity against human U937 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID70208	Inhibitory concentration against normal epithelial HMEC cell line	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID1380947	Antiproliferative activity against human KG1 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1380955	Inhibition of HDAC6 (unknown origin) using fluorogenic Boc-Lys(acetyl)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by fluorescence-based assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1596066	Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.73%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID717811	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate assessed as remaining activity at 6.25 x 10'-5 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1596065	Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=2.88%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1732193	Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID1879893	Inhibition of recombinant human HDAC6 using ZMAL (Z-(Ac)Lys-AMC as substrate incubated for 20 mins and measured by homogenous fluorescence assay	2022	European journal of medicinal chemistry, Apr-15, Volume: 234	Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells.
AID525023	Inhibition of HDAC in human CFBE41o- cell line assessed as increase in CFTR mRNA at 5 uM by RT-PCR	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID328800	Inhibition of HDAC7 expressed in Escherichia coli	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1541554	Inhibition of class 1 HDAC in human CAL27 cells assessed as increase in histone H3 acetylation at 1 uM measured after 24 hrs by immunoblot analysis	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID1479842	Cell cycle arrest in human HEL cells at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric method	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID670719	Inhibition of HDAC1 in human HeLa cell lysate using KI-104 as substrate after 40 mins by fluorescence analysis	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.
AID1847035	In vivo inhibition of HDAC in tumor of mouse B16-F10 cells xenografted in C57BL/6 mouse assessed as increase in acetylated histone-H3 expression in presence of (2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone by H and E staining based immunohistoch
AID1876492	Antiproliferative activity against rat C6 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.
AID488359	Solubility in 10% DMSO-water	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1864220	Binding affinity to 5' FAM and 3' TAMRA-labeled c-myc G4-quadruplex DNA Pu22 (unknown origin) assessed as change in melting temperature at 1 uM by fluorescence resonance energy transfer assay	2022	Journal of medicinal chemistry, 09-22, Volume: 65, Issue:18	Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer.
AID1401905	Selectivity ratio of IC50 for human recombinant HDAC1 to IC50 for human recombinant HDAC6	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1486673	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID1901147	Inhibition of recombinant human full-length C-terminal Flag-His6-tagged HDAC1 (1 to 482 residues) expressed in Sf9 insect cells using fluorogenic HDAC substrate measured after 30 mins by fluorimetry	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1676594	Binding affinity to gallium ion assessed as accounting ratio by measuring total compound detected/total compound adsorbed at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1727729	Inhibition of HDAC1 (unknown origin) by fluorescence based assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1596059	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 1 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=6.83%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1737650	Inhibition of human recombinant HDAC5 expressed in baculovirus using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate by Fluorescence analysis
AID1479843	Cell cycle arrest in human Jurkat cells at 5 uM after 24 hrs by propidium iodide staining-based flow cytometric method	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID324949	Inhibition of HDAC3 in HEK293 cells	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID329931	Induction of apoptosis in human U937 cells at 5 uM after 30 hrs	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID1324232	Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced AR protein level at 10 uM measured after 24 hrs relative to control	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
AID538408	Inhibition of recombinant human HDAC1 using Cbz-Lys(TFAc)-AMC as substrate by fluorometric analysis	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Inhibitors selective for HDAC6 in enzymes and cells.
AID1401891	Antiproliferative activity against human A375 cells at 2 uM after 72 hrs by CCK-8 assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1706070	Increase in LPS/IFNgamma-induced iNOS mRNA expression in mouse RAW26.7 cells at 1 uM incubated for 20 hrs followed by LPS/IFNgamma stimulation and measured after 4 hrs by RT-qPCR analysis	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
AID1901154	Inhibition of HDAC8 (unknown origin) using FAM-RHKK(Ac)-NH2/FAM-RHKK(trifluoroacetyl)-NH2 as substrate preincubated for 15 mins followed by substrate addition and measured after 3 hrs by microfluidic chip based fluorescence assay	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID717812	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate assessed as remaining activity at 1.56 x 10'-5 M pretreated for 30 mins before substrate addition by fluorescence assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	The structural requirements of histone deacetylase inhibitors: suberoylanilide hydroxamic acid analogs modified at the C6 position.
AID1403454	Inhibition of human FLAG-tagged HDAC1 expressed in HEK293T cells using acetylated lysine side chain as substrate after 1 hr by colorimetric detection based assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors.
AID328831	Toxicity against human HCT116 cells xenografted BALB/c mouse assessed as body weight loss at 25 mg/kg, ip administered 5 days per week for 2.5 weeks	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1380950	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID650228	Inhibition of HDAC2	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1846956	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based MTT assay
AID1263143	Antagonist activity at ERalpha in human T47D-KBLuc cells assessed as inhibition of E2-induced transcriptional activity by luciferase reporter gene assay	2015	Bioorganic & medicinal chemistry, Dec-15, Volume: 23, Issue:24	Design, synthesis and evaluation of antiestrogen and histone deacetylase inhibitor molecular hybrids.
AID1853011	Inhibition of HDAC3-SMRT (unknown origin) using Boc-(Ac)Lys-AMC as substrate preincubated with compound for 1 hrs followed by substrate addition and measured after 1 hrs by fluorescent assay	2022	RSC medicinal chemistry, Dec-14, Volume: 13, Issue:12	A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras.
AID1847013	Antitumor activity against mouse B16-F10 cells allografted in C57BL/6 mouse assessed as tumor growth inhibition at 10 mg/kg, ip administered for 14 days
AID670720	Inhibition of HDAC2 in human HeLa cell lysate using KI-104 as substrate after 40 mins by fluorescence analysis	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Synthesis, biological evaluation and molecular docking studies of 3-(1,3-diphenyl-1H-pyrazol-4-yl)-N-phenylacrylamide derivatives as inhibitors of HDAC activity.
AID1691061	Induction of apoptosis in human KB7D cells assessed as increase in activated gammaH2AX expression at 5 uM measured after 24 hrs by Western blot analysis
AID102520	Inhibitory concentration against lung A549 cell line	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID1881857	Vasodilating activity in rat aorta in presence of ODQ	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	NO-HDAC dual inhibitors.
AID1737640	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
AID488371	Cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by flow cytometry analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1873428	Inhibition of HDAC2 (unknown origin) at 2 uM preincubated for 1 hr followed by 100-fold dilution and subsequent substrate addition measured after 1 hr	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1380942	Antiproliferative activity against human AGS cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1676598	Binding affinity to cupric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID488275	Inhibition of HDAC3	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID1596045	Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1548730	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1189851	Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Hydroxamic acids block replication of hepatitis C virus.
AID303015	Inhibition of human recombinant HDAC2	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
AID609490	Antiproliferative activity against human HCT116 cells	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID316927	Inhibition of human CCD1059SK cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1586081	Inhibition of human HDAC6 using RHKKAc as substrate by fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID316893	Inhibition of HDAC8	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1596074	Induction of apoptosis in human SMMC7721 cells assessed as late apoptotic cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=1.73%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID274117	Inhibition of HeLa cell proliferation	2006	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 16, Issue:23	A series of novel, potent, and selective histone deacetylase inhibitors.
AID420324	Inhibition of HDAC1 by fluorogenic enzyme assay	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1882461	Displacement of [3H]-acetylated histones from HDAC3 derived from human K562 cell nuclear extract incubated for 10 mins by liquid scintillation counting method	2022	Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.
AID764209	Partition coefficient, log D of the compound at pH 7.4 by Avdeef-Tsinman potentiometric titration method	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID488364	Inhibition of HDAC1 in human HCT116 cells assessed as induction of hyperacetylation of histone H3 at 10 uM after 24 hrs by Western blot analysis	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group.
AID1686358	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay	2016	Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21	Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.
AID1466056	Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Lys(Ac)-pNA as substrate after 30 mins by fluorescence assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
AID1737668	Induction of apoptosis in human MDA-MB-231 cells assessed as increase in cleaved caspase-8 level incubated for 24 hrs by Western blot analysis
AID1548275	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay
AID1873473	Inhibition of full length C-terminal His-tagged HDAC3 (unknown origin)/N-terminal GST-tagged NCoR2 (unknown origin) assessed as dissociation half-life of EI complex using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescen	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1873429	Mixed-type inhibition of HDAC3 (unknown origin) at 3.90625 to 62.5 nM by Lineweaver-Burk plot analysis	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID329920	Induction of granulocytic differentiation in human U937 cells	2008	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 18, Issue:8	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.
AID374817	Inhibition of human C-terminal FLAG-tagged HDAC2 in HEK293 cells	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID316926	Inhibition of human SW620 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID492812	Induction of p21WAF1/CIP1 expression in human NB4 cells at 5 uM after 24 hrs by Western blot analysis	2010	Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.
AID777589	Effect on HDAC in human HaCaT cells assessed as downregulation of miR-941 at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1401896	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1596073	Induction of apoptosis in human SMMC7721 cells assessed as early apoptotic cells at 4 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=2.88%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID609497	Half life in rat liver microsomes	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID1479845	Induction of apoptosis in human PBMC at 5 uM after 24 hrs by Annexin V/propidium iodide staining-based flow cytometric method	2018	Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8	Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.
AID1380949	Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID328797	Inhibition of HDAC4 gain-of-function phenotype expressed in Escherichia coli	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.
AID1556407	Inhibition of HDAC1/2 in LPS/IFNgamma-stimulated mouse RAW264.7 cells assessed as upregulation of IL-6 gene expression at 1 uM pretreated for 16 hrs followed by LPS stimulation and measured after 4 hrs by RT-qPCR analysis	2019	European journal of medicinal chemistry, Sep-01, Volume: 177	Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
AID1380946	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID1764256	Induction of histone H-3 expression in human CAL-27 cells for 24 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Feb-05, Volume: 211	Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
AID1486669	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 08-01, Volume: 25, Issue:15	Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-cheromene derivatives as histone deacetylaes inhibitors.
AID316943	Inhibition of human HDAC1 assessed as histone H4 acetylation in cell based assay	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID488277	Inhibition of HDAC8	2010	Bioorganic & medicinal chemistry, Jun-01, Volume: 18, Issue:11	On the inhibition of histone deacetylase 8.
AID1915580	Cytotoxicity against human K562 cells	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
AID1474457	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID316935	Inhibition of HDAC5	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID613114	Cell cycle arrest in human U937 cells assessed as accumulation at G1 phase at 5 uM after 30 hrs by propidium iodide staining based flow cytometry	2011	Bioorganic & medicinal chemistry, Jun-15, Volume: 19, Issue:12	Epigenetic profiling of the antitumor natural product psammaplin A and its analogues.
AID1280294	Inhibition of KDAC1 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID1847037	Antitumor activity against mouse B16-F10 cells allografted in C57BL/6 mouse assessed as tumor growth inhibition at 10 mg/kg, ip administered for 14 days in presence of (2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone
AID708271	Growth inhibition of human BGC823 cells incubated for 72 hrs by WST dye reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.
AID1888466	Inhibition of purified human HDAC1 using Ac-Leu-Gly-(e-Ac)Lys-AMC by fluorometric HDAC assay	2022	Bioorganic & medicinal chemistry letters, 01-01, Volume: 55	Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.
AID1596036	Antiproliferative activity against human A375 cells assessed as reduction in cell growth at 2 uM incubated for 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1548726	Inhibition of recombinant HDAC1 (unknown origin) using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID269169	Antitumor activity against human A549 cells xenografted in mouse at 20 mg/kg, ip	2006	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 16, Issue:15	Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.
AID1578488	Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID313735	Inhibition of HDAC7	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID1737643	Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
AID286791	Effect on alpha tubulin acetylation in U937 cells at 5 uM after 24 hrs by Western blot analysis	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	Bispyridinium dienes: histone deacetylase inhibitors with selective activities.
AID1586077	Inhibition of human HDAC1 using RHKKAc as substrate by fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID90347	Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) prepared from K562 erythroleukemia cells.	2002	Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23	Trifluoromethyl ketones as inhibitors of histone deacetylase.
AID1578489	Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	2020	ACS medicinal chemistry letters, Jan-09, Volume: 11, Issue:1	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.
AID1548287	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as necrotic cells level at 50 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.11%)
AID1732171	Induction of cell cycle arrest in human MDA-MB-231 cells assessed as sub-G1 phase at 4 uM incubated for 72 hrs by PI staining based flow cytometry analysis (Rvb = 0.8 %)	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID525033	Inhibition of HDAC in human primary bronchial epithelial cells assessed as induction of mutant Fdelta508 CFTR protein apical surface localization at 5 uM	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID106868	Compound was tested for antiproliferative activity against human MKN45 cancer cell lines	2003	Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26	Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors.
AID1727745	Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation at G0/G1 phase after 24 hrs by flow cytometry	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1873426	Inhibition of HDAC1 (unknown origin) at 2 uM preincubated for 1 hr followed by 100-fold dilution and subsequent substrate addition measured after 1 hr	2022	Bioorganic & medicinal chemistry letters, 08-15, Volume: 70	Comparison of three zinc binding groups for HDAC inhibitors - A potency, selectivity and enzymatic kinetics study.
AID1431820	Selectivity ratio of IC50 for human KDAC8 to IC50 for human KDAC6	2017	European journal of medicinal chemistry, Feb-15, Volume: 127	Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors.
AID1203891	Inhibition of recombinant HDAC8 (unknown origin) using fluorogenic substrate Boc-Lys (acetyl)-AMC after 20 mins by homogeneous fluorescence release assay	2015	European journal of medicinal chemistry, , Volume: 96	Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
AID1740017	Inhibition of recombinant human HDAC7 using pan-HDAC substrate incubated for 3 hrs by fluorescence method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1596061	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at G0/G1 phase at 4 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=77%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID764208	Intrinsic aqueous solubility of the compound at pH 7.4 by Avdeef-Tsinman potentiometric titration method	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
AID1446915	Inhibition of Schistosoma mansoni KDAC8 using (FAM)-labeled peptide as substrate after 60 mins by microfluidic assay	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Structural insights of SmKDAC8 inhibitors: Targeting Schistosoma epigenetics through a combined structure-based 3D QSAR, in vitro and synthesis strategy.
AID1449333	Inhibition of HDAC6 in human Cal27CisR cells assessed accumulation of acetylated alpha tubulin at 1 uM after 24 hrs by immunoblot analysis	2017	Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
AID1541445	Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID610089	Anticancer activity against human DU145 cells after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.
AID525001	Inhibition of HDAC2 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID650222	Induction of cell cycle arrest in human HCT116 cells assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs by flow cytometry (Rvb = 74.2 %)	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1596046	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID316922	Antitumor activity against human SW48 cells xenografted in nude mouse model at 20 mg/kg, ip	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID609493	Inhibition of human ERG by automated patch clamp assay	2011	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 21, Issue:16	The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
AID324954	Inhibition of wild type HDAC4 expressed in Escherichia coli at 10 uM	2008	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6	Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.
AID650223	Induction of cell cycle arrest in human HCT116 cells assessed as accumulation at SubG1 phase at 10 uM after 48 hrs by flow cytometry (Rvb = 2.3 %)	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1541550	Inhibition of HDAC6 in human CAL27 cells assessed as acetylation of alpha-tubulin at 1 uM measured after 24 hrs by immunoblot analysis	2019	Journal of medicinal chemistry, 12-26, Volume: 62, Issue:24	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
AID385686	Inhibition of flag-tagged HDAC4 by Biomol assay	2007	Proceedings of the National Academy of Sciences of the United States of America, Oct-30, Volume: 104, Issue:44	Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.
AID607634	Inhibition of HDAC6 in human Hela cells assessed as increase in total lysine acetylation at 0.6 uM after 16 hrs by immunofluorescence microscopy	2011	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14	A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.
AID1466403	Antitumor activity against human HCT116 cells xenografted in BALB/c nude mouse assessed as relative tumor increment ratio at 50 mg/kg/day administered via oral gavage for 16 days measured every 3 days	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1847003	Induction of apoptosis in mouse B16-F10 cells assessed as necrotic cells at 100 nM incubated for 48 hrs by Annexin V-FITC/PI analysis (Rvb = 0.012 %)
AID1231807	Inhibition of recombinant HDAC1 (unknown origin) incubated for 10 mins using Boc-Lys(acetyl)-AMC fluorogenic substrate by homogeneous fluorescence release assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
AID1466397	Antitumor activity against human U937 cells xenografted in BALB/c nude mouse assessed as relative tumor increment ratio at 50 mg/kg/day administered via oral gavage for 13 days measured every 3 days	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID420322	Inhibition of Bordetella / Alcaligenes strain FB188 HDAC6 by fluorogenic enzyme assay	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Non-isotopic dual parameter competition assay suitable for high-throughput screening of histone deacetylases.
AID1846957	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based CCK-8 assay
AID313731	Inhibition of HDAC3	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
AID1873479	Inhibition of full length C-terminal His-tagged HDAC3 (unknown origin)/N-terminal GST-tagged NCoR2 (unknown origin) using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate preincubated with enzyme and inositol hexa phosphate for 2 hrs followed by substrate addition an	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1453358	Antiproliferative activity against HEL cells after 48 hrs by MTT assay	2017	Bioorganic & medicinal chemistry, 06-15, Volume: 25, Issue:12	Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.
AID777597	Effect on HDAC in human HaCaT cells assessed as downregulation of miR-629 at 10 uM after 1 hr by RT-PCR analysis	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1466392	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID360094	Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay	2007	The Journal of biological chemistry, Sep-28, Volume: 282, Issue:39	Histone deacetylase inhibitors suppress TF-kappaB-dependent agonist-driven tissue factor expression in endothelial cells and monocytes.
AID1548299	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as necrotic cells level at 200 nM incubated for 24 hrs in presence of bortezomib by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.11%)
AID385691	Inhibition of flag-tagged HDAC4 expressed in HEK293 cells upto 10,000 nM by Biomol assay	2007	Proceedings of the National Academy of Sciences of the United States of America, Oct-30, Volume: 104, Issue:44	Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.
AID1454739	Lipophilicity, log P of the compound at pH 7.4	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).
AID1401904	Inhibition of human recombinant HDAC6 using Fluor de Lys-Green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID90666	Inhibitory activity on partially purified recombinant human Histone deacetylase 1 (HDAC-1)	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
AID316918	Antitumor activity against human A549 cells xenografted in nude mouse model at 20 mg/kg, ip	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID519594	Selectivity index, ratio of IC50 for breast fibroblasts to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1732208	Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Apr-05, Volume: 215	CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
AID90529	Inhibitory concentration against histone deacetylase	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Histone deacetylase inhibitors.
AID1466399	Toxicity in BALB/c nude mouse xenografted with human U937 cells assessed as body weight at 50 mg/kg/day administered via oral gavage for 13 days (Rvb = 25.39 +/- 1.18 g)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1401895	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1548736	Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs b	2020	Journal of medicinal chemistry, 05-28, Volume: 63, Issue:10	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
AID1586080	Inhibition of human HDAC4 using Boc-Lys(trifluoroacetyl)-AMC as substrate by fluorescence assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID1881856	Vasodilating activity in rat aorta	2022	European journal of medicinal chemistry, Jan-05, Volume: 227	NO-HDAC dual inhibitors.
AID1401889	Antiproliferative activity against human MGC803 cells at 2 uM after 72 hrs by CCK-8 assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1466389	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1466404	Toxicity in BALB/c nude mouse xenografted with human HCT116 cells assessed as body weight at 50 mg/kg/day administered via oral gavage for 16 days (Rvb = 19.91 +/- 1.26 g)	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1548286	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as late apoptotic cells level at 50 nM incubated for 24 hrs by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.38%)
AID1596037	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID650219	Induction of cell cycle arrest in human HCT116 cells assessed as accumulation at S phase at 10 uM after 48 hrs by flow cytometry (Rvb = 10.4 %)	2012	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5	Anti-tumor activity of new orally bioavailable 2-amino-5-(thiophen-2-yl)benzamide-series histone deacetylase inhibitors, possessing an aqueous soluble functional group as a surface recognition domain.
AID1401919	Induction of apoptosis in human SMMC7721 cells assessed as necrotic cells at 4 umol/L after 72 hrs by Alexa Fluor 488 Annexin/propidium iodide staining-based flow cytometric analysis (Rvb = 2.48%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID1676596	Binding affinity to Ferric ion assessed as retention ratio by measuring compound detected in elution fraction/total compound detected at 2.55 umol by immobilized metal-ion affinity chromatography	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
AID1474458	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, May-26, Volume: 132	Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
AID374827	Antiproliferative activity against human P53 expressing A549 cells after 72 hrs by celltiter-blue cell viability assay	2009	Journal of medicinal chemistry, Jun-11, Volume: 52, Issue:11	Discovery of a potent class I selective ketone histone deacetylase inhibitor with antitumor activity in vivo and optimized pharmacokinetic properties.
AID1235132	Inhibition of HDAC1 (unknown origin) preincubated for 5 mins followed by fluorogenic substrate addition measured after 30 mins by microplate reader analysis	2015	European journal of medicinal chemistry, Jul-15, Volume: 100	Design, synthesis and antiproliferative activities of novel benzamides derivatives as HDAC inhibitors.
AID1548276	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells assessed combination index in presence of bortezomib at 1:1 compound to bortezomib ratio incubated for 48 hrs by MTT assay
AID1873445	Inhibition of full length C-terminal His-tagged HDAC1 (unknown origin) assessed as rate constant (k-2) of EI complex using (Ac-Leu-Gly-Lys(Ac)-AMC as substrate measured every 30 sec for 60 mins by fluorescence based assay	2022	ACS medicinal chemistry letters, May-12, Volume: 13, Issue:5	Determination of Slow-Binding HDAC Inhibitor Potency and Subclass Selectivity.
AID1401921	Cell cycle arrest in human SMMC7721 cells assessed as accumulation of cells at S phase at 0.125 umol/L after 72 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 5.21%)	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
AID525002	Inhibition of HDAC3 by in vitro deacetylation assay	2010	Nature chemical biology, Jan, Volume: 6, Issue:1	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.
AID777601	Induction of HDAC4 nuclear shuttling in human HaCaT cells at 10 uM after 1 hr by immunofluorescence method relative to DMSO-treated control	2013	ACS medicinal chemistry letters, Oct-10, Volume: 4, Issue:10	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor.
AID1596035	Antiproliferative activity against human A375 cells assessed as reduction in cell growth at 8 uM incubated for 72 hrs by CCK-8 assay relative to control	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID316886	Antiproliferative activity against human SKBR3 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Histone deacetylase inhibitors: from bench to clinic.
AID1847012	Upregulation of AC-H3 in mouse B16-F10 cells incubated for 12 hrs by Western blot analysis
AID1466391	Antiproliferative activity against human U266 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Jul-07, Volume: 134	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
AID1548298	Induction of apoptosis in bortezomib resistant human KM3/BTZ cells assessed as late apoptotic cells level at 200 nM incubated for 24 hrs in presence of bortezomib by Annexin V-FITC/PI staining based FCAS analysis (Rvb = 0.38%)
AID1901173	Inhibition of HDAC1/HDAC2/HDAC3 in human HCT-116 cells assessed as increase in accumulation of acetylated H3K9 at 5 uM treated for 48 hrs by Western blot analysis	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors.
AID1380941	Antiproliferative activity against human ACHN cells after 72 hrs by MTT assay	2018	Journal of medicinal chemistry, 06-28, Volume: 61, Issue:12	Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously.
AID664384	Inhibition of HDAC10	2012	European journal of medicinal chemistry, Jul, Volume: 53	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID1548304	Induction of cell cycle arrest in bortezomib resistant human KM3/BTZ cells assessed as accumulation at S phase at 100 nM incubated for 24 hrs in presence of bortezomib by propidium iodide staining based flow cytometry (Rvb = 46%)
AID1596056	Cell cycle arrest in human SMMC7721 cells assessed as accumulation at S phase at 0.25 uM incubated for 48 hrs by propidium iodide staining based flow cytometry (Rvb=6.83%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID322414	Antiproliferative activity against human LNCap by MTT assay	2008	Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6	Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
AID519584	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in O+ human erythrocytes by [3H]hypoxanthine incorporation assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Potent antimalarial activity of histone deacetylase inhibitor analogues.
AID1586068	Growth inhibition of human A549 cells after 48 hrs by SRB assay	2019	European journal of medicinal chemistry, Jan-15, Volume: 162	1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase.
AID1280297	Inhibition of KDAC8 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	2016	Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4	Design and Synthesis of Simplified Largazole Analogues as Isoform-Selective Human Lysine Deacetylase Inhibitors.
AID664381	Inhibition of HDAC8	2012	European journal of medicinal chemistry, Jul, Volume: 53	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID90208	Inhibitory activity against partially purified histone deacetylase of human leukemia K562 cells.	1999	Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15	Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.
AID664383	Inhibition of HDAC6	2012	European journal of medicinal chemistry, Jul, Volume: 53	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.
AID1737654	Cytotoxicity against human HDACi-sensitive YCC3 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
AID1740015	Inhibition of recombinant human HDAC8 using pan-HDAC substrate incubated for 3 hrs by fluorescence method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight.
AID1847018	Toxicity in C57BL/6 mouse allografted with mouse B16-F10 cells assessed as morphological abnormalities in kidney at 5 mg/kg, ip administered for 14 days in presence of (2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone by H and E staining based analy
AID1596064	Induction of apoptosis in human SMMC7721 cells assessed as viable cells at 0.25 uM incubated for 48 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometry (Rvb=93.5%)	2019	European journal of medicinal chemistry, Jul-01, Volume: 173	Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	2 (0.36)	18.2507
2000's	125 (22.73)	29.6817
2010's	312 (56.73)	24.3611
2020's	111 (20.18)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	31 (5.57%)	5.53%
Reviews	32 (5.75%)	6.00%
Case Studies	1 (0.18%)	4.05%
Observational	0 (0.00%)	0.25%
Other	493 (88.51%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (71)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase I Study of GSK525762C and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas [NCT03925428]	Phase 1	0 participants (Actual)	Interventional	2020-09-18	Withdrawn(stopped due to Other - Protocol moved to Disapproved)
A Phase Ib Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma [NCT03760614]	Phase 1	0 participants (Actual)	Interventional	2021-01-31	Withdrawn(stopped due to Lack of Funding)
A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460) [NCT02909452]	Phase 1	30 participants (Actual)	Interventional	2016-09-20	Completed
Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma [NCT01038778]	Phase 1/Phase 2	47 participants (Actual)	Interventional	2009-10-29	Active, not recruiting
A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure [NCT02936752]	Phase 1	27 participants (Anticipated)	Interventional	2017-04-03	Active, not recruiting
A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas [NCT03179930]	Phase 2	47 participants (Anticipated)	Interventional	2017-06-07	Recruiting
A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer [NCT03829930]	Phase 1	6 participants (Actual)	Interventional	2019-05-01	Terminated(stopped due to Sponsor discontinued the drug)
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Pri [NCT03018249]	Early Phase 1	50 participants (Actual)	Interventional	2017-10-11	Completed
A Phase 2, Randomized, Double-Blind, Multicenter Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer [NCT02115594]	Phase 2	0 participants (Actual)	Interventional	2014-04-30	Withdrawn(stopped due to Internal decision)
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers [NCT04708470]	Phase 1/Phase 2	90 participants (Anticipated)	Interventional	2021-10-05	Recruiting
A Phase 2 Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing [NCT00828854]	Phase 2	27 participants (Actual)	Interventional	2008-10-01	Completed
A Phase I Study of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, NSC 706995) Plus Clofarabine for Philadelphia Chromosome-Negative, Poor Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia in Newly Diagnosed Older Adults or in A [NCT01132573]	Phase 1	27 participants (Actual)	Interventional	2010-04-30	Completed
A Phase II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination With Nivolumab Plus Ipilimumab in Patients With Renal Cell Carcinoma Previously Treated With Nivolumab Plus Ipilimumab [NCT03552380]	Phase 2	18 participants (Anticipated)	Interventional	2018-08-31	Active, not recruiting
A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers [NCT03924245]	Phase 1	3 participants (Actual)	Interventional	2020-10-01	Terminated(stopped due to Change in participant landscape and other treatment availability)
A Phase I Study of Sorafenib in Combination With the Histone Deacetylase Inhibitor, Entinostat in Patients With Advanced Cancers [NCT01159301]	Phase 1	44 participants (Actual)	Interventional	2010-06-30	Terminated
A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy [NCT03473639]	Phase 1	13 participants (Actual)	Interventional	2019-01-29	Completed
A Phase 1b Trial of Sequential Combinations of BN-Brachyury, Entinostat, Ado-trastuzuamb Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) [NCT04296942]	Phase 1	1 participants (Actual)	Interventional	2021-05-04	Terminated(stopped due to One participant was accrued, and the study was stopped due to new safety data from the company for M7824 and slow accrual.)
A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase I [NCT00676663]	Phase 2	130 participants (Actual)	Interventional	2008-06-13	Completed
A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination With 5-Azacytidine (5AC, NSC 102816) in Elderly Patients With Acute Myeloid Leukemia (AML) [NCT01305499]	Phase 2	52 participants (Actual)	Interventional	2011-07-01	Active, not recruiting
A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function [NCT03192111]	Phase 1	40 participants (Actual)	Interventional	2017-07-27	Completed
A Randomized Phase III Clinical Study of Entinostat/Placebo in Combination With Exemestane in Chinese Patients With Hormone Receptor-positive Advanced Breast Cancer [NCT03538171]	Phase 3	375 participants (Actual)	Interventional	2018-05-15	Active, not recruiting
Breaking Innate PD-1 Inhibitor (PD1i) Resistance Using Epigenetic Modifiers; Antitumor Efficacy and Correlative Analyses of Entinostat Plus Pembrolizumab in Non-Inflamed Metastatic Melanoma (MM) [NCT03765229]	Phase 2	11 participants (Actual)	Interventional	2019-03-22	Completed
A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors [NCT02897778]	Phase 1	30 participants (Actual)	Interventional	2016-08-24	Completed
An Open-Label, 3-Part, 2-Period Study to Examine the Effect of Omeprazole (Part 1), Famotidine (Part 2), and of an Acidic Beverage (Part 3) on the Single-Dose Pharmacokinetics of Entinostat in Healthy Adult Subjects [NCT02922933]	Phase 1	66 participants (Actual)	Interventional	2016-10-25	Completed
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease [NCT00602030]	Phase 1/Phase 2	141 participants (Actual)	Interventional	2008-01-08	Completed
A Phase I/II Study of Entinostat in Combination With 5-Azacytidine in Patients With Recurrent Advanced Non-Small Cell Lung Cancer [NCT00387465]	Phase 1/Phase 2	94 participants (Actual)	Interventional	2006-08-31	Completed
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patients With Relapsed or Refractory Hodgkin's Lymphoma [NCT00866333]	Phase 2	49 participants (Actual)	Interventional	2009-04-13	Terminated(stopped due to Terminated prior to completion of accrual per corporate decision.)
Phase II Study of Azacitidine and Entinostat (SNDX-275) in Patients With Advanced Breast Cancer [NCT01349959]	Phase 2	58 participants (Actual)	Interventional	2011-04-21	Active, not recruiting
A Phase I and Pharmacokinetic Study to Evaluate Histone Deacetylase Inhibitor, Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer [NCT02833155]	Phase 1	19 participants (Actual)	Interventional	2016-08-29	Completed
Phase I Clinical-Labratory Study of the Histone Deacetylase (HDA) Inhibitor MS-275 in Adults With Refractory and Relapsed Hematologic Malignancies [NCT00015925]	Phase 1	0 participants	Interventional	2001-02-28	Completed
A 2-Stage, Open-Label, Randomized, Single-Dose, Crossover Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat in Healthy Adult Subjects [NCT02922946]	Phase 1	47 participants (Actual)	Interventional	2016-10-11	Completed
GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response [NCT01234532]	Phase 2	5 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to low accrual)
A Phase 2, Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib [NCT00750698]	Phase 2	8 participants (Actual)	Interventional	2008-08-31	Terminated(stopped due to Due to business reasons, enrollment on the study was halted and the study terminated. The decision to close enrollment was not due to any safety concern.)
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer) [NCT03280563]	Phase 1/Phase 2	138 participants (Actual)	Interventional	2017-12-26	Active, not recruiting
A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor Entinostat for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasi [NCT00313586]	Phase 2	197 participants (Actual)	Interventional	2006-08-31	Completed
Genome-Wide Methylation and Gene Re-expression Analysis of Resectable Lung Tumor Tissue Pairs Obtained Pre- and Post-Treatment With 5-Azacytidine and Entinostat [NCT01886573]	Phase 1	40 participants (Anticipated)	Interventional	2013-06-30	Terminated
A Phase II Study of and Oral Histone Deacytylase Inhibitor, MS-275 (NSC 706995), in Combination With Sargramostim (GM-CSF, Berlex, Inc.) Treating Relapsed and Refractory Myeloid Malignancies [NCT00462605]	Phase 2	24 participants (Actual)	Interventional	2007-04-30	Completed
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer [NCT05898828]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2024-01-03	Recruiting
A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Color [NCT02437136]	Phase 1/Phase 2	196 participants (Actual)	Interventional	2015-07-31	Completed
Phase II Study of Azacitadine and Entinostat in Patients With Metastatic Colorectal Cancer [NCT01105377]	Phase 2	47 participants (Actual)	Interventional	2010-04-30	Completed
A Phase II Randomized, Open Label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 Plus Entinostat in Advanced Renal Cell Carcinoma [NCT03501381]	Phase 2	46 participants (Anticipated)	Interventional	2018-05-24	Active, not recruiting
Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer [NCT03291886]	Phase 2	133 participants (Actual)	Interventional	2017-09-22	Completed
Phase II Study of MS-275, a Histone Deacetylase Inhibitor, Comparing 2 Dosage Schedules in Patients With Metastatic Melanoma [NCT00185302]	Phase 2	28 participants (Actual)	Interventional	2004-12-31	Completed
Phase 1 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer [NCT02623751]	Phase 1	15 participants (Actual)	Interventional	2015-11-30	Completed
A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma [NCT02780804]	Phase 1	21 participants (Actual)	Interventional	2017-01-06	Completed
A Phase I Study to Assess the Food Effect on the Pharmacokinetics of Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer and Men and Women With Progressive Non-Small Cell Lung Cancer [NCT01594398]	Phase 1	14 participants (Actual)	Interventional	2012-05-31	Completed
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer [NCT02115282]	Phase 3	608 participants (Actual)	Interventional	2014-03-29	Active, not recruiting
A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275 (NSC 706995, IND 61,198), in Combination With 13-Cis-Retinoic Acid in Metastatic Progressive Cancer. [NCT00098891]	Phase 1	24 participants (Actual)	Interventional	2004-10-31	Completed
A Dose-Finding Trial of the Histone Deacetylase Inhibitor MS-275 (NSC 706995) in Combination With 5-Azacitidine (5AC, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMMoL) and Acute Myeloid Leukemia (AML) [NCT00101179]	Phase 1	63 participants (Actual)	Interventional	2004-11-03	Completed
A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas [NCT00020579]	Phase 1	75 participants (Anticipated)	Interventional	2001-03-31	Completed
A Phase I/II Study to Evaluate the Safety, Pharmacodynamics and Efficacy of Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma [NCT03024437]	Phase 1/Phase 2	72 participants (Anticipated)	Interventional	2017-06-29	Suspended(stopped due to Major review underway)
A Phase 1/2 Study of SNDX-275 in Combination With Imatinib for Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [NCT01383447]	Phase 1/Phase 2	2 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to This study was halted prematurely by the NCI for low accrual.)
Phase I and Phase I Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed [NCT01434303]	Phase 1	37 participants (Actual)	Interventional	2012-01-10	Completed
A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer [NCT00754312]	Phase 1	1 participants (Actual)	Interventional	2008-06-30	Terminated
Randomized Phase II Trial of Adjuvant Combined Epigenetic Therapy With 5-Azacitidine and Entinostat in Resected Stage I Non-small Cell Lung Cancer Versus Standard Care [NCT01207726]	Phase 2	13 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to Slow Accrual due to patients not wanting daily clinic administration of 5AZA and/or 6 months of treatment after surgery.)
A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma [NCT02697630]	Phase 2	29 participants (Actual)	Interventional	2018-02-21	Completed
A Phase 2 Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma [NCT03250273]	Phase 2	44 participants (Actual)	Interventional	2017-11-06	Completed
A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exemestane in Patients With Newly Diagnosed, Stage I-IIIC, Hormone Receptor - Positive (HR+) or Triple Negative Breast Cancer (TNBC) [NCT03361800]	Early Phase 1	5 participants (Actual)	Interventional	2018-11-28	Terminated(stopped due to Funding withdrawn.)
An Open Label, 2-Period Study to Assess the Effect of Entinostat on the Pharmacokinetics of Midazolam in Healthy Adult Subjects [NCT03187015]	Phase 1	26 participants (Actual)	Interventional	2017-05-23	Completed
Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer [NCT03215264]	Phase 1	20 participants (Actual)	Interventional	2017-10-02	Completed
A Phase 2 Single-Arm Multicenter Study of Entinostat in Patients With Relapsed or Refractory Abdominal Neuroendocrine (NE) Tumors [NCT03211988]	Phase 2	5 participants (Actual)	Interventional	2017-12-23	Terminated(stopped due to Lack of funding and drug supply)
A Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab in Subjects With Metastatic Non-Small Cell Lung Cancer. [NCT01928576]	Phase 2	101 participants (Actual)	Interventional	2013-11-06	Completed
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase [NCT02708680]	Phase 1/Phase 2	89 participants (Actual)	Interventional	2016-05-31	Completed
Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas [NCT05053971]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2022-11-16	Recruiting
A Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-Small Cell Lung Cancer [NCT01935947]	Phase 2	17 participants (Actual)	Interventional	2013-05-31	Terminated
Window of Opportunity Platform Study to Define Immunogenomic Changes With Pembrolizumab Alone and in Rational Combinations in Muscle-Invasive Bladder Cancer [NCT03978624]	Phase 2	20 participants (Anticipated)	Interventional	2020-09-23	Active, not recruiting
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Le [NCT02915523]	Phase 1/Phase 2	140 participants (Actual)	Interventional	2017-01-10	Completed
A Phase 1, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer [NCT02820961]	Phase 1	61 participants (Actual)	Interventional	2016-06-29	Completed
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors [NCT02453620]	Phase 1	57 participants (Actual)	Interventional	2016-02-12	Active, not recruiting
A Phase 1 Study of Entinostat in Combination With Atezolizumab / Carboplatin / Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer [NCT04631029]	Phase 1	3 participants (Actual)	Interventional	2021-04-27	Completed
INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies [NCT03838042]	Phase 1/Phase 2	128 participants (Anticipated)	Interventional	2020-05-26	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00313586 (1) [back to overview]	Proportion of Patients With Clinical Response
NCT00387465 (9) [back to overview]	(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT)
NCT00387465 (9) [back to overview]	Effect of Entinostat and Azacitidine on DNA Methylation and Response
NCT00387465 (9) [back to overview]	Overall Survival
NCT00387465 (9) [back to overview]	Pharmacokinetic Profile of Azacitidine as Measured by AUC (ng*hr/mL)
NCT00387465 (9) [back to overview]	Pharmacokinetic Profile of Azacitidine as Measured by Cmax
NCT00387465 (9) [back to overview]	Pharmacokinetic Profile of Azacitidine as Measured by Half-life
NCT00387465 (9) [back to overview]	Pharmacokinetic Profile of Azacytidine as Measured by Tmax
NCT00387465 (9) [back to overview]	Progression-free Survival
NCT00387465 (9) [back to overview]	Average Steady State Trough Concentration (ng/mL) of Entinostat
NCT00462605 (1) [back to overview]	Clinical Activity Assessed by Change in Peripheral Blood Counts
NCT00602030 (16) [back to overview]	6-Month PFS Rate in the Double-blind Phase
NCT00602030 (16) [back to overview]	Number of Participants With Grade 3 or 4 Laboratory Variables in the Double-blind Phase
NCT00602030 (16) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) by Severity in the Double-blind Phase
NCT00602030 (16) [back to overview]	Tmax: Time to Cmax of Entinostat in the Lead-in Phase
NCT00602030 (16) [back to overview]	Vital Sign Values: Diastolic Blood Pressure in the Double-blind Phase
NCT00602030 (16) [back to overview]	Vital Sign Values: Heart Rate in the Double-blind Phase
NCT00602030 (16) [back to overview]	Vital Sign Values: Respiration Rate in the Double-blind Phase
NCT00602030 (16) [back to overview]	Vital Sign Values: Systolic Blood Pressure in the Double-blind Phase
NCT00602030 (16) [back to overview]	Vital Sign Values: Temperature in the Double-blind Phase
NCT00602030 (16) [back to overview]	Vital Sign Values: Weight in the Double-blind Phase
NCT00602030 (16) [back to overview]	4-Month Progression-free Survival (PFS) Rate in the Double-blind Phase
NCT00602030 (16) [back to overview]	Identification of Safe-dose for the Phase 2 Double-blind Phase in the Lead-in Phase
NCT00602030 (16) [back to overview]	Objective Response Rate (ORR) in the Double-blind Phase
NCT00602030 (16) [back to overview]	AUC(0-24): Area Under the Concentration-time Curve From Time 0 to 24 Hours in the Lead-in Phase
NCT00602030 (16) [back to overview]	AUC(0-last): Area Under the Concentration-time Curve From Time 0 to Last Quantifiable Concentration in the Lead-in Phase
NCT00602030 (16) [back to overview]	Cmax: Maximum Plasma Concentration of Entinostat in the Lead-in Phase
NCT00676663 (5) [back to overview]	Clinical Benefit Rate (CBR)
NCT00676663 (5) [back to overview]	Objective Response Rate (ORR)
NCT00676663 (5) [back to overview]	Overall Survival (OS)
NCT00676663 (5) [back to overview]	Progression-free Survival (PFS)
NCT00676663 (5) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT00828854 (4) [back to overview]	Objective Response Rate (ORR) During the First 6 Cycles of Study Treatment
NCT00828854 (4) [back to overview]	Progression-Free Survival (PFS)
NCT00828854 (4) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00828854 (4) [back to overview]	Clinical Benefit Rate (CBR)
NCT00866333 (4) [back to overview]	Percentage of Participants With Best Overall Response Based on the Participant's Best Response That is Documented Within the First 6 Cycles of Protocol Therapy
NCT00866333 (4) [back to overview]	Duration of Objective Response for Participants Achieving CR or PR
NCT00866333 (4) [back to overview]	Percentage of Participants With Best Overall Response Based on the Participant's Best Response Documented Through the Entire Course of Protocol Therapy
NCT00866333 (4) [back to overview]	Number of Participants With Serious Adverse Events (SAE) and Adverse Events (AEs)
NCT01038778 (8) [back to overview]	Incidence of Toxicities
NCT01038778 (8) [back to overview]	Incidence of Toxicity (Phase I)
NCT01038778 (8) [back to overview]	Overall Response Rate (Complete Plus Partial) (Phase II)
NCT01038778 (8) [back to overview]	Overall Survival
NCT01038778 (8) [back to overview]	Progression-free Survival
NCT01038778 (8) [back to overview]	Time-to-tumor Progression
NCT01038778 (8) [back to overview]	Dose-limiting Toxicities of Entinostat When Combined With Aldesleukin Within the Phase I
NCT01038778 (8) [back to overview]	Changes in the Level of Specific T Lymphocytes
NCT01105377 (2) [back to overview]	Confirmed Tumor Response
NCT01105377 (2) [back to overview]	Time to Progression
NCT01234532 (5) [back to overview]	Change in HER2
NCT01234532 (5) [back to overview]	Change in Proliferative Index (Ki67) (Phase II)
NCT01234532 (5) [back to overview]	Number of Participants With Adverse Events
NCT01234532 (5) [back to overview]	Recommended Phase II Dose of Entinostat in Combination With Anastrozole (Pilot)
NCT01234532 (5) [back to overview]	Change in Estrogen-receptor (ER) Expression (Phase II)
NCT01349959 (8) [back to overview]	Clinical Benefit Rate
NCT01349959 (8) [back to overview]	Confirmed Response Rate (Percentage of Participants With Complete or Partial Response Noted as the Objective Status on Two Consecutive Evaluations at Least 4 Weeks Apart) Assessed by RECIST
NCT01349959 (8) [back to overview]	Confirmed Response Rate to Azacitidine and Entinostat Plus the Addition of Hormone Therapy
NCT01349959 (8) [back to overview]	Feasibility of the Addition of Hormone Therapy, Evaluated by Calculating the Number of Patients With Disease Progression That go on to Receive Hormonal Therapy
NCT01349959 (8) [back to overview]	Number of Participants With Change in Expression of Relevant Genes (e.g., ER Alpha and RAR Beta) Evaluated by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
NCT01349959 (8) [back to overview]	Number of Participants With Change in Gene Methylation Evaluated Using Quantitative Multiple Methylation-specific Polymerase Chain Reaction (QM-MSP)
NCT01349959 (8) [back to overview]	Overall Survival
NCT01349959 (8) [back to overview]	Progression-free Survival (PFS)
NCT02115282 (9) [back to overview]	Time-to-treatment Deterioration (TTD)
NCT02115282 (9) [back to overview]	Patient-reported Fatigue
NCT02115282 (9) [back to overview]	Lysine Acetylation Change in CD45 Blood Mononuclear Cells Between C1D1 and C1D15 and PFS in Patients on Arm A
NCT02115282 (9) [back to overview]	Objective Response Rate (ORR)
NCT02115282 (9) [back to overview]	Overall Survival (OS)
NCT02115282 (9) [back to overview]	Patient-reported Diarrhea
NCT02115282 (9) [back to overview]	Patient-reported Health-related Quality of Life
NCT02115282 (9) [back to overview]	Patient-reported Nausea and Anorexia
NCT02115282 (9) [back to overview]	Progression-free Survival (PFS)
NCT02708680 (7) [back to overview]	Phase 1b: Participants Experiencing DLT
NCT02708680 (7) [back to overview]	Phase 2 Expansion: Overall Survival (OS)
NCT02708680 (7) [back to overview]	Phase 2 Expansion: Duration of Progression-free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
NCT02708680 (7) [back to overview]	Phase 2 Expansion: Duration of PFS Using Immune Response RECIST (irRECIST)
NCT02708680 (7) [back to overview]	Phase 2 Expansion: Overall Response Rate (ORR) Using RECIST 1.1 and irRECIST
NCT02708680 (7) [back to overview]	Phase 2 Expansion: Clinical Benefit Rate (CBR) Using RECIST 1.1 and irRECIST
NCT02708680 (7) [back to overview]	Phase 1b: Determination of the RP2D
NCT02780804 (7) [back to overview]	Total Area Under the Plasma Concentration Curve of Entinostat: AUC
NCT02780804 (7) [back to overview]	Antitumor Activity of Entinostat
NCT02780804 (7) [back to overview]	Frequency of Adverse Events for Entinostat
NCT02780804 (7) [back to overview]	Half-life of Entinostat
NCT02780804 (7) [back to overview]	Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat
NCT02780804 (7) [back to overview]	Peak Plasma Concentration of Entinostat: C-Max
NCT02780804 (7) [back to overview]	Time to Reach Maximum Plasma Concentration of Entinostat: T-Max
NCT03018249 (4) [back to overview]	Percent of Participants With a Ki67 Response
NCT03018249 (4) [back to overview]	The Frequency and Severity of CTCAE Version 4.0 Graded Adverse Events (AE)
NCT03018249 (4) [back to overview]	Percentage of Participants With a Histologic Response
NCT03018249 (4) [back to overview]	Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score)
NCT03215264 (1) [back to overview]	Maximum Tolerated Dose (MTD) of Hydroxychloroquine and Entinostat in Combination With Regorafenib
NCT03250273 (11) [back to overview]	Overall Survival (OS) at 24 Months
NCT03250273 (11) [back to overview]	Overall Survival (OS) at 36 Months
NCT03250273 (11) [back to overview]	Overall Survival (OS) at 6 Months
NCT03250273 (11) [back to overview]	Progression Free Survival (PFS) at 12 Months
NCT03250273 (11) [back to overview]	Progression Free Survival (PFS) at 24 Months
NCT03250273 (11) [back to overview]	Progression Free Survival (PFS) at 6 Months
NCT03250273 (11) [back to overview]	Overall Survival (OS)
NCT03250273 (11) [back to overview]	Overall Survival (OS) at 12 Months
NCT03250273 (11) [back to overview]	Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)
NCT03250273 (11) [back to overview]	Number of Patients Experiencing a Grade 3 or Above Treatment-related Adverse Event (AE)
NCT03250273 (11) [back to overview]	Duration of Response (DOR)
NCT04296942 (4) [back to overview]	Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
NCT04296942 (4) [back to overview]	Progression-free Survival (PFS) in Triple Negative Breast Cancer (TNBC)
NCT04296942 (4) [back to overview]	Overall Response (Partial Response + Complete Response) for Participants With Triple Negative Breast Cancer (TNBC)
NCT04296942 (4) [back to overview]	Number of Participants Experiencing at Least One Grade 3 to 5 Adverse Events for Each of the Three Combinations of Agents
NCT04631029 (4) [back to overview]	Number of Participants Experiencing Grade 3 and 4 Adverse Events
NCT04631029 (4) [back to overview]	Number of Participants Who Received 3 or More Cycles of the Combination of Entinostat, Atezolizumab, Carboplatin, and Etoposide
NCT04631029 (4) [back to overview]	Number of Participants With Dose Limiting Toxicities
NCT04631029 (4) [back to overview]	Progression Free Survival (PFS) Rate

Proportion of Patients With Clinical Response

"Clinical response is defined as a complete response (CR), partial response (PR) or trilineage response (TR) graded according to the following criteria:~World Health Organization classification of the acute leukemias and myelodysplastic syndrome (by Bennett)~Myelodysplastic syndromes standardized response criteria: further definition (by Cheson et al.)~Report of an international working group to standardize response criteria for myelodysplastic syndromes (by Cheson et al.)" (NCT00313586)
Timeframe: Assessed every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2 - 5 years from study entry.

Intervention	Proportion of patients (Number)
Arm A (Azacitidine; Non-treatment-induced Cohort)	0.32
Arm B (Azacitidine + Entinostat; Non-treatment-induced Cohort)	0.27
Arm A (Azacitidine; Treatment-induced Cohort)	0.46
Arm B (Azacitidine + Entinostat; Treatment-induced Cohort)	0.17

Intervention	Participants (Count of Participants)
Phase I - 30mg/m2 Azacitidine	0
Phase I - 40mg/m2 Azacitidine	0

Intervention	cell/mm^3 (Mean)
	ANC +/- SEM at baseline	ANC +/- SEM after 2 cycles
Arm I	578	1137

Intervention	percentage of participants (Number)
Double-blind Phase: Erlotinib + Placebo	10.8
Double-blind Phase: Erlotinib + Entinostat 10 mg	11.9

Intervention	Participants (Count of Participants)
	White Blood Count decreased	Absolute Neutrophil Count decreased	Lymphocytes decreased	Platelets decreased	Phosphorus decreased	Alanine aminotransferase increased	Sodium decreased	Glucose increased	Albumin decreased	Potassium decreased	Aspartate aminotransferase increased	Bilirubin increased	Creatinine abnormal	Magnesium decreased	Potassium increased	Calcium increased	Calcium decreased
Double-blind Phase: Erlotinib + Entinostat 10 mg	1	2	18	2	6	6	4	3	2	2	2	0	1	1	1	0	0
Double-blind Phase: Erlotinib + Placebo	1	1	9	1	4	1	5	2	4	2	0	3	1	0	0	2	1

Intervention	Participants (Count of Participants)
	Any SAE	Any TEAE	Grade 1 TEAE	Grade 2 TEAE	Grade 3 TEAE	Grade 4 TEAE	Grade 5 TEAE
Double-blind Phase: Erlotinib + Entinostat 10 mg	32	65	1	12	34	6	12
Double-blind Phase: Erlotinib + Placebo	29	63	7	16	20	5	15

Intervention	hour (Mean)
	Day 1 (entinostat alone)	Day 15 (entinostat + erlotinib)
Lead-in Phase: Erlotinib + Entinostat 10 mg	0.50	1.3
Lead-in Phase: Erlotinib + Entinostat 5 mg	0.83	1.0

Intervention	mm Hg (Mean)
	Baseline	Minimum Post-Baseline Value	Maximum Post-Baseline Value
Double-blind Phase: Erlotinib + Entinostat 10 mg	72.1	61.3	78.5
Double-blind Phase: Erlotinib + Placebo	72.5	64.7	78.8

Intervention	percentage of participants (Number)
Double-blind Phase: Erlotinib + Placebo	24.0
Double-blind Phase: Erlotinib + Entinostat 10 mg	20.8

Intervention	percentage of participants (Number)
Exemestane 25 mg + Placebo	25.8
Exemestane 25 mg + Entinostat 5 mg	26.6

Intervention	months (Median)
Exemestane 25 mg + Placebo (EP)	19.84
Exemestane 25 mg + Entinostat 5 mg (EE)	28.13

Intervention	months (Median)
Exemestane 25 mg + Placebo	2.27
Exemestane 25 mg + Entinostat 5 mg	4.28

Intervention	Participants (Count of Participants)
	TEAE	SAE
Exemestane 25 mg + Entinostat 5 mg	60	10
Exemestane 25 mg + Placebo	56	8

Intervention	percentage of participants (Number)
Regimen 1: Entinostat 10 mg	8.3
Regimen 2: Entinostat 10 mg/15 mg	11.8
Regimen 3: Entinostat 15 mg	16.7

Intervention	months (Median)
Regimen 1: Entinostat 10 mg	NA
Regimen 2: Entinostat 10 mg/15 mg	28.6
Regimen 3: Entinostat 15 mg	8.3

Intervention	percentage of participants (Number)
Regimen 1: Entinostat 10 mg	8.3
Regimen 2: Entinostat 10 mg/15 mg	17.6
Regimen 3: Entinostat 15 mg	16.7

Intervention	percentage of participants (Number)
	Triple-negative Breast Cancer (TNBC)	Hormone-resistant Breast Cancer (HRBC)
Treatment (Entinostat and Azacitidine)	0	4

Intervention	months (Median)
Arm A (Exemestane, Entinostat)	2.9
Arm B (Exemestane, Placebo)	2.9

Intervention	T-score (Mean)
Arm A (Exemestane, Entinostat)	55.5
Arm B (Exemestane, Placebo)	54.1

Intervention	months (Median)
Arm A (Exemestane, Entinostat)- Lysine Acetylation Change>=1.5 Fold	2.8
Arm A (Exemestane, Entinostat)- Lysine Acetylation Change<1.5 Fold	2.7

Intervention	months (Median)
Arm A (Exemestane, Entinostat)	23.4
Arm B (Exemestane, Placebo)	21.7

entinostat

Cross-References

Synonyms (111)

Research Excerpts

Overview

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (5)

Protein Targets (29)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (418)

Molecular Functions (148)

Ceullar Components (62)

Bioassays (920)

Research

Studies (550)

Market Indicators

Research Demand Index: 42.81

Study Types

Clinical Trials (71)

Trial Overview

Trial Outcomes

Proportion of Patients With Clinical Response

(Phase I) Maximum Tolerated Dose (MTD) of Azacitidine When Given Together With Entinostat as Determined by Number of Participants Experiencing Dose-limiting Toxicity (DLT)

Effect of Entinostat and Azacitidine on DNA Methylation and Response

Overall Survival

Pharmacokinetic Profile of Azacitidine as Measured by AUC (ng*hr/mL)

Pharmacokinetic Profile of Azacitidine as Measured by Cmax

Pharmacokinetic Profile of Azacitidine as Measured by Half-life

Pharmacokinetic Profile of Azacytidine as Measured by Tmax

Progression-free Survival

Average Steady State Trough Concentration (ng/mL) of Entinostat

Clinical Activity Assessed by Change in Peripheral Blood Counts

6-Month PFS Rate in the Double-blind Phase

Number of Participants With Grade 3 or 4 Laboratory Variables in the Double-blind Phase

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) by Severity in the Double-blind Phase

Tmax: Time to Cmax of Entinostat in the Lead-in Phase

Vital Sign Values: Diastolic Blood Pressure in the Double-blind Phase

Vital Sign Values: Heart Rate in the Double-blind Phase

Vital Sign Values: Respiration Rate in the Double-blind Phase

Vital Sign Values: Systolic Blood Pressure in the Double-blind Phase

Vital Sign Values: Temperature in the Double-blind Phase

Vital Sign Values: Weight in the Double-blind Phase

4-Month Progression-free Survival (PFS) Rate in the Double-blind Phase

Identification of Safe-dose for the Phase 2 Double-blind Phase in the Lead-in Phase

Objective Response Rate (ORR) in the Double-blind Phase

AUC(0-24): Area Under the Concentration-time Curve From Time 0 to 24 Hours in the Lead-in Phase

AUC(0-last): Area Under the Concentration-time Curve From Time 0 to Last Quantifiable Concentration in the Lead-in Phase

Cmax: Maximum Plasma Concentration of Entinostat in the Lead-in Phase

Clinical Benefit Rate (CBR)

Objective Response Rate (ORR)

Overall Survival (OS)

Progression-free Survival (PFS)

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Objective Response Rate (ORR) During the First 6 Cycles of Study Treatment

Progression-Free Survival (PFS)

Number of Participants With Adverse Events (AEs)

Clinical Benefit Rate (CBR)

Percentage of Participants With Best Overall Response Based on the Participant's Best Response That is Documented Within the First 6 Cycles of Protocol Therapy

Duration of Objective Response for Participants Achieving CR or PR

Percentage of Participants With Best Overall Response Based on the Participant's Best Response Documented Through the Entire Course of Protocol Therapy

Number of Participants With Serious Adverse Events (SAE) and Adverse Events (AEs)

Incidence of Toxicities

Incidence of Toxicity (Phase I)

Overall Response Rate (Complete Plus Partial) (Phase II)

Overall Survival

Progression-free Survival

Time-to-tumor Progression

Dose-limiting Toxicities of Entinostat When Combined With Aldesleukin Within the Phase I

Changes in the Level of Specific T Lymphocytes

Confirmed Tumor Response

Time to Progression

Change in HER2

Intervention	units on a scale (Mean)
Arm A (Exemestane, Entinostat)	38.8
Arm B (Exemestane, Placebo)	41.5

Intervention	units on a scale (Mean)
Arm A (Exemestane, Entinostat)	20.5
Arm B (Exemestane, Placebo)	20.9

Intervention	units on a scale (Mean)
Arm A (Exemestane, Entinostat)	35.8
Arm B (Exemestane, Placebo)	37.0

Intervention	months (Median)
Phase 2 Expansion: Entinostat Plus Atezolizumab	12.25
Phase 2 Expansion: Placebo Plus Atezolizumab	11.20

Intervention	months (Median)
Phase 2 Expansion: Entinostat Plus Atezolizumab	1.68
Phase 2 Expansion: Placebo Plus Atezolizumab	1.51

Intervention	percentage of participants (Number)
	ORR per RECIST 1.1	ORR per irRECIST 1.1
Phase 2 Expansion: Entinostat Plus Atezolizumab	12.5	12.5
Phase 2 Expansion: Placebo Plus Atezolizumab	2.4	2.4

Intervention	percentage of participants (Number)
	CBR per RECIST 1.1	CBR per irRECIST 1.1
Phase 2 Entinostat Plus Atezolizumab	15.0	15.0
Placebo Plus Atezolizumab	7.3	7.3

Intervention	hr*ng/mL (Median)
Stratum 1 With 3 mg/m²	755
Stratum 1 With 4 mg/m²	1111
PK Part With 4 mg/m²	1147

Intervention	Hours (Median)
Stratum 1 With 3 mg/m²	50.96
Stratum 1 With 4 mg/m²	46.04
PK Part With 4 mg/m²	44.23

Intervention	ng/ml (Median)
Stratum 1 With 3 mg/m²	54.4
Stratum 1 With 4 mg/m²	61.5
PK Part With 4 mg/m²	23.8